var title_f24_54_25440="Secretory diarrhea child";
var content_f24_54_25440=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=PEDS%2F57351&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=PEDS%2F57351&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 622px\">",
"   <div class=\"ttl\">",
"    Algorithm for evaluation of a child with secretory diarrhea",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 602px; height: 571px; background-image: url(data:image/gif;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    This algorithm shows a typical diagnostic pathway for many patients in this age group. Other sequences of testing may be appropriate in some cases.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f24_54_25440=[""].join("\n");
var outline_f24_54_25440=null;
var title_f24_54_25441="Patient information: Blocked tear duct (The Basics)";
var content_f24_54_25441=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"1\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div>",
"   &nbsp;",
"  </div>",
"  <div id=\"basicsTopicMinWidth\">",
"   <div id=\"basicsTopicRight\">",
"    <div id=\"placeholder\">",
"     <div class=\"ieSpacer\">",
"     </div>",
"     <div id=\"basics-more\">",
"      <h4>",
"       <img src=\"file://www.uptodate.com/images/basics-more-title.png\"/>",
"      </h4>",
"      <dl>",
"       <dt class=\"basics\">",
"        The Basics",
"       </dt>",
"       <dd>",
"        <a href=\"UTD.htm?26/6/26721\">",
"         Patient information: Conjunctivitis (pinkeye) (The Basics)",
"        </a>",
"       </dd>",
"       <dt class=\"beyondthebasics\">",
"        Beyond the Basics",
"       </dt>",
"       <dd>",
"        <a href=\"UTD.htm?19/51/20274\">",
"         Patient information: Conjunctivitis (pinkeye) (Beyond the Basics)",
"        </a>",
"       </dd>",
"      </dl>",
"      <div id=\"tooltipper\">",
"      </div>",
"     </div>",
"    </div>",
"   </div>",
"   <div id=\"basicsTopicLeft\">",
"    <div id=\"topicTitle\">",
"     Patient information: Blocked tear duct (The Basics)",
"    </div>",
"    <span class=\"view\">",
"     View in",
"     <a class=\"lang\" href=\"./es-419/blocked-tear-duct-the-basics?source=topic_page\">",
"      Spanish",
"     </a>",
"    </span>",
"    <a class=\"contributor contributor_credentials\" href=\"./authors-and-editors/patient-information\">",
"     Written by the doctors and editors at UpToDate",
"    </a>",
"    <div id=\"topicText\">",
"     <p class=\"headingAnchor\" id=\"H25519641\">",
"      <span class=\"h1\">",
"       What is a blocked tear duct?",
"      </span>",
"      &nbsp;&mdash;&nbsp;A blocked tear duct is a condition that causes the eyes to tear much more than usual. The tear duct is how tears drain from the eye. It is a path of small tubes that runs from the inner eyelid to the inside of the nose. If the tear duct is blocked, tears can&rsquo;t drain normally. This causes symptoms.",
"     </p>",
"     <p>",
"      A blocked tear duct is a common condition in babies. Babies who have a blocked tear duct are usually born with it.",
"     </p>",
"     <p>",
"      Older children and adults can also get a blocked tear duct. The cause of the blockage is usually an eye infection or injury.",
"     </p>",
"     <p class=\"headingAnchor\" id=\"H25519656\">",
"      <span class=\"h1\">",
"       What are the symptoms of a blocked tear duct?",
"      </span>",
"      &nbsp;&mdash;&nbsp;Symptoms of a blocked tear duct can include:",
"     </p>",
"     <p>",
"      <ul class=\"bullet-block\">",
"       <li>",
"        Increased tearing &ndash; This can happen some or all of the time.",
"       </li>",
"       <li>",
"        Crusting of the eyelids",
"       </li>",
"       <li>",
"        Redness of the white part of the eye",
"       </li>",
"       <li>",
"        A blue-colored area of swelling between the eye and nose &ndash; This only happens if both ends of the tear duct are blocked.",
"       </li>",
"      </ul>",
"     </p>",
"     <p>",
"      Sometimes, a blocked tear duct gets infected. An infection happens when germs grow in the tears that are stuck in the tear duct.",
"     </p>",
"     <p>",
"      Symptoms of a tear duct infection can include:",
"     </p>",
"     <p>",
"      <ul class=\"bulletCompact-block\">",
"       <li>",
"        Redness",
"       </li>",
"       <li>",
"        Swelling",
"       </li>",
"       <li>",
"        Warmth",
"       </li>",
"       <li>",
"        Pain",
"       </li>",
"       <li>",
"        Pus draining from the eye",
"       </li>",
"      </ul>",
"     </p>",
"     <p class=\"headingAnchor\" id=\"H25519671\">",
"      <span class=\"h1\">",
"       Will my child need tests?",
"      </span>",
"      &nbsp;&mdash;&nbsp;Probably not. The doctor or nurse should be able to tell if your child has a blocked tear duct by learning about his or her symptoms and doing an exam.",
"     </p>",
"     <p>",
"      The doctor or nurse might do a test to check how well the tear duct is working.",
"     </p>",
"     <p class=\"headingAnchor\" id=\"H25519686\">",
"      <span class=\"h1\">",
"       How is a blocked tear duct treated?",
"      </span>",
"      &nbsp;&mdash;&nbsp;Treatment depends on the person&rsquo;s age, the cause of the blockage, and if there is an infection.",
"     </p>",
"     <p>",
"      Doctors treat infected tear ducts with antibiotics. Some antibiotics go in the eye. Others come in pills or liquids that you swallow.",
"     </p>",
"     <p>",
"      Most babies do not need treatment unless their tear duct is infected. That&rsquo;s because most blocked tear ducts open up on their own by the time a baby is 6 months old.",
"     </p>",
"     <p>",
"      To help your baby&rsquo;s tear duct open up, your doctor or nurse might recommend that you gently massage it. He or she will show you how to do this.",
"     </p>",
"     <p>",
"      If the tear duct doesn&rsquo;t open up on its own, your baby might need to see an eye specialist (called an ophthalmologist). This doctor can do a procedure to open up the tear duct. During the procedure, he or she will put a thin tool into the tear duct and push open the blockage.",
"     </p>",
"     <p>",
"      If the tear duct stays blocked, or the blockage comes back, your doctor will talk with you about other possible treatments. These include procedures to widen the tear duct.",
"     </p>",
"     <p>",
"      The treatment for older children and adults with a blocked tear duct depends on the cause of the blockage. Different treatments might include:",
"     </p>",
"     <p>",
"      <ul class=\"bulletCompact-block\">",
"       <li>",
"        A procedure to widen the tear duct",
"       </li>",
"       <li>",
"        Surgery to make a new pathway that will allow tears to drain",
"       </li>",
"      </ul>",
"     </p>",
"     <p class=\"headingAnchor\" id=\"H25519701\">",
"      <span class=\"h1\">",
"       More on this topic",
"      </span>",
"     </p>",
"     <p>",
"      <a class=\"medical medical_basics\" href=\"UTD.htm?26/6/26721?source=see_link\">",
"       Patient information: Conjunctivitis (pinkeye) (The Basics)",
"      </a>",
"     </p>",
"     <p>",
"      <a class=\"medical medical_patient\" href=\"UTD.htm?19/51/20274?source=see_link\">",
"       Patient information: Conjunctivitis (pinkeye) (Beyond the Basics)",
"      </a>",
"     </p>",
"    </div>",
"    <div id=\"reviewProcess\">",
"     <span>",
"      All topics are updated as new evidence becomes available and our",
"      <a class=\"policy policy_editorialpolicy\" href=\"/home/editorial-policy\">",
"       peer review process",
"      </a>",
"      is complete.",
"     </span>",
"    </div>",
"    <div id=\"topicRetrievedDate\">",
"     <span class=\"emphasis\">",
"      This topic retrieved from UpToDate on:",
"     </span>",
"     Apr 20, 2013.",
"    </div>",
"    <div class=\"patTopicTool\" id=\"patTopicToolBottom\">",
"     <a class=\"toolbutton findicon findInPageLink\" href=\"#\" title=\"Find in Topic\">",
"      Find",
"     </a>",
"     <a class=\"toolbutton printicon\" href=\"UTD.htm?24/54/25441?view=print\" title=\"Print This Topic\">",
"      Print",
"     </a>",
"     <a class=\"toolbutton emailicon etacLink\" href=\"#\" title=\"Email This Topic\">",
"      Email",
"     </a>",
"    </div>",
"    <div id=\"disclaimer\">",
"     The content on the UpToDate website is not intended nor recommended as a substitute for medical advice, diagnosis, or treatment.  Always seek the advice of your own physician or other qualified health care professional regarding any medical questions or conditions.",
"The use of UpToDate content is governed by the",
"     <a class=\"legal legal_termsofuse\" href=\"/home/terms-use\" target=\"_blank\">",
"      UpToDate Terms of Use",
"     </a>",
"     . &copy;2013 UpToDate, Inc. All rights reserved.",
"    </div>",
"    <div id=\"topicVersionRevision\">",
"     Topic 16717 Version 2.0",
"    </div>",
"   </div>",
"   <!--  basicsTopicLeft -->",
"  </div>",
"  <!-- basicsTopicMinWidth -->",
" </div>",
" <!-- topicContent -->",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.6- C21.56",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     AsanBook Dig. Med. Lib.",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [0505-91.202.164.29-A3F5C7E4D9-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f24_54_25441=[""].join("\n");
var outline_f24_54_25441=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H25519641\">",
"      What is a blocked tear duct?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H25519656\">",
"      What are the symptoms of a blocked tear duct?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H25519671\">",
"      Will my child need tests?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H25519686\">",
"      How is a blocked tear duct treated?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H25519701\">",
"      More on this topic",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_patient\" href=\"UTD.htm?19/51/20274?source=related_link\">",
"      Patient information: Conjunctivitis (pinkeye) (Beyond the Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_basics\" href=\"UTD.htm?26/6/26721?source=related_link\">",
"      Patient information: Conjunctivitis (pinkeye) (The Basics)",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f24_54_25442="Gastroschisis1";
var content_f24_54_25442=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=OBGYN%2F76768&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=OBGYN%2F76768&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    Classical ultrasound image of fetal gastroschisis",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 331px; height: 331px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    This image is taken at the level of the cord insertion site. The cord insertion appears normal; echolucent vessels can be seen entering the abdominal cavity. The abdominal wall defect can be seen adjacent to the cord insertion site: there is loss of continuity of the abdominal skin line where the bowel protrudes through the abdominal wall defect.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Courtesy of Courtney D Stephenson, DO and Andrew P Schuller, RDMS.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f24_54_25442=[""].join("\n");
var outline_f24_54_25442=null;
var title_f24_54_25443="Urothelial CIS A";
var content_f24_54_25443=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=ONC%2F65140&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=ONC%2F65140&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    Urothelial carcinoma in situ (CIS)",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 433px; height: 296px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Courtesy of Cristina Magi-Galluzzi, MD, PhD.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f24_54_25443=[""].join("\n");
var outline_f24_54_25443=null;
var title_f24_54_25444="Microcystic adnexal carcinoma on cheek outlined";
var content_f24_54_25444=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=DERM%2F86195&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=DERM%2F86195&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 524px\">",
"   <div class=\"ttl\">",
"    Microcystic adnexal carcinoma",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 504px; height: 501px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    Microcystic adnexal carcinoma presenting as a white-yellow plaque on the cheek. The palpable tumor is outlined. Note the asymmetrical extension.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f24_54_25444=[""].join("\n");
var outline_f24_54_25444=null;
var title_f24_54_25445="Membranous Silver";
var content_f24_54_25445=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=NEPH%2F69629&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=NEPH%2F69629&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    Silver stain in membranous nephropathy",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 396px; height: 273px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    Light micrograph silver stain of membranous nephropathy shows a spike appearance (arrows). The spikes represent new basement membrane growing between the subepithelial immune deposits which are visible on electron microscopy, but not with this stain.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Courtesy of Helmut Rennke, MD.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f24_54_25445=[""].join("\n");
var outline_f24_54_25445=null;
var title_f24_54_25446="Amlodipine, olmesartan, and hydrochlorothiazide: Patient drug information";
var content_f24_54_25446=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"1\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"disclaimer\">",
"   The content on the UpToDate website is not intended nor recommended as a substitute",
"for medical advice, diagnosis, or treatment.  Always seek the advice of your own physician or",
"other qualified health care professional regarding any medical questions or conditions.  The",
"use of this website is governed by the",
"   <a href=\"/home/terms-use\" target=\"_blank\">",
"    UpToDate Terms of Use",
"   </a>",
"   &copy;2013 UpToDate, Inc.",
"  </div>",
"  <div id=\"drugTitle\">",
"   Amlodipine, olmesartan, and hydrochlorothiazide: Patient drug information",
"  </div>",
"  <div id=\"lexiTitleImg\">",
"   <img height=\"17\" src=\"./../images/lexiComp/Lexicomp_2012_71x17.myextg\" width=\"71\"/>",
"  </div>",
"  <div class=\"clear\">",
"  </div>",
"  <div id=\"drugCopy\">",
"   Copyright 1978-2013 Lexicomp, Inc. All rights reserved.",
"  </div>",
"  <div id=\"topicText\">",
"   <p>",
"    (For additional information",
"    <a class=\"drug drug_general\" href=\"UTD.htm?8/2/8232?source=see_link\">",
"     see \"Amlodipine, olmesartan, and hydrochlorothiazide: Drug information\"",
"    </a>",
"    )",
"   </p>",
"   <div class=\"list ubnlist drugH1Div drugBrandNames\" id=\"F10481074\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Brand Names: U.S.",
"    </span>",
"    <ul>",
"     <li>",
"      Tribenzor&trade;",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt war-os drugH1Div\" id=\"F10495067\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Warning",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2700281",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Do not take if you are pregnant. Use during pregnancy may cause birth defects or loss of the unborn baby. If you get pregnant or plan on getting pregnant while taking this drug, call your doctor right away.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2700602",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Sometimes drugs are not safe when you take them with certain other drugs. Taking them together can cause bad side effects. This is one of those drugs. Be sure to talk to your doctor about all the drugs you take.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yya-os drugH1Div\" id=\"F10495069\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     What is this drug used for?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2691888",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       It is used to treat high blood pressure.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2691367",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       It is used to get rid of extra fluid.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt coi-os drugH1Div\" id=\"F10495068\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     What do I need to tell my doctor before I take this drug?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2847799",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you have an allergy to olmesartan, amlodipine, hydrochlorothiazide, or any other part of this drug.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2705171",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you are allergic to any drugs, foods, or other substances. Tell your doctor about the allergy and what signs you had, like rash; hives; itching; shortness of breath; wheezing; cough; swelling of face, lips, tongue, or throat; or any other signs.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2701385",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you have a sulfa (sulfonamide) allergy, talk with your doctor.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2701336",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you are not able to pass urine.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s3915366",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you have high blood sugar (diabetes) and are taking aliskiren.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2701080",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you are pregnant or may be pregnant.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2701047",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you are breast-feeding.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yye-os drugH1Div\" id=\"F10495073\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     What are some things I need to know or do while I take this drug?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2697780",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Wear disease medical alert ID (identification).",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2696820",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Do not run out of this drug.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2697207",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you have high blood sugar (diabetes), this drug may sometimes raise blood sugar. Talk with your doctor about how to fine tune this.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2697282",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you have kidney disease, talk with your doctor.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2697290",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you have liver disease, talk with your doctor.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698416",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Have your blood pressure and heart rate checked often. Talk with your doctor.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698465",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Have your blood work checked. Talk with your doctor.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2696717",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Check all drugs you are taking with your doctor. This drug may not mix well with some other drugs.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699677",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Keep a list of all your drugs (prescription, natural products, vitamins, OTC) with you. Give this list to your doctor.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2697100",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you are taking a salt substitute that has potassium, potassium-sparing diuretics, or potassium, talk with your doctor.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2697627",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Talk with your doctor before using OTC products that may raise blood pressure. These include cough or cold drugs, diet pills, stimulants, ibuprofen or like products, and some natural products or aids.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2697562",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Limit your drinking of wine, beer, or mixed drinks.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s4128402",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you drink grapefruit juice or eat grapefruit often, talk with your doctor.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2697788",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       You may get sunburned more easily. Avoid sun, sunlamps, and tanning beds. Use sunscreen and wear clothing and eyewear that protects you from the sun.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2696701",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Be careful in hot weather. Drink lots of fluids to stop fluid loss.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2697779",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Watch for gout attacks.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2697740",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Use birth control that you can trust to stop pregnancy while taking this drug.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yyf-os drugH1Div\" id=\"F10495074\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     What are some side effects of this drug?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698051",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Feeling dizzy. Rise slowly over a few minutes when sitting or lying down. Be careful climbing.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698148",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       High potassium level. Signs include feeling weak, lightheaded, dizzy, feel like passing out, or have numbness or tingling.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698217",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Signs of low potassium levels like muscle pain or weakness, muscle cramps, or a heartbeat that does not feel normal.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698119",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Headache.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2697983",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Cough.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698360",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Swelling in the arms or legs.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698272",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Upset stomach or throwing up. Many small meals, good mouth care, sucking hard, sugar-free candy, or chewing sugar-free gum may help.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698027",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Dry mouth. Good mouth care, sucking hard, sugar-free candy, or chewing sugar-free gum may help. See a dentist often.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698395",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Kidney function that gets worse.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yyh-os drugH1Div\" id=\"F10495076\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     What are some side effects that I need to call my doctor about right away?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698721",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you think there has been an overdose, call 1-800-222-1222 (the American Association of Poison Control Centers), your local poison control center (file://www.aapcc.org), or emergency room (ER) right away.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699066",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Signs of an allergic reaction, like rash; hives; itching; red, swollen, blistered, or peeling skin with or without fever; wheezing; tightness in the chest or throat; trouble breathing or talking; unusual hoarseness; or swelling of the mouth, face, lips, tongue, or throat.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698655",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       A fast heartbeat.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699023",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Very bad dizziness or passing out.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698640",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Trouble breathing.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699031",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Very bad headache.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699042",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Very upset stomach or throwing up.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699070",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Signs of high potassium.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699072",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Signs of low potassium.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698998",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Cough that does not go away.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698650",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Tell your doctor if you have too much sweat, fluid loss, throwing up, or loose stools. This may lead to low blood pressure.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699104",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Not able to pass urine.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699086",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Sudden change in eyesight, eye pain, or irritation.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698670",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       For women, if you get pregnant while taking this drug.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698603",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Any rash.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698977",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Side effect or health problem is not better or you are feeling worse.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yyc-os drugH1Div\" id=\"F10495071\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     How is this drug best taken?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2695786",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Take as you have been told, even if you feel well.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2695852",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Take this drug at the same time of day.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2695872",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       This drug may cause you to pass urine more often. To keep from having sleep problems, try to take before 6 pm.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2695914",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Take with or without food. Take with food if it causes an upset stomach.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2694865",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Follow the diet and workout plan that your doctor told you about.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yyd-os drugH1Div\" id=\"F10495072\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     What do I do if I miss a dose?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2696563",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Take a missed dose as soon as you think about it.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2696496",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If it is close to the time for your next dose, skip the missed dose and go back to your normal time.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2696475",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Do not take 2 doses at the same time or extra doses.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2696457",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Do not change the dose or stop this drug. Talk with the doctor.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yyi-os drugH1Div\" id=\"F10495077\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     How do I store and/or throw out this drug?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699336",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Store at room temperature.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699266",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Store in a dry place. Do not store in a bathroom.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yyj-os drugH1Div\" id=\"F10495078\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     General drug facts",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s2699675",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If your symptoms or health problems do not get better or if they become worse, call your doctor.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s2699673",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Do not share your drugs with others and do not take anyone else's drugs.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s2699678",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Keep all drugs out of the reach of children and pets.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s2699709",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you have any questions about this drug, please talk with your doctor, pharmacist, or other health care provider.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s3302581",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       In Canada, take any unused drugs to the pharmacy. Also, visit file://www.hc-sc.gc.ca/hl-vs/iyh-vsv/med/disposal-defaire-eng.php#th to learn about the right way to get rid of unused drugs.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s2699677",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Keep a list of all your drugs (prescription, natural products, vitamins, OTC) with you. Give this list to your doctor.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s2699671",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       These are not all of the side effects that may occur. If you have questions about side effects, call your doctor. Call your doctor for medical advice about side effects.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s2699683",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Talk with the doctor before starting any new drug, including prescription or OTC, natural products, or vitamins.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 15585 Version 35.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.6- C21.56",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     AsanBook Dig. Med. Lib.",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [1104-58.240.98.179-6A22C7A760-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f24_54_25446=[""].join("\n");
var outline_f24_54_25446=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10481074\">",
"      Brand Names: U.S.",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10495067\">",
"      Warning",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10495069\">",
"      What is this drug used for?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10495068\">",
"      What do I need to tell my doctor before I take this drug?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10495073\">",
"      What are some things I need to know or do while I take this drug?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10495074\">",
"      What are some side effects of this drug?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10495076\">",
"      What are some side effects that I need to call my doctor about right away?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10495071\">",
"      How is this drug best taken?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10495072\">",
"      What do I do if I miss a dose?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10495077\">",
"      How do I store and/or throw out this drug?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10495078\">",
"      General drug facts",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"drug drug_general\" href=\"UTD.htm?8/2/8232?source=related_link\">",
"      Amlodipine, olmesartan, and hydrochlorothiazide: Drug information",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f24_54_25447="Chloroquine: Drug information";
var content_f24_54_25447=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"2\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"drugTitle\">",
"   Chloroquine: Drug information",
"  </div>",
"  <div id=\"lexiTitleImg\">",
"   <img height=\"17\" src=\"./../images/lexiComp/Lexicomp_2012_71x17.myextg\" width=\"71\"/>",
"  </div>",
"  <div class=\"clear\">",
"  </div>",
"  <div id=\"drugCopy\">",
"   Copyright 1978-2013 Lexicomp, Inc. All rights reserved.",
"  </div>",
"  <div id=\"topicText\">",
"   (For additional information",
"   <a class=\"drug drug_patient\" href=\"UTD.htm?1/35/1589?source=see_link\">",
"    see \"Chloroquine: Patient drug information\"",
"   </a>",
"   and",
"   <a class=\"drug drug_pediatric\" href=\"UTD.htm?39/53/40790?source=see_link\">",
"    see \"Chloroquine: Pediatric drug information\"",
"   </a>",
"   )",
"   <br/>",
"   For abbreviations and symbols that may be used in Lexicomp (",
"   <a class=\"graphic graphic_table\" href=\"UTD.htm?23/39/24183\">",
"    show table",
"   </a>",
"   )",
"   <div class=\"block black-box-warn drugH1Div\" id=\"F7885889\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     ALERT: U.S. Boxed Warning",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     The FDA-approved labeling includes a boxed warning. See Warnings/Precautions section for a concise summary of this information.  For verbatim wording of the boxed warning, consult the product labeling or",
"     <a href=\"file://www.fda.gov\" target=\"_blank\">",
"      www.fda.gov",
"     </a>",
"     .",
"    </p>",
"   </div>",
"   <div class=\"list ubnlist drugH1Div drugBrandNames\" id=\"F149782\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Brand Names: U.S.",
"    </span>",
"    <ul>",
"     <li>",
"      Aralen&reg;",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"list cbnlist drugH1Div drugBrandNames\" id=\"F149783\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Brand Names: Canada",
"    </span>",
"    <ul>",
"     <li>",
"      Aralen&reg;;",
"     </li>",
"     <li>",
"      Novo-Chloroquine",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ex_sect_xr thclist drugH1Div drugBrandNames\" id=\"F149826\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pharmacologic Category",
"    </span>",
"    <ul>",
"     <li>",
"      Aminoquinoline (Antimalarial)",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"block doa drugH1Div\" id=\"F149786\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosing: Adult",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Malaria chemoprophylaxis:",
"     </b>",
"     Oral: 500 mg/week (300 mg base) on the same day each week; begin 1-2 weeks prior to exposure; continue while in endemic area and for 4 weeks after leaving endemic area (CDC, 2010)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Malaria treatment:",
"     </b>",
"     Oral: 1 g (600 mg base) on day 1, followed by 500 mg (300 mg base) 6-, 24-, and 48 hours after first dose (CDC, 2009)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Extraintestinal amebiasis:",
"     </b>",
"     Oral: 1 g/day (600 mg base) for 2 days followed by 500 mg/day (300 mg base) for at least 2-3 weeks.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Rheumatoid arthritis, lupus erythematosus (unlabeled uses):",
"     </b>",
"     Oral: 250 mg (150 mg base) once daily; reduce dosage following maximal response (taper to discontinue after response in lupus); generally requires 3-6 weeks.",
"     <b>",
"      Note:",
"     </b>",
"     Not considered first-line agent.",
"    </p>",
"   </div>",
"   <div class=\"block dop drugH1Div\" id=\"F149806\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosing: Pediatric",
"    </span>",
"    <p>",
"     (For additional information",
"     <a class=\"drug drug_pediatric\" href=\"UTD.htm?39/53/40790?source=see_link\">",
"      see \"Chloroquine: Pediatric drug information\"",
"     </a>",
"     )",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Malaria chemoprophylaxis:",
"     </b>",
"     Oral: Administer 8.3 mg/kg/week (5 mg/kg base) on the same day each week (not to exceed 500 mg/dose [300 mg base/dose]); begin 1-2 weeks prior to exposure; continue while in endemic area and for 4 weeks after leaving endemic area (CDC, 2010)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Malaria treatment:",
"     </b>",
"     Oral: 16.6 mg/kg (10 mg/kg base) on day 1 (maximum: 1000 mg [600 mg base]), followed by 8.3 mg/kg (5 mg/kg base) (maximum: 500 mg [300 mg base]) 6-, 24-, and 48 hours after first dose (CDC, 2009)",
"    </p>",
"   </div>",
"   <div class=\"block doe drugH1Div\" id=\"F149787\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosing: Geriatric",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Refer to adult dosing.",
"    </p>",
"   </div>",
"   <div class=\"block dor drugH1Div\" id=\"F149788\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosing: Renal Impairment",
"    </span>",
"    <p style=\"text-indent:0em;margin-left:0em;margin-top:0em;text-align:justify;display:inline\">",
"     The FDA-approved labeling does not contain renal dosing adjustment guidelines; the following guidelines have been used by some clinicians (Arnoff, 2007):",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;margin-top:0em;text-align:justify;\">",
"     Cl",
"     <sub>",
"      cr",
"     </sub>",
"     &ge;10 mL/minute: No dosage adjustment needed.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;margin-top:0em;text-align:justify;\">",
"     Cl",
"     <sub>",
"      cr",
"     </sub>",
"     &lt;10 mL/minute: Administer 50% of dose.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Hemodialysis effects: Minimally removed by hemodialysis.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Hemodialysis, peritoneal dialysis: Administer 50% of dose.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Continuous renal replacement therapy (CRRT): Administer 100% of normal dose.",
"    </p>",
"   </div>",
"   <div class=\"block doh drugH1Div\" id=\"F15682601\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosing: Hepatic Impairment",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     No dosage adjustment provided in manufacturer&rsquo;s labeling; use with caution.",
"    </p>",
"   </div>",
"   <div class=\"block foc drugH1Div\" id=\"F149758\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosage Forms: U.S.",
"    </span>",
"    <p style=\"text-indent:0em;text-align:justify;display:inline\">",
"     Excipient information presented when available (limited, particularly for generics); consult specific product labeling.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Tablet, oral, as phosphate: 250 mg [equivalent to chloroquine base 150 mg], 500 mg [equivalent to chloroquine base 300 mg]",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Aralen&reg;: 500 mg [equivalent to chloroquine base 300 mg]",
"    </p>",
"   </div>",
"   <div class=\"block geq drugH1Div\" id=\"F149743\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Generic Equivalent Available: U.S.",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Yes",
"    </p>",
"   </div>",
"   <div class=\"block adm drugH1Div\" id=\"F149761\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Administration",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     May be taken with meals to decrease GI upset. Chloroquine phosphate tablets have also been mixed with chocolate syrup or enclosed in gelatin capsules to mask the bitter taste.",
"    </p>",
"   </div>",
"   <div class=\"block use drugH1Div\" id=\"F149759\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Use",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Suppression/chemoprophylaxis or treatment of acute malaria due to susceptible",
"     <i>",
"      Plasmodium malariae, P. vivax, P. ovale, P. falciparum",
"     </i>",
"     ; extraintestinal amebiasis",
"    </p>",
"   </div>",
"   <div class=\"block usu drugH1Div\" id=\"F149823\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Use - Unlabeled",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Rheumatoid arthritis; discoid lupus erythematosus",
"    </p>",
"   </div>",
"   <div class=\"block mst drugH1Div\" id=\"F3195083\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Medication Safety Issues",
"    </span>",
"    <div class=\"collapsible\">",
"     <span class=\"collapsible-title\">",
"      International issues:",
"     </span>",
"     <div class=\"collapsible-wrap\">",
"      <p style=\"text-indent:-2em;margin-left:4em;\">",
"       Aralen [U.S., Mexico] may be confused with Paralen brand name for acetaminophen [Czech Republic]",
"      </p>",
"     </div>",
"    </div>",
"   </div>",
"   <div class=\"block ars drugH1Div\" id=\"F149824\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Adverse Reactions Significant",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Frequency not defined.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Cardiovascular: Cardiomyopathy, ECG changes (rare; including prolonged QRS and QT",
"     <sub>",
"      c",
"     </sub>",
"     intervals), hypotension (rare),  torsade de pointes (rare)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Central nervous system: Agitation, anxiety, confusion, delirium, depression, hallucinations, headache, insomnia, personality changes, polyneuritis, psychosis,",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Dermatologic: Alopecia, erythema multiforme (rare), exfoliative dermatitis (rare), hair bleaching, lichen planus eruptions, photosensitivity, pleomorphic skin eruptions, pruritus, skin/mucosal pigmentary changes (blue-black), Stevens-Johnson syndrome (rare), toxic epidermal necrolysis (rare), urticaria",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Gastrointestinal: Abdominal cramps, anorexia, diarrhea, nausea, vomiting",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Hematologic: Rare cases of agranulocytosis (reversible), aplastic anemia, neutropenia, pancytopenia, thrombocytopenia",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Hepatic: Hepatitis, liver enzymes increased",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Neuromuscular &amp; skeletal: Depression of deep tendon reflexes, myopathy, neuromyopathy, proximal muscle atrophy",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Ocular: Accommodation disturbances, blurred vision, corneal opacities (reversible), nyctalopia, retinopathy (including irreversible changes in some patients long-term or high-dose therapy), visual field defects",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Otic: Hearing reduced (risk increased in patients with pre-existing auditory damage), nerve deafness, tinnitus",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Miscellaneous: Anaphylaxis, angioedema",
"    </p>",
"   </div>",
"   <div class=\"block coi drugH1Div\" id=\"F149765\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Contraindications",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Hypersensitivity to 4-aminoquinoline compounds (eg, chloroquine, hydroxychloroquine) or any component of the formulation; retinal or visual field changes",
"    </p>",
"   </div>",
"   <div class=\"block war drugH1Div\" id=\"F149747\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Warnings/Precautions",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      <i>",
"       Concerns related to adverse effects:",
"      </i>",
"     </b>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Cardiovascular: Chloroquine has been associated with ECG changes, AV block, and cardiomyopathy (rare). Generally these are dose and/or duration dependent. May cause QT prolongation and subsequent torsade de pointes; avoid use in patients with diagnosed or suspected congenital long QT syndrome.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Hematologic: Aminoquinolones have been associated with rare hematologic reactions including agranulocytosis, aplastic anemia, and thrombocytopenia; monitoring (CBC) is recommended in prolonged therapy.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Neuromuscular: Myopathy, neuromyopathy, and progressive weakness have been reported with aminoquinolones (chloroquine); muscle strength (especially proximal muscles) should be assessed periodically during prolonged therapy.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Ophthalmic effects: Retinopathy has occurred with chloroquine; effect is duration- and dose-related and may be reversible if detected early. Other effects include blurred vision or keratopathy. Monitoring is required. Discontinue immediately if signs/symptoms occur; visual changes may progress even after therapy discontinued.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      <i>",
"       Disease-related concerns:",
"      </i>",
"     </b>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Auditory damage: Use with caution in patients with pre-existing auditory damage; discontinue immediately if hearing defects are noted.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; G6PD deficiency: Use with caution in patients with known G6PD; use of 4-aminoquinolines such as chloroquine has been associated with hemolysis and renal impairment  in this population.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Hepatic impairment: Use with caution in patients with hepatic impairment, alcoholism, or concurrent therapy with hepatotoxic agents.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Porphyria: Use with caution in patients with porphyria; may exacerbate disease symptoms.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Psoriasis: Use with caution in patients with psoriasis; may exacerbate disease symptoms.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Seizure disorder: Use with caution in patients with a history of seizure disorder; may cause seizures.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      <i>",
"       Concurrent drug therapy issues:",
"      </i>",
"     </b>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Drugs with QT prolongation potential: Avoid concurrent use with other drugs known to prolong QT",
"     <sub>",
"      c",
"     </sub>",
"     interval.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      <i>",
"       Other warnings/precautions:",
"      </i>",
"     </b>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Appropriate use: Also consult current CDC guidelines for treatment recommendations.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Safety:",
"     <b>",
"      [U.S. Boxed Warning]: Physicians should be familiar with chloroquine before prescribing.",
"     </b>",
"    </p>",
"   </div>",
"   <div class=\"block cyt drugH1Div\" id=\"F149821\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Metabolism/Transport Effects",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     <b>",
"      Substrate",
"     </b>",
"     of CYP2D6 (major), CYP3A4 (major);",
"     <b>",
"      Note:",
"     </b>",
"     Assignment of Major/Minor substrate status based on clinically relevant drug interaction potential;",
"     <b>",
"      Inhibits",
"     </b>",
"     CYP2D6 (moderate)",
"    </p>",
"   </div>",
"   <div class=\"block dri drugH1Div\" id=\"F149752\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Drug Interactions",
"    </span>",
"    <br/>",
"    <br/>",
"    <div class=\"lexi\" id=\"lexiInteractAddInfo\">",
"     (For additional information:",
"     <a class=\"dip\" href=\"./drug-interaction\" target=\"_blank\">",
"      Launch Lexi-Interact&trade; Drug Interactions Program",
"     </a>",
"     )",
"    </div>",
"    <div class=\"lexi\" id=\"lexiInteractImgB\">",
"     <img border=\"0\" height=\"17\" src=\"./../images/lexiComp/Lexicomp_2012_71x17.myextg\" width=\"71\"/>",
"    </div>",
"    <div class=\"clear\">",
"    </div>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Abiraterone Acetate: May increase the serum concentration of CYP2D6 Substrates. Management: Avoid concurrent use of abiraterone with CYP2D6 substrates that have a narrow therapeutic index whenever possible.  When concurrent use is not avoidable, monitor patients closely for signs/symptoms of toxicity.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Agalsidase Alfa: Chloroquine may diminish the therapeutic effect of Agalsidase Alfa.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Agalsidase Beta: Chloroquine may diminish the therapeutic effect of Agalsidase Beta.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Ampicillin: Chloroquine may decrease the serum concentration of Ampicillin.  Management: Chloroquine prescribing information recommends separating administration of ampicillin and chloroquine by at least 2 hours to minimize any potential negative impact of chloroquine on ampicillin bioavailability.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Antacids: May decrease the serum concentration of Chloroquine. Management: Separate administration of antacids and chloroquine by at least 4 hours to minimize any potential negative impact of antacids on chloroquine bioavailability.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Anthelmintics: Aminoquinolines (Antimalarial) may decrease the serum concentration of Anthelmintics.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Antipsychotic Agents (Phenothiazines): Antimalarial Agents may increase the serum concentration of Antipsychotic Agents (Phenothiazines).",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     ARIPiprazole: CYP2D6 Inhibitors (Moderate) may increase the serum concentration of ARIPiprazole.  Management: Monitor for increased aripiprazole pharmacologic effects. Aripiprazole dose adjustments may or may not be required based on concomitant therapy and/or indication. Consult full interaction monograph for specific recommendations.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Artemether: May enhance the adverse/toxic effect of Antimalarial Agents. Management: Artemether/Lumefantrine (combination product) should not be used with other antimalarials unless there is no other treatment option.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Beta-Blockers: Aminoquinolines (Antimalarial) may decrease the metabolism of Beta-Blockers.",
"     <b>",
"      Exceptions:",
"     </b>",
"     Atenolol; Carteolol (Ophthalmic); Levobunolol; Metipranolol; Nadolol.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Cardiac Glycosides: Aminoquinolines (Antimalarial) may increase the serum concentration of Cardiac Glycosides.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Codeine: CYP2D6 Inhibitors (Moderate) may diminish the therapeutic effect of Codeine. These CYP2D6 inhibitors may prevent the metabolic conversion of codeine to its active metabolite morphine.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Conivaptan: May increase the serum concentration of CYP3A4 Substrates.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     CYP2D6 Inhibitors (Moderate): May decrease the metabolism of CYP2D6 Substrates.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     CYP2D6 Inhibitors (Strong): May decrease the metabolism of CYP2D6 Substrates.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     CYP2D6 Substrates: CYP2D6 Inhibitors (Moderate) may decrease the metabolism of CYP2D6 Substrates.",
"     <b>",
"      Exceptions:",
"     </b>",
"     Tamoxifen.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     CYP3A4 Inducers (Strong): May increase the metabolism of CYP3A4 Substrates. Management: Consider an alternative for one of the interacting drugs. Some combinations may be specifically contraindicated. Consult appropriate manufacturer labeling.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     CYP3A4 Inhibitors (Moderate): May decrease the metabolism of CYP3A4 Substrates.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     CYP3A4 Inhibitors (Strong): May decrease the metabolism of CYP3A4 Substrates.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Dapsone (Systemic): Antimalarial Agents may enhance the adverse/toxic effect of Dapsone (Systemic). Specifically, concomitant use of antimalarial agents with dapsone may increase the risk of hemolytic reactions. Dapsone (Systemic) may enhance the adverse/toxic effect of Antimalarial Agents. Specifically, concomitant use of dapsone with antimalarial agents may increase the risk for hemolytic reactions.  Management: Closely monitor patients for signs/symptoms of hemolytic reactions with concomitant use of dapsone and antimalarial agents, particularly in patients deficient in glucose-6-phosphate dehydrogenase (G6PD), methemoglobin reductase, or with hemoglobin M.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Dapsone (Topical): Antimalarial Agents may enhance the adverse/toxic effect of Dapsone (Topical). Specifically, the risk of hemolytic reactions may be increased.  Management: Closely monitor for signs/symptoms of hemolytic reactions with concomitant use of topical dapsone and antimalarial agents. Patients with glucose-6-phosphate dehydrogenase deficiency may be at particularly high risk for adverse hematologic effects.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Darunavir: May increase the serum concentration of CYP2D6 Substrates.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Dasatinib: May increase the serum concentration of CYP3A4 Substrates.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Deferasirox: May decrease the serum concentration of CYP3A4 Substrates.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Fesoterodine: CYP2D6 Inhibitors may increase serum concentrations of the active metabolite(s) of Fesoterodine.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Herbs (CYP3A4 Inducers): May increase the metabolism of CYP3A4 Substrates. Management: Consider avoiding CYP3A4 inducing herbs in order to avoid therapeutic failure of the substrate. Some combinations may be specifically contraindicated. Consult appropriate manufacturer labeling.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Highest Risk QTc-Prolonging Agents: Moderate Risk QTc-Prolonging Agents may enhance the QTc-prolonging effect of Highest Risk QTc-Prolonging Agents.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Ivabradine: May enhance the QTc-prolonging effect of Moderate Risk QTc-Prolonging Agents.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Ivacaftor: May increase the serum concentration of CYP3A4 Substrates.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Kaolin: May decrease the serum concentration of Chloroquine. Management: Separate administration of kaolin and chloroquine by at least 4 hours to minimize any potential negative impact of kaolin on chloroquine bioavailability.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Lanthanum: May decrease the serum concentration of Chloroquine. Management: Administer chloroquine at least two hours before or after lanthanum.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Lumefantrine: Antimalarial Agents may enhance the adverse/toxic effect of Lumefantrine.  Management: Artemether/Lumefantrine (combination product) should not be used with other antimalarials unless there is no other treatment option.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Mefloquine: Aminoquinolines (Antimalarial) may enhance the adverse/toxic effect of Mefloquine. Specifically, the risk for QTc-prolongation and the risk for convulsions may be increased. Mefloquine may increase the serum concentration of Aminoquinolines (Antimalarial).  Management: Avoid concurrent use, and delay administration of mefloquine until at least 12 hours after the last dose of an aminoquinoline antimalarial when possible.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Metoprolol: CYP2D6 Inhibitors may increase the serum concentration of Metoprolol.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Mifepristone: May enhance the QTc-prolonging effect of Moderate Risk QTc-Prolonging Agents.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Moderate Risk QTc-Prolonging Agents: May enhance the QTc-prolonging effect of other Moderate Risk QTc-Prolonging Agents. Management: Avoid such combinations when possible.  Use should be accompanied by close monitoring for evidence of QT prolongation or other alterations of cardiac rhythm.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Peginterferon Alfa-2b: May decrease the serum concentration of CYP2D6 Substrates.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Prilocaine: Methemoglobinemia Associated Agents may enhance the adverse/toxic effect of Prilocaine. Combinations of these agents may increase the likelihood of significant methemoglobinemia.  Management: Monitor patients for signs of methemoglobinemia (e.g., hypoxia, cyanosis) when prilocaine is used in combination with other agents associated with development of methemoglobinemia.  Avoid lidocaine/prilocaine in infants receiving such agents.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     QTc-Prolonging Agents (Indeterminate Risk and Risk Modifying): May enhance the QTc-prolonging effect of Moderate Risk QTc-Prolonging Agents.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Rabies Vaccine: Chloroquine may diminish the therapeutic effect of Rabies Vaccine.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Tamoxifen: CYP2D6 Inhibitors (Moderate) may decrease serum concentrations of the active metabolite(s) of Tamoxifen. Specifically, CYP2D6 inhibitors may decrease the metabolic formation of highly potent active metabolites.  Management: Consider alternatives with less of an inhibitory effect on CYP2D6 activity when possible.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Thioridazine: CYP2D6 Inhibitors may decrease the metabolism of Thioridazine.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Tocilizumab: May decrease the serum concentration of CYP3A4 Substrates.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     TraMADol: CYP2D6 Inhibitors (Moderate) may diminish the therapeutic effect of TraMADol. These CYP2D6 inhibitors may prevent the metabolic conversion of tramadol to its active metabolite that accounts for much of its opioid-like effects.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"   </div>",
"   <div class=\"block foi drugH1Div\" id=\"F149778\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Ethanol/Nutrition/Herb Interactions",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Ethanol: Avoid ethanol (may increase GI irritation).",
"    </p>",
"   </div>",
"   <div class=\"block pri drugH1Div\" id=\"F149768\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pregnancy Implications",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     There are no adequate and well-controlled studies using chloroquine during pregnancy. However, based on clinical experience and because malaria infection in pregnant women may be more severe than in nonpregnant women, chloroquine prophylaxis may be considered in areas of chloroquine-sensitive",
"     <i>",
"      P. falciparum",
"     </i>",
"     malaria. Pregnant women should be advised not to travel to areas of",
"     <i>",
"      P. falciparum",
"     </i>",
"     resistance to chloroquine. Consult current CDC guidelines for the treatment of malaria during pregnancy.",
"    </p>",
"   </div>",
"   <div class=\"block lac drugH1Div\" id=\"F149792\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Lactation",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Enters breast milk/not recommended (AAP considers &ldquo;compatible&rdquo;; AAP 2001 update pending)",
"    </p>",
"   </div>",
"   <div class=\"block dic drugH1Div\" id=\"F149769\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dietary Considerations",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     May be taken with meals to decrease GI upset.",
"    </p>",
"   </div>",
"   <div class=\"block fee drugH1Div\" id=\"F149767\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pricing: U.S. (Medi-Span&reg;)",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Tablets",
"     </b>",
"     (Aralen Oral)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     500 mg (25): $194.39",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Tablets",
"     </b>",
"     (Chloroquine Phosphate Oral)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     250 mg (50): $123.00",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     500 mg (25): $135.00",
"    </p>",
"   </div>",
"   <div class=\"block mop drugH1Div\" id=\"F149756\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Monitoring Parameters",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Ophthalmic exams at baseline and every 3 months during prolonged therapy. Visual acuity, slit-lamp, fundoscopic and visual field examination are recommended. Evaluate neuromuscular function during prolonged therapy. Periodic CBC in patients receiving prolonged therapy",
"    </p>",
"   </div>",
"   <div class=\"list fbnlist drugH1Div drugBrandNames\" id=\"F149770\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     International Brand Names",
"    </span>",
"    <ul>",
"     <li>",
"      Aralen (MX);",
"     </li>",
"     <li>",
"      Aralen Phosphate (AE, BF, BH, BJ, CI, CO, CY, EC, EG, ET, GH, GM, GN, IL, IQ, IR, JO, KE, KW, LB, LR, LY, MA, ML, MR, MU, MW, NE, NG, OM, PE, QA, SA, SC, SD, SL, SN, SY, TN, TZ, UG, YE, ZA, ZM, ZW);",
"     </li>",
"     <li>",
"      Arechin (PL);",
"     </li>",
"     <li>",
"      Avloclor (BF, BJ, CI, ET, GB, GH, GM, GN, IE, KE, LR, MA, ML, MR, MU, MW, NE, NG, SC, SD, SL, SN, TN, TZ, UG, ZA, ZM, ZW);",
"     </li>",
"     <li>",
"      Cadiquin (BF, BJ, CI, ET, GH, GM, GN, KE, LR, MA, ML, MR, MU, MW, NE, NG, SC, SD, SL, SN, TN, TZ, UG, ZA, ZM, ZW);",
"     </li>",
"     <li>",
"      Chemochin (HR);",
"     </li>",
"     <li>",
"      Chlorochin (CH, HR);",
"     </li>",
"     <li>",
"      Chlorofoz (PH);",
"     </li>",
"     <li>",
"      Chloromax (PH);",
"     </li>",
"     <li>",
"      Chloroquini Diphosphas (NL);",
"     </li>",
"     <li>",
"      Chlorquin (AU, NZ);",
"     </li>",
"     <li>",
"      Cidanchin (ES);",
"     </li>",
"     <li>",
"      Clo-Kit Junior (IN);",
"     </li>",
"     <li>",
"      Clorochina Bayer (IT);",
"     </li>",
"     <li>",
"      Clorochina Bifosfato (IT);",
"     </li>",
"     <li>",
"      Cloroquina Llorente (ES);",
"     </li>",
"     <li>",
"      Delagil (BB, BM, BS, BZ, CZ, GY, HN, HU, JM, PR, RU, SR, TT);",
"     </li>",
"     <li>",
"      Dichinalex (IT);",
"     </li>",
"     <li>",
"      Diclokin (BR);",
"     </li>",
"     <li>",
"      Diroquine (TH);",
"     </li>",
"     <li>",
"      Dolquine (SG);",
"     </li>",
"     <li>",
"      Emquin (IN);",
"     </li>",
"     <li>",
"      Genocin (TH);",
"     </li>",
"     <li>",
"      Haloxin (SG);",
"     </li>",
"     <li>",
"      Heliopar (FI);",
"     </li>",
"     <li>",
"      Klarquine (PK);",
"     </li>",
"     <li>",
"      Klorokinfosfat (NO, SE);",
"     </li>",
"     <li>",
"      Lagaquin (BB, BF, BJ, BM, BS, BZ, CI, ET, GH, GM, GN, GY, JM, KE, LR, MA, ML, MR, MU, MW, NE, NG, PR, SC, SD, SL, SN, SR, TN, TT, TZ, UG, ZA, ZM, ZW);",
"     </li>",
"     <li>",
"      Malachlo (KP);",
"     </li>",
"     <li>",
"      Malaquin (AE, BH, CY, EG, IL, IQ, IR, JO, KW, LB, LY, OM, QA, SA, SY, YE);",
"     </li>",
"     <li>",
"      Malarex (AE, BH, CY, DK, EG, ID, IL, IQ, IR, JO, KW, LB, LY, MY, OM, PH, QA, SA, SY, YE);",
"     </li>",
"     <li>",
"      Malarivon (BB, BM, BS, BZ, GY, JM, PR, SR, TT);",
"     </li>",
"     <li>",
"      Malaviron (BF, BJ, CI, ET, GH, GM, GN, KE, LR, MA, ML, MR, MU, MW, NE, NG, SC, SD, SL, SN, TN, TZ, UG, ZA, ZM, ZW);",
"     </li>",
"     <li>",
"      Maquine (AE, BH, CY, EG, IL, IQ, IR, JO, KW, LB, LY, OM, QA, SA, SY, YE);",
"     </li>",
"     <li>",
"      Nivaquine (AR, BE, FR, LU);",
"     </li>",
"     <li>",
"      Resochin (AE, AT, BF, BG, BH, BJ, CI, CY, DE, EG, ES, ET, GH, GM, GN, HR, IL, IN, IQ, IR, IT, JO, KE, KW, LB, LR, LY, MA, ML, MR, MU, MW, NE, NG, NL, OM, QA, SA, SC, SD, SL, SN, SY, TN, TZ, UG, YE, ZA, ZM, ZW);",
"     </li>",
"     <li>",
"      Resochina (PT)",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"block pha drugH1Div\" id=\"F149746\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Mechanism of Action",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Binds to and inhibits DNA and RNA polymerase; interferes with metabolism and hemoglobin utilization by parasites; inhibits prostaglandin effects; chloroquine concentrates within parasite acid vesicles and raises internal pH resulting in inhibition of parasite growth; may involve aggregates of ferriprotoporphyrin IX acting as chloroquine receptors causing membrane damage; may also interfere with nucleoprotein synthesis",
"    </p>",
"   </div>",
"   <div class=\"block phk drugH1Div\" id=\"F149764\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pharmacodynamics/Kinetics",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Duration: Small amounts may be present in urine months following discontinuation of therapy",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Absorption: Oral: Rapid (~89%)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Distribution: Widely in body tissues (eg, brain, eyes, heart, kidneys, leukocytes, liver, lungs, spleen) where retention prolonged",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Protein binding: 55%",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Metabolism: Partially hepatic",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Half-life elimination: 3-5 days",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Time to peak, serum: 1-2 hours",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Excretion: Urine (~70% as unchanged drug); acidification of urine increases elimination",
"    </p>",
"   </div>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <h1>",
"    REFERENCES",
"   </h1>",
"   <ol id=\"reference\">",
"    <li>",
"     <div class=\"reference\">",
"      American Academy of Pediatrics Committee on Drugs, &ldquo;Transfer of Drugs and Other Chemicals Into Human Milk,&rdquo;",
"      <i>",
"       Pediatrics",
"      </i>",
"      , 2001, 108(3):776-89.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?24/54/25447/abstract-text/11533352/pubmed\" id=\"11533352\" target=\"_blank\">",
"        11533352",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Aronoff GR, Bennett WM, Berns JS, et al,",
"      <i>",
"       Drug Prescribing in Renal Failure: Dosing Guidelines for Adults and Children",
"      </i>",
"      , 5th ed. Philadelphia, PA: American College of Physicians; 2007, p 73.",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Avina-Zubieta JA, Johnson ES, Suarez-Almazor ME, et al, &ldquo;Incidence of Myopathy in Patients Treated With Antimalarials. A Report of Three Cases and a Review of the Literature,&rdquo;",
"      <i>",
"       Br J Rheumatol",
"      </i>",
"      , 1995, 34(2):166-70.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?24/54/25447/abstract-text/7704464/pubmed\" id=\"7704464\" target=\"_blank\">",
"        7704464",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Centers for Disease Control and Prevention, &ldquo;Guidelines for the Prevention and Treatment of Opportunistic Infections Among HIV-Exposed and HIV-Infected Children: Recommendations from CDC, the National Institutes of Health, the HIV Medicine Association of the Infectious Diseases Society of America, the Pediatric Infectious Diseases Society, and the American Academy of Pediatrics,&rdquo;",
"      <i>",
"       MMWR Recomm Rep",
"      </i>",
"      , 2009, 58(RR-11):1-166. Available at",
"      <a href=\"file://aidsinfo.nih.gov/contentfiles/Pediatric_OI.pdf\" target=\"_blank\">",
"       file://aidsinfo.nih.gov/contentfiles/Pediatric_OI.pdf",
"      </a>",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?24/54/25447/abstract-text/19730409/pubmed\" id=\"19730409\" target=\"_blank\">",
"        19730409",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Centers for Disease Control and Prevention (CDC), &ldquo;Guidelines for Treatment of Malaria in the United States,&rdquo; Treatment Table Update, September 23, 2011. Available at",
"      <a href=\"file://www.cdc.gov/malaria/resources/pdf/treatmenttable.pdf\" target=\"_blank\">",
"       file://www.cdc.gov/malaria/resources/pdf/treatmenttable.pdf",
"      </a>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Centers for Disease Control and Prevention (CDC), &ldquo;The Pre-Travel Consultation, Malaria.&rdquo; Available at",
"      <a href=\"file://wwwnc.cdc.gov/travel/yellowbook/2010/chapter-2/malaria.htm\" target=\"_blank\">",
"       file://wwwnc.cdc.gov/travel/yellowbook/2010/chapter-2/malaria.htm",
"      </a>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Centers for Disease Control and Prevention (CDC), &ldquo;Treatment of Malaria (Guidelines for Clinicians).&rdquo; Available at",
"      <a href=\"file://www.cdc.gov/malaria/resources/pdf/clinicalguidance.pdf\" target=\"_blank\">",
"       file://www.cdc.gov/malaria/resources/pdf/clinicalguidance.pdf",
"      </a>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Freedman, DO, \"Clinical Practice. Malaria Prevention in Short-Term Travelers,\"",
"      <i>",
"       N Engl J Med",
"      </i>",
"      , 2008, 359(6):603-612.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?24/54/25447/abstract-text/18687641/pubmed\" id=\"18687641\" target=\"_blank\">",
"        18687641",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Hill DR, Ericsson CD, Pearson RD, et al, &ldquo;The Practice of Travel Medicine: Guidelines by the Infectious Diseases Society of America,&rdquo;",
"      <i>",
"       Clin Infect Dis",
"      </i>",
"      , 2006, 43(12):1499-539.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?24/54/25447/abstract-text/17109284/pubmed\" id=\"17109284\" target=\"_blank\">",
"        17109284",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Liu AC, &ldquo;Hepatotoxic Reaction to Chloroquine Phosphate in a Patient With Previously Unrecognized Porphyria Cutanea Tarda,&rdquo;",
"      <i>",
"       West J Med",
"      </i>",
"      , 1995, 162(6):548-51.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?24/54/25447/abstract-text/7618323/pubmed\" id=\"7618323\" target=\"_blank\">",
"        7618323",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Mirochnick M, Barnett E, Clarke DF, et al, &ldquo;Stability of Chloroquine in an Extemporaneously Prepared Suspension Stored at Three Temperatures,&rdquo;",
"      <i>",
"       Pediatr Infect Dis J",
"      </i>",
"      , 1994, 13(9):827-8.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?24/54/25447/abstract-text/7808855/pubmed\" id=\"7808855\" target=\"_blank\">",
"        7808855",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      van den Borne BE, Landewe RB, Rietveld JH, et al, &ldquo;Chloroquine Therapy in Patients With Recent-Onset Rheumatoid Arthritis: The Clinical Response Can Be Predicted by the Low Level of Acute-Phase Reaction at Baseline,&rdquo;",
"      <i>",
"       Clin Rheumatol",
"      </i>",
"      , 1999, 18(5):369-72.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?24/54/25447/abstract-text/10524550/pubmed\" id=\"10524550\" target=\"_blank\">",
"        10524550",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      White NJ, &ldquo;Cardiotoxicity of Antimalarial Drugs,&rdquo;",
"      <i>",
"       Lancet Infect Dis",
"      </i>",
"      , 2007, 7(8):549-58.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?24/54/25447/abstract-text/17646028/pubmed\" id=\"17646028\" target=\"_blank\">",
"        17646028",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Yap YG and Camm AJ, &ldquo;Drug Induced QT Prolongation and Torsades de Pointes,&rdquo;",
"      <i>",
"       Heart",
"      </i>",
"      , 2003, 89(11):1363-72.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?24/54/25447/abstract-text/14594906/pubmed\" id=\"14594906\" target=\"_blank\">",
"        14594906",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"   </ol>",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 9247 Version 42.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.6- C21.56",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     AsanBook Dig. Med. Lib.",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [1005-183.1.191.153-B28792CD2A-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f24_54_25447=[""].join("\n");
var outline_f24_54_25447=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F7885889\">",
"      ALERT: U.S. Boxed Warning",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F149782\">",
"      Brand Names: U.S.",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F149783\">",
"      Brand Names: Canada",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F149826\">",
"      Pharmacologic Category",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F149786\">",
"      Dosing: Adult",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F149806\">",
"      Dosing: Pediatric",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F149787\">",
"      Dosing: Geriatric",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F149788\">",
"      Dosing: Renal Impairment",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F15682601\">",
"      Dosing: Hepatic Impairment",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F149758\">",
"      Dosage Forms: U.S.",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F149743\">",
"      Generic Equivalent Available: U.S.",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F149761\">",
"      Administration",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F149759\">",
"      Use",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F149823\">",
"      Use - Unlabeled",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F3195083\">",
"      Medication Safety Issues",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F149824\">",
"      Adverse Reactions Significant",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F149765\">",
"      Contraindications",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F149747\">",
"      Warnings/Precautions",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F149821\">",
"      Metabolism/Transport Effects",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F149752\">",
"      Drug Interactions",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F149778\">",
"      Ethanol/Nutrition/Herb Interactions",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F149768\">",
"      Pregnancy Implications",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F149792\">",
"      Lactation",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F149769\">",
"      Dietary Considerations",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F149767\">",
"      Pricing: U.S. (Medi-Span&reg;)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F149756\">",
"      Monitoring Parameters",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F149770\">",
"      International Brand Names",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F149746\">",
"      Mechanism of Action",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F149764\">",
"      Pharmacodynamics/Kinetics",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a href=\"#references\">",
"      REFERENCES",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   <div class=\"openRelatedGraphics\" id=\"DRUG_GEN/9247\" rel=\"outline_link\">",
"    GRAPHICS",
"    <a class=\"graphics_icon\" href=\"#\" title=\"View All Related Graphics\">",
"     View All",
"    </a>",
"   </div>",
"  </h1>",
"  <div id=\"relatedGraphics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"DRUG_GEN/9247|TAB\">",
"      <a href=\"#\" title=\"TABLES\">",
"       TABLES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?23/39/24183\" title=\"Lexicomp clinical abbreviations\">",
"      Lexicomp clinical abbreviations",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"drug drug_patient\" href=\"UTD.htm?1/35/1589?source=related_link\">",
"      Chloroquine: Patient drug information",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"drug drug_pediatric\" href=\"UTD.htm?39/53/40790?source=related_link\">",
"      Chloroquine: Pediatric drug information",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f24_54_25448="Selegiline: Drug information";
var content_f24_54_25448=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/wk_utd-rgb.myextg\" width=\"220px\">",
"   </img>",
"  </div>",
"  <div id=\"printHeaderText\">",
"   Official reprint from  UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"   <a href=\"file://www.uptodate.com\">",
"    www.uptodate.com",
"   </a>",
"   <br>",
"    &copy;2013 UpToDate",
"    <sup>",
"     &reg;",
"    </sup>",
"   </br>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"3\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"drugTitle\">",
"   Selegiline: Drug information",
"  </div>",
"  <div id=\"lexiTitleImg\">",
"   <img height=\"17\" src=\"./../images/lexiComp/Lexicomp_2012_71x17.myextg\" width=\"71\"/>",
"  </div>",
"  <div class=\"clear\">",
"  </div>",
"  <div id=\"drugCopy\">",
"   Copyright 1978-2013 Lexicomp, Inc. All rights reserved.",
"  </div>",
"  <div id=\"topicText\">",
"   (For additional information",
"   <a class=\"drug drug_patient\" href=\"UTD.htm?17/52/18246?source=see_link\">",
"    see \"Selegiline: Patient drug information\"",
"   </a>",
"   )",
"   <br/>",
"   For abbreviations and symbols that may be used in Lexicomp (",
"   <a class=\"graphic graphic_table\" href=\"UTD.htm?23/39/24183\">",
"    show table",
"   </a>",
"   )",
"   <div class=\"block black-box-warn drugH1Div\" id=\"F5709409\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     ALERT: U.S. Boxed Warning",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     The FDA-approved labeling includes a boxed warning. See Warnings/Precautions section for a concise summary of this information.  For verbatim wording of the boxed warning, consult the product labeling or",
"     <a href=\"file://www.fda.gov\" target=\"_blank\">",
"      www.fda.gov",
"     </a>",
"     .",
"    </p>",
"   </div>",
"   <div class=\"list ubnlist drugH1Div drugBrandNames\" id=\"F220310\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Brand Names: U.S.",
"    </span>",
"    <ul>",
"     <li>",
"      Eldepryl&reg;;",
"     </li>",
"     <li>",
"      Emsam&reg;;",
"     </li>",
"     <li>",
"      Zelapar&reg;",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"list cbnlist drugH1Div drugBrandNames\" id=\"F220311\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Brand Names: Canada",
"    </span>",
"    <ul>",
"     <li>",
"      Apo-Selegiline&reg;;",
"     </li>",
"     <li>",
"      Gen-Selegiline;",
"     </li>",
"     <li>",
"      Mylan-Selegiline;",
"     </li>",
"     <li>",
"      Novo-Selegiline;",
"     </li>",
"     <li>",
"      Nu-Selegiline",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ex_sect_xr thclist drugH1Div drugBrandNames\" id=\"F220352\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pharmacologic Category",
"    </span>",
"    <ul>",
"     <li>",
"      Anti-Parkinson's Agent, MAO Type B Inhibitor;",
"     </li>",
"     <li>",
"      Antidepressant, Monoamine Oxidase Inhibitor",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"block doa drugH1Div\" id=\"F220315\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosing: Adult",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Parkinson&rsquo;s disease:",
"     </b>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Capsule/tablet: 5 mg twice daily with breakfast and lunch",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Orally disintegrating tablet (Zelapar&reg;): Initial 1.25 mg daily for at least 6 weeks; may increase to 2.5 mg daily based on clinical response (maximum: 2.5 mg daily)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     <b>",
"      Depression:",
"     </b>",
"     Transdermal (Emsam&reg;): Initial: 6 mg/24 hours once daily; may titrate based on clinical response in increments of 3 mg/day every 2 weeks up to a maximum of 12 mg/24 hours",
"    </p>",
"   </div>",
"   <div class=\"block dop drugH1Div\" id=\"F220329\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosing: Pediatric",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     <b>",
"      ADHD",
"     </b>",
"     (unlabeled use): Children and Adolescents: Oral: 5-15 mg/day (Jankovic, 1993)",
"    </p>",
"   </div>",
"   <div class=\"block doe drugH1Div\" id=\"F220316\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosing: Geriatric",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     <b>",
"      Parkinson's disease:",
"     </b>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;\">",
"     Capsule/tablet: &le;5 mg/day (when combined with levodopa) is recommended by some clinicians to decrease the enhanced dopaminergic side effects  (Olanow, 2001)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;\">",
"     Orally disintegrating tablet (Zelapar&reg;): Refer to adult dosing",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     <b>",
"      Depression:",
"     </b>",
"     Transdermal (Emsam&reg;): 6 mg/24 hours",
"    </p>",
"   </div>",
"   <div class=\"block dor drugH1Div\" id=\"F2730980\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosing: Renal Impairment",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Oral: Use caution, has not been studied.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Transdermal: No adjustment required in patients with mild-to-moderate impairment.",
"    </p>",
"   </div>",
"   <div class=\"block doh drugH1Div\" id=\"F2730981\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosing: Hepatic Impairment",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Oral: Use caution, has not been studied.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Transdermal: No adjustment required in patients with mild-to-moderate impairment.",
"    </p>",
"   </div>",
"   <div class=\"block foc drugH1Div\" id=\"F220292\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosage Forms: U.S.",
"    </span>",
"    <p style=\"text-indent:0em;text-align:justify;display:inline\">",
"     Excipient information presented when available (limited, particularly for generics); consult specific product labeling.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Capsule, oral, as hydrochloride: 5 mg",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Eldepryl&reg;: 5 mg",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Patch, transdermal:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Emsam&reg;: 6 mg/24 hours (30s) [20 cm",
"     <sup>",
"      2",
"     </sup>",
"     , total selegiline 20 mg]",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Emsam&reg;: 9 mg/24 hours (30s) [30 cm",
"     <sup>",
"      2",
"     </sup>",
"     , total selegiline 30 mg]",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Emsam&reg;: 12 mg/24 hours (30s) [40 cm",
"     <sup>",
"      2",
"     </sup>",
"     , total selegiline 40 mg]",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Tablet, oral, as hydrochloride: 5 mg",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Tablet, orally disintegrating, oral, as hydrochloride:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Zelapar&reg;: 1.25 mg [contains phenylalanine 1.25 mg/tablet; grapefruit flavor]",
"    </p>",
"   </div>",
"   <div class=\"block geq drugH1Div\" id=\"F220278\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Generic Equivalent Available: U.S.",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Yes: Capsule, tablet",
"    </p>",
"   </div>",
"   <div class=\"block meg drugH1Div\" id=\"F7874988\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Medication Guide",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     An FDA-approved patient medication guide, which is available with the product information and as follows, must be dispensed with this medication:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;\">",
"     Emsam&reg;:",
"     <a href=\"file://www.fda.gov/downloads/Drugs/DrugSafety/ucm088589.pdf\" target=\"_blank\">",
"      file://www.fda.gov/downloads/Drugs/DrugSafety/ucm088589.pdf",
"     </a>",
"    </p>",
"   </div>",
"   <div class=\"block adm drugH1Div\" id=\"F2730983\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Administration",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Oral: Orally disintegrating tablet (Zelapar&reg;): Take in morning before breakfast; place on top of tongue and allow to dissolve. Avoid food or liquid 5 minutes before and after administration.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Topical: Transdermal (Emsam&reg;): Apply to clean, dry, intact skin to the upper torso (below the neck and above the waist), upper thigh, or outer surface of the upper arm. Avoid exposure of application site to external heat source, which may increase the amount of drug absorbed. Apply at the same time each day and rotate application sites. Wash hands with soap and water after handling. Avoid touching the sticky side of the patch.",
"    </p>",
"   </div>",
"   <div class=\"block use drugH1Div\" id=\"F220295\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Use",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Adjunct in the management of parkinsonian patients in which levodopa/carbidopa therapy is deteriorating (oral products); treatment of major depressive disorder (transdermal product)",
"    </p>",
"   </div>",
"   <div class=\"block usu drugH1Div\" id=\"F220349\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Use - Unlabeled",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Early Parkinson's disease; attention-deficit/hyperactivity disorder (ADHD)",
"    </p>",
"   </div>",
"   <div class=\"block mst drugH1Div\" id=\"F220361\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Medication Safety Issues",
"    </span>",
"    <div class=\"collapsible\">",
"     <span class=\"collapsible-title\">",
"      Sound-alike/look-alike issues:",
"     </span>",
"     <div class=\"collapsible-wrap\">",
"      <p style=\"text-indent:-2em;margin-left:4em;\">",
"       Selegiline may be confused with Salagen&reg;, sertraline, Serzone, Stelazine",
"      </p>",
"      <p style=\"text-indent:-2em;margin-left:4em;\">",
"       Eldepryl&reg; may be confused with Elavil&reg;, enalapril",
"      </p>",
"      <p style=\"text-indent:-2em;margin-left:4em;\">",
"       Zelapar&reg; may be confused with zaleplon, Zemplar&reg;, zolpidem, ZyPREXA&reg; Zydis&reg;",
"      </p>",
"     </div>",
"    </div>",
"   </div>",
"   <div class=\"block ars drugH1Div\" id=\"F220350\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Adverse Reactions Significant",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Unless otherwise noted, the percentage of adverse events is reported for the transdermal patch (",
"     <b>",
"      Note:",
"     </b>",
"     ODT = orally disintegrating tablet, Oral = capsule/tablet)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     &gt;10%:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;\">",
"     Central nervous system: Headache (18%; ODT 7%; oral 4%), insomnia (12%; ODT 7%), dizziness (oral 14%; ODT 11%)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;\">",
"     Gastrointestinal: Nausea (oral 20%; ODT 11%)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Local: Application site reaction (24%)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     1% to 10%:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Cardiovascular: Hypotension (including postural 3% to 10%), palpitation (oral 2%), chest pain (&ge;1%; ODT 2%), hypertension (&ge;1%; ODT 3%), peripheral edema (&ge;1%)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Central nervous system: Pain (ODT 8%; oral 2%), hallucinations (oral 6%; ODT 4%), confusion (oral 6%; ODT 4%), vivid dreams (oral 4%), ataxia (ODT 3%), somnolence (ODT 3%), lethargy (oral 2%), agitation (&ge;1%), amnesia (&ge;1%), paresthesia (&ge;1%), thinking abnormal (&ge;1%), depression (&lt;1%; ODT 2%)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Dermatologic: Rash (4%), bruising (&ge;1%; ODT 2%), pruritus (&ge;1%), acne (&ge;1%)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Endocrine &amp; metabolic: Weight loss (5%; oral 2%), hypokalemia (ODT 2%), sexual side effects (&le;1%)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Gastrointestinal: Diarrhea (9%; ODT 2%; oral 2%), xerostomia (8%; oral 6%; ODT 4%), stomatitis (ODT 5%), abdominal pain (oral 8%), dyspepsia (4%; ODT 5%), dysphagia (ODT 2%), dental caries (ODT 2%), constipation (&ge;1%; ODT 4%), flatulence (&ge;1%; ODT 2%), anorexia (&ge;1%), gastroenteritis (&ge;1%), taste perversion (&ge;1%; ODT 2%), vomiting (&ge;1%; ODT 3%)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Genitourinary: Urinary retention (oral 2%), dysmenorrhea (&ge;1%), metrorrhagia (&ge;1%), UTI (&ge;1%), urinary frequency (&ge;1%)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Neuromuscular &amp; skeletal: Dyskinesia (ODT 6%), back pain (ODT 5%; oral 2%), ataxia (&lt;1%; ODT 3%), leg cramps (ODT 3%; oral 2%), myalgia (&ge;1%; ODT 3%), neck pain (&ge;1%), tremor (&lt;1%; ODT 3%)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Otic: Tinnitus (&ge;1%)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Respiratory: Rhinitis (ODT 7%), pharyngitis (3%; ODT 4%), sinusitis (3%), cough (&ge;1%), bronchitis (&ge;1%), dyspnea (&lt;1%; ODT 3%)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Miscellaneous: Diaphoresis (&ge;1%)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Oral and/or transdermal patch: &lt;1% or frequency not defined (limited to important or life-threatening): Abnormal liver function tests, alkaline phosphatase increased, appetite increased, arrhythmia, asthma, ataxia, atrial fibrillation, bacterial infection, behavior/mood changes, bilirubinemia, bradycardia, bradykinesia, breast neoplasm (female), breast pain, chorea, circumoral paresthesia, colitis, dehydration, delusions, depersonalization, depression, emotional lability, epistaxis, eructation, euphoria, face edema, fever, fungal infection, gastritis, generalized spasm, glossitis, heat stroke, hematuria (female), hernia, hostility, hypercholesterolemia, hyperesthesia, hyperglycemia, hyperkinesias, hypertonia, hypoglycemic reaction, hyponatremia, impulsive/compulsive behaviors (eg, pathological gambling, hypersexuality, binge eating), kidney calculus (female), lactate dehydrogenase increased, laryngismus, leukocytosis, leukopenia, libido increased, loss of balance, lymphadenopathy, maculopapular rash, manic reaction, melena, MI, migraine, moniliasis, myasthenia, myoclonus, neoplasia, neurosis, osteoporosis, otitis external, palpitation, paranoid reaction, parasitic infection, parosmia, pelvic pain, periodontal abscess, peripheral vascular disorder, pneumonia, polyuria (female), prostatic hyperplasia, rectal hemorrhage, salivation increased, skin hypertrophy, skin benign neoplasm, suicide attempt, syncope, tachycardia, tenosynovitis, tongue edema, twitching, urinary retention, urinary urgency (male and female), urination impaired (male), urticaria, vaginal hemorrhage, vaginal moniliasis, vaginitis, vasodilatation, vertigo, vesiculobullous rash, viral infection, visual field defect",
"    </p>",
"   </div>",
"   <div class=\"block coi drugH1Div\" id=\"F220298\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Contraindications",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Hypersensitivity to selegiline or any component of the formulation; concomitant use of meperidine",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Orally disintegrating tablet: Additional contraindications: Concomitant use of dextromethorphan, methadone, propoxyphene, tramadol, oral selegiline, other MAO inhibitors",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Transdermal: Additional contraindications: Pheochromocytoma; concomitant use of bupropion, selective or dual serotonin reuptake inhibitors (including SSRIs and SNRIs), tricyclic antidepressants, tramadol, propoxyphene, methadone, dextromethorphan, St. John&rsquo;s wort, mirtazapine, cyclobenzaprine, oral selegiline and other MAO inhibitors; carbamazepine, and oxcarbazepine; elective surgery requiring general anesthesia, local anesthesia containing sympathomimetic vasoconstrictors; sympathomimetics (and related compounds); foods high in tyramine content; supplements containing tyrosine, phenylalanine, tryptophan, or caffeine",
"    </p>",
"   </div>",
"   <div class=\"block war drugH1Div\" id=\"F220282\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Warnings/Precautions",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      <i>",
"       Major psychiatric warnings (transdermal product):",
"      </i>",
"     </b>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Suicidal thinking/behavior:",
"     <b>",
"      [U.S. Boxed Warning]: Antidepressants increase the risk of suicidal thinking and behavior in children, adolescents, and young adults (18-24 years of age) with major depressive disorder (MDD) and other psychiatric disorders;",
"     </b>",
"     consider risk prior to prescribing. Short-term studies did not show an increased risk in patients &gt;24 years of age and showed a decreased risk in patients &ge;65 years. Closely monitor patients for clinical worsening, suicidality, or unusual changes in behavior, particularly during the initial 1-2 months of therapy or during periods of dosage adjustments (increases or decreases); the patient&rsquo;s family or caregiver should be instructed to closely observe the patient and communicate condition with healthcare provider. A medication guide concerning the use of antidepressants should be dispensed with each prescription.",
"     <b>",
"      Transdermal selegiline is not FDA approved for use in children &lt;12 years of age.",
"     </b>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; The possibility of a suicide attempt is inherent in major depression and may persist until remission occurs. Patients treated with antidepressants should be observed for clinical worsening and suicidality, especially during the initial few months of a course of drug therapy, or at times of dose changes, either increases or decreases. Worsening depression and severe abrupt suicidality that are not part of the presenting symptoms may require discontinuation or modification of drug therapy. Use caution in high-risk patients during initiation of therapy.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Prescriptions should be written for the smallest quantity consistent with good patient care. The patient's family or caregiver should be alerted to monitor patients for the emergence of suicidality and associated behaviors such as anxiety, agitation, panic attacks, insomnia, irritability, hostility, impulsivity, akathisia, hypomania, and mania; patients should be instructed to notify their healthcare provider if any of these symptoms or worsening depression or psychosis occur.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      <i>",
"       Concerns related to adverse effects:",
"      </i>",
"     </b>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Impulse control disorders: Dopaminergic agents used for Parkinson&rsquo;s disease or restless legs syndrome have been associated with compulsive behaviors and/or loss of impulse control, which has manifested as pathological gambling, libido increases (hypersexuality), and/or binge eating. Causality has not been established, and controversy exists as to whether this phenomenon is related to the underlying disease, prior behaviors/addictions and/or drug therapy. Dose reduction or discontinuation of therapy has been reported to reverse these behaviors in some, but not all cases.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Melanoma: Risk for melanoma development is increased in Parkinson&rsquo;s disease patients; drug causation or factors contributing to risk have not been established. Patients should be monitored closely and periodic skin examinations should be performed.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Orthostatic hypotension: Transdermal product may cause orthostatic hypotension; use with caution in patients at risk of this effect or in those who would not tolerate transient hypotensive episodes (cerebrovascular disease, cardiovascular disease, hypovolemia, or concurrent medication use which may predispose to hypotension/bradycardia). Incidence may also be increased in older adults and when titrating to the 2.5 mg dosage in patients taking the orally disintegrating tablet.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      <i>",
"       Disease-related concerns:",
"      </i>",
"     </b>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Hepatic impairment: Use oral products with caution in patients with hepatic impairment; not studied.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Mania/hypomania: Transdermal product: May worsen psychosis in some patients or precipitate a shift to mania or hypomania in patients with bipolar disorder. Monotherapy in patients with bipolar disorder should be avoided. Patients presenting with depressive symptoms should be screened for bipolar disorder.",
"     <b>",
"      Selegiline is not FDA approved for the treatment of bipolar depression.",
"     </b>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Renal impairment: Use oral products with caution in patients with renal impairment; not studied.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      <i>",
"       Concurrent drug therapy issues:",
"      </i>",
"     </b>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Antidepressants: Use of oral selegiline with tricyclic antidepressants and SSRIs has also been associated with rare reactions and should generally be avoided. Transdermal selegiline should not be used in combination with other antidepressants. Do not use within 5 weeks of fluoxetine discontinuation or 2 weeks of other antidepressant discontinuation. Wait 2 weeks after discontinuing transdermal selegiline before initiating therapy with buspirone or any other contraindicated drug.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Levodopa: Addition of oral selegiline to levodopa therapy may result in exacerbation of levodopa adverse effects, requiring a reduction in levodopa dosage.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      <i>",
"       Dosage form specific issues:",
"      </i>",
"     </b>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Orally disintegrating tablet: May cause oral mucosa edema, irritation, pain, ulceration and/or swallowing pain. Do not use concurrently with other selegiline products; wait at least 14 days from discontinuation before initiating treatment with another selegiline dosage form.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Phenylalanine: Some products may contain phenylalanine.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Transdermal patch: May contain conducting metal (eg, aluminum); remove patch prior to MRI. Avoid exposure of application site and surrounding area to direct external heat sources.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      <i>",
"       Other warnings/precautions:",
"      </i>",
"     </b>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Discontinuation of therapy: Medication should not be stopped abruptly; taper off as rapidly as possible.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Elective surgery: Discontinue transdermal product at least 10 days prior to elective surgery.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Tyramine-containing products: Nonselective MAO inhibition occurs with transdermal delivery and is necessary for antidepressant efficacy. Hypertensive crisis as a result of ingesting tyramine-rich foods is always a concern with nonselective MAO inhibition. Although transdermal delivery minimizes inhibition of MAO-A in the gut, there is limited data with higher transdermal doses; dietary modifications are recommended with doses &gt;6 mg/24 hours. With the oral product, MAO-B selective inhibition should not pose a problem with tyramine-containing products as long as the typical oral doses are employed, however, rare reactions have been reported. Increased risk of nonselective MAO inhibition occurs with oral capsule/tablet doses &gt;10 mg/day or orally disintegrating tablet doses &gt;2.5 mg/day.",
"    </p>",
"   </div>",
"   <div class=\"block cyt drugH1Div\" id=\"F220347\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Metabolism/Transport Effects",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     <b>",
"      Substrate",
"     </b>",
"     of CYP1A2 (minor), CYP2A6 (minor), CYP2B6 (major), CYP2C8 (minor), CYP2D6 (minor), CYP3A4 (minor);",
"     <b>",
"      Note:",
"     </b>",
"     Assignment of Major/Minor substrate status based on clinically relevant drug interaction potential;",
"     <b>",
"      Inhibits",
"     </b>",
"     CYP1A2 (weak), CYP2A6 (weak), CYP2C19 (weak), CYP2D6 (weak), CYP2E1 (weak), CYP3A4 (weak), Monoamine Oxidase",
"    </p>",
"   </div>",
"   <div class=\"block dri drugH1Div\" id=\"F220287\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Drug Interactions",
"    </span>",
"    <br/>",
"    <br/>",
"    <div class=\"lexi\" id=\"lexiInteractAddInfo\">",
"     (For additional information:",
"     <a class=\"dip\" href=\"./drug-interaction\" target=\"_blank\">",
"      Launch Lexi-Interact&trade; Drug Interactions Program",
"     </a>",
"     )",
"    </div>",
"    <div class=\"lexi\" id=\"lexiInteractImgB\">",
"     <img border=\"0\" height=\"17\" src=\"./../images/lexiComp/Lexicomp_2012_71x17.myextg\" width=\"71\"/>",
"    </div>",
"    <div class=\"clear\">",
"    </div>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Alpha-/Beta-Agonists (Direct-Acting): MAO Inhibitors may enhance the vasopressor effect of Alpha-/Beta-Agonists (Direct-Acting). Primarily with oral administration of phenylephrine.",
"     <b>",
"      Exceptions:",
"     </b>",
"     Dipivefrin.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Alpha-/Beta-Agonists (Indirect-Acting): MAO Inhibitors may enhance the hypertensive effect of Alpha-/Beta-Agonists (Indirect-Acting).",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Alpha1-Agonists: MAO Inhibitors may enhance the hypertensive effect of Alpha1-Agonists.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Alpha2-Agonists (Ophthalmic): MAO Inhibitors may enhance the hypertensive effect of Alpha2-Agonists (Ophthalmic).",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Altretamine: May enhance the orthostatic hypotensive effect of MAO Inhibitors.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Amphetamines: MAO Inhibitors may enhance the hypertensive effect of Amphetamines.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Anilidopiperidine Opioids: May enhance the serotonergic effect of MAO Inhibitors. This could result in serotonin syndrome. Management: Avoid use of fentanyl (and other anilidopiperidine opioids when possible) in patients who have used a monoamine oxidase inhibitor within the past 14 days due to reports of unpredictable but severe adverse effects.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Antidepressants (Serotonin Reuptake Inhibitor/Antagonist): MAO Inhibitors may enhance the adverse/toxic effect of Antidepressants (Serotonin Reuptake Inhibitor/Antagonist).",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Antihypertensives: MAO Inhibitors may enhance the hypotensive effect of Antihypertensives. MAO Inhibitors may enhance the orthostatic hypotensive effect of Antihypertensives.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Antipsychotics: May enhance the serotonergic effect of Serotonin Modulators. This could result in serotonin syndrome.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     AtoMOXetine: MAO Inhibitors may enhance the neurotoxic (central) effect of AtoMOXetine.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Beta2-Agonists: MAO Inhibitors may enhance the adverse/toxic effect of Beta2-Agonists.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Bezafibrate: MAO Inhibitors may enhance the adverse/toxic effect of Bezafibrate.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Buprenorphine: May enhance the adverse/toxic effect of MAO Inhibitors.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     BuPROPion: MAO Inhibitors may enhance the neurotoxic (central) effect of BuPROPion.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     BusPIRone: May enhance the adverse/toxic effect of MAO Inhibitors. Specifically, blood pressure elevations been reported.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     CarBAMazepine: May enhance the adverse/toxic effect of MAO Inhibitors. Management: Avoid concurrent use of carbamazepine during, or within 14 days of discontinuing, treatment with a monoamine oxidase inhibitor.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     COMT Inhibitors: May enhance the adverse/toxic effect of MAO Inhibitors.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Contraceptives (Estrogens): May increase the serum concentration of Selegiline.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Contraceptives (Progestins): May increase the serum concentration of Selegiline.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Cyclobenzaprine: May enhance the serotonergic effect of MAO Inhibitors. This could result in serotonin syndrome.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     CYP2B6 Inducers (Strong): May increase the metabolism of CYP2B6 Substrates. Management: Consider an alternative for one of the interacting drugs. Some combinations may be specifically contraindicated. Consult appropriate manufacturer labeling.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     CYP2B6 Inhibitors (Moderate): May decrease the metabolism of CYP2B6 Substrates.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     CYP2B6 Inhibitors (Strong): May decrease the metabolism of CYP2B6 Substrates.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Dexmethylphenidate: MAO Inhibitors may enhance the hypertensive effect of Dexmethylphenidate.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Dextromethorphan: MAO Inhibitors may enhance the serotonergic effect of Dextromethorphan. This may cause serotonin syndrome.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Diethylpropion: MAO Inhibitors may enhance the hypertensive effect of Diethylpropion.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Doxapram: MAO Inhibitors may enhance the hypertensive effect of Doxapram.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     HYDROmorphone: MAO Inhibitors may enhance the adverse/toxic effect of HYDROmorphone.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Hypoglycemic Agents: MAO Inhibitors may enhance the hypoglycemic effect of Hypoglycemic Agents.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Ioflupane I 123: Selegiline may diminish the diagnostic effect of Ioflupane I 123.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Levodopa: May enhance the adverse/toxic effect of MAO Inhibitors. Of particular concern is the development of hypertensive reactions when levodopa is used with nonselective MAOI.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Linezolid: MAO Inhibitors may enhance the adverse/toxic effect of Linezolid.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Lithium: MAO Inhibitors may enhance the adverse/toxic effect of Lithium.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Lomitapide: CYP3A4 Inhibitors (Weak) may increase the serum concentration of Lomitapide.  Management: Limit the maximum adult dose of lomitapide to 30 mg daily when used in combination with any weak CYP3A4 inhibitor.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     MAO Inhibitors: May enhance the orthostatic hypotensive effect of Orthostatic Hypotension Producing Agents.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Maprotiline: May enhance the adverse/toxic effect of MAO Inhibitors.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Meperidine: MAO Inhibitors may enhance the serotonergic effect of Meperidine. This may cause serotonin syndrome.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Methadone: MAO Inhibitors may enhance the adverse/toxic effect of Methadone.  Management: Initial safety testing, where small incremental doses of methadone are given with the patient closely monitored (including vitals, etc.), is recommended if methadone is to be used with (or within 14 days of) an MAO inhibitor. Avoid transdermal selegiline.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Methyldopa: MAO Inhibitors may enhance the adverse/toxic effect of Methyldopa.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Methylene Blue: MAO Inhibitors may enhance the serotonergic effect of Methylene Blue. This could result in serotonin syndrome.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Methylphenidate: MAO Inhibitors may enhance the hypertensive effect of Methylphenidate.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Metoclopramide: Serotonin Modulators may enhance the adverse/toxic effect of Metoclopramide. This may be manifest as symptoms consistent with serotonin syndrome or neuroleptic malignant syndrome.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Mirtazapine: MAO Inhibitors may enhance the neurotoxic (central) effect of Mirtazapine.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Orthostatic Hypotension Producing Agents: MAO Inhibitors may enhance the orthostatic hypotensive effect of Orthostatic Hypotension Producing Agents.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     OXcarbazepine: May enhance the serotonergic effect of Selegiline.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Oxymorphone: May enhance the adverse/toxic effect of MAO Inhibitors.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Peginterferon Alfa-2b: May decrease the serum concentration of CYP2D6 Substrates.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Pizotifen: MAO Inhibitors may enhance the anticholinergic effect of Pizotifen.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Quazepam: May increase the serum concentration of CYP2B6 Substrates.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Reserpine: MAO Inhibitors may enhance the adverse/toxic effect of Reserpine. Existing MAOI therapy can result in paradoxical effects of added reserpine (e.g., excitation, hypertension).  Management: Monoamine oxidase inhibitors (MAOIs) should be avoided or used with great caution in patients who are also receiving reserpine.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Selective Serotonin Reuptake Inhibitors: MAO Inhibitors may enhance the serotonergic effect of Selective Serotonin Reuptake Inhibitors. This may cause serotonin syndrome.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Serotonin 5-HT1D Receptor Agonists: MAO Inhibitors may decrease the metabolism of Serotonin 5-HT1D Receptor Agonists.  Management: If MAO inhibitor therapy is required, naratriptan, eletriptan or frovatriptan may be a suitable 5-HT1D agonist to employ.",
"     <b>",
"      Exceptions:",
"     </b>",
"     Eletriptan; Frovatriptan; Naratriptan.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Serotonin Modulators: May enhance the adverse/toxic effect of other Serotonin Modulators. The development of serotonin syndrome may occur.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Serotonin/Norepinephrine Reuptake Inhibitors: MAO Inhibitors may enhance the serotonergic effect of Serotonin/Norepinephrine Reuptake Inhibitors. This may cause serotonin syndrome.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Tapentadol: May enhance the adverse/toxic effect of MAO Inhibitors.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Tetrabenazine: May enhance the adverse/toxic effect of MAO Inhibitors.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Tetrahydrozoline (Nasal): MAO Inhibitors may enhance the hypertensive effect of Tetrahydrozoline (Nasal).",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     TraMADol: May enhance the neuroexcitatory and/or seizure-potentiating effect of MAO Inhibitors. TraMADol may enhance the serotonergic effect of MAO Inhibitors. Management: Consider alternatives to combined treatment with tramadol and monoamine oxidase inhibitors due to an increased risk of serotonin syndrome and seizures. Avoid transdermal selegiline.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Tricyclic Antidepressants: MAO Inhibitors may enhance the serotonergic effect of Tricyclic Antidepressants. This may cause serotonin syndrome.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Tryptophan: May enhance the adverse/toxic effect of MAO Inhibitors.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"   </div>",
"   <div class=\"block foi drugH1Div\" id=\"F220308\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Ethanol/Nutrition/Herb Interactions",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Ethanol: Ethanol may enhance the adverse/toxic effects of selegiline. Beverages containing tyramine (eg, hearty red wine and beer) may increase toxic effects. Management: Avoid ethanol and beverages containing tyramine.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Food: Concurrent ingestion of foods rich in tyramine, dopamine, tyrosine, phenylalanine, tryptophan, or caffeine may cause sudden and severe high blood pressure (hypertensive crisis or serotonin syndrome). Management: Avoid tyramine-containing foods (aged or matured cheese, air-dried or cured meats including sausages and salamis; fava or broad bean pods, tap/draft beers, Marmite concentrate, sauerkraut, soy sauce, and other soybean condiments). Food&rsquo;s freshness is also an important concern; improperly stored or spoiled food can create an environment in which tyramine concentrations may increase. Avoid foods containing dopamine, tyrosine, phenylalanine, tryptophan, or caffeine.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Herb/Nutraceutical: Kava kava, valerian, St John's wort, and SAMe may increase risk of serotonin syndrome and/or excessive sedation. Supplements containing caffeine, tyrosine, tryptophan, or phenylalanine may increase the risk of severe side effects like hypertensive reactions or serotonin syndrome. Management: Avoid kava kava, valerian, St John's wort, SAMe, and supplements containing caffeine, tyrosine, tryptophan, or phenylalanine.",
"    </p>",
"   </div>",
"   <div class=\"block prf drugH1Div\" id=\"F220288\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pregnancy Risk Factor",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     C (",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?16/42/17068\">",
"      show table",
"     </a>",
"     )",
"    </p>",
"   </div>",
"   <div class=\"block pri drugH1Div\" id=\"F2730972\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pregnancy Implications",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Teratogenic and adverse behavioral events were noted in animal studies. There are no adequate and well-controlled studies in pregnant women.",
"    </p>",
"   </div>",
"   <div class=\"block lac drugH1Div\" id=\"F220318\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Lactation",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Excretion in breast milk unknown/use caution",
"    </p>",
"   </div>",
"   <div class=\"block dic drugH1Div\" id=\"F2730982\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dietary Considerations",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Avoid or limit tyramine-containing foods/beverages (product and/or dose-dependent). Some examples include aged or matured cheese, air-dried or cured meats (including sausages and salamis), fava or broad bean pods, tap/draft beers, Marmite concentrate, sauerkraut, soy sauce and other soybean condiments. Food&rsquo;s freshness is also an important concern; improperly stored or spoiled food can create an environment where tyramine concentrations may increase.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;margin-top:2em;text-align:justify;\">",
"     Emsam&reg; 9 mg/24 hours or 12 mg/24 hours: Avoid tyramine-rich foods or beverages beginning the first day of treatment or for 2 weeks after discontinuation or dose reduction to 6 mg/24 hours.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Zelapar&reg;: Do not take with food or liquid.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Some products may contain phenylalanine.",
"    </p>",
"   </div>",
"   <div class=\"block fee drugH1Div\" id=\"F220301\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pricing: U.S. (Medi-Span&reg;)",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Capsules",
"     </b>",
"     (Eldepryl Oral)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     5 mg (60): $239.86",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Capsules",
"     </b>",
"     (Selegiline HCl Oral)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     5 mg (60): $138.10",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Patch, 24-hour",
"     </b>",
"     (Emsam Transdermal)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     6 mg/24 hrs (30): $713.02",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     9 mg/24 hrs (30): $713.02",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     12 mg/24 hrs (30): $713.02",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Tablet, orally-disintegrating",
"     </b>",
"     (Zelapar Oral)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     1.25 mg (10): $134.09",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Tablets",
"     </b>",
"     (Selegiline HCl Oral)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     5 mg (60): $126.10",
"    </p>",
"   </div>",
"   <div class=\"block mop drugH1Div\" id=\"F220290\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Monitoring Parameters",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Blood pressure; symptoms of parkinsonism; general mood and behavior (increased anxiety, presence of mania or agitation); suicidal ideation (especially at the beginning of therapy or when doses are increased or decreased)",
"    </p>",
"   </div>",
"   <div class=\"list fbnlist drugH1Div drugBrandNames\" id=\"F220302\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     International Brand Names",
"    </span>",
"    <ul>",
"     <li>",
"      Antiparkin (LU);",
"     </li>",
"     <li>",
"      Apo-Selegiline (NZ);",
"     </li>",
"     <li>",
"      Brintenal (AR);",
"     </li>",
"     <li>",
"      Cognitiv (RU);",
"     </li>",
"     <li>",
"      Comenter (EC);",
"     </li>",
"     <li>",
"      Deprenyl (FR);",
"     </li>",
"     <li>",
"      Eldepryl (AU, BE, DK, FI, GB, IE, NL, NO, NZ, SE, TW);",
"     </li>",
"     <li>",
"      Endopryl (CY);",
"     </li>",
"     <li>",
"      Jin Si Ping (CL);",
"     </li>",
"     <li>",
"      Julab (TH);",
"     </li>",
"     <li>",
"      Jumex (AR, AT, BG, CR, CZ, DO, HK, HN, HR, HU, ID, IL, IT, KP, MY, NI, PH, PL, PT, PY, SG, TH, UY, VE);",
"     </li>",
"     <li>",
"      Jumexal (CH);",
"     </li>",
"     <li>",
"      Mao-B (KP);",
"     </li>",
"     <li>",
"      MAOtil (DE);",
"     </li>",
"     <li>",
"      Movergan (DE, HR);",
"     </li>",
"     <li>",
"      Niar (BR, MX);",
"     </li>",
"     <li>",
"      Parkilyne (ZA);",
"     </li>",
"     <li>",
"      Plurimen (ES);",
"     </li>",
"     <li>",
"      Procythol (GR);",
"     </li>",
"     <li>",
"      Sefmex (HK, MY);",
"     </li>",
"     <li>",
"      Seldepar (TR);",
"     </li>",
"     <li>",
"      Selegil (CO, PE);",
"     </li>",
"     <li>",
"      Selegos (SG);",
"     </li>",
"     <li>",
"      Selezin (TW);",
"     </li>",
"     <li>",
"      Selgene (AU);",
"     </li>",
"     <li>",
"      Selgin (IN, PK);",
"     </li>",
"     <li>",
"      Selgina (CN);",
"     </li>",
"     <li>",
"      Siltin (TW);",
"     </li>",
"     <li>",
"      Xilopar (DE)",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"block pha drugH1Div\" id=\"F220281\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Mechanism of Action",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Potent, irreversible inhibitor of monoamine oxidase (MAO). Plasma concentrations achieved via administration of oral dosage forms in recommended doses confer selective inhibition of MAO type B, which plays a major role in the metabolism of dopamine; selegiline may also increase dopaminergic activity by interfering with dopamine reuptake at the synapse. When administered transdermally in recommended doses, selegiline achieves higher blood levels and effectively inhibits both MAO-A and MAO-B, which blocks catabolism of other centrally-active biogenic amine neurotransmitters.",
"    </p>",
"   </div>",
"   <div class=\"block phk drugH1Div\" id=\"F220297\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pharmacodynamics/Kinetics",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Onset of action: Therapeutic: Oral:  Within 1 hour",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Duration: Oral: 24-72 hours",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Absorption:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Orally disintegrating tablet: Rapid; greater bioavailability than capsule/tablet",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Transdermal: 25% to 30% (of total selegiline content) over 24 hours",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Protein binding: ~90%",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Metabolism: Hepatic, primarily via CYP2B6 to active (N-desmethylselegiline, amphetamine, methamphetamine) and inactive metabolites",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Half-life elimination: Oral: 10 hours; Transdermal: 18-25 hours",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Excretion: Urine (primarily metabolites); feces",
"    </p>",
"   </div>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <h1>",
"    REFERENCES",
"   </h1>",
"   <ol id=\"reference\">",
"    <li>",
"     <div class=\"reference\">",
"      Akhondzadeh S, Tavakolian R, Davari-Ashtiani R, et al, \"Selegiline in the Treatment of Attention Deficit Hyperactivity Disorder in Children: A Double Blind and Randomized Trial,\"",
"      <i>",
"       Prog Neuropsychopharmacol Biol Psychiatry",
"      </i>",
"      , 2003, 27(5):841-5.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?24/54/25448/abstract-text/12921918/pubmed\" id=\"12921918\" target=\"_blank\">",
"        12921918",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Collier DS, Berg MJ, and Fincham RW, &ldquo;Parkinsonism Treatment: Part III - Update,&rdquo;",
"      <i>",
"       Ann Pharmacother",
"      </i>",
"      , 1992, 26(2):227-33.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?24/54/25448/abstract-text/1348193/pubmed\" id=\"1348193\" target=\"_blank\">",
"        1348193",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Huyse FJ, Touw DJ, van Schijndel RS, et al, &ldquo;Psychotropic Drugs and the Perioperative Period: A Proposal for a Guideline in Elective Surgery,&rdquo;",
"      <i>",
"       Psychosomatics",
"      </i>",
"      , 2006, 47(1):8-22.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?24/54/25448/abstract-text/16384803 /pubmed\" id=\"16384803 \" target=\"_blank\">",
"        16384803",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Jankovic J, &ldquo;Deprenyl in Attention Deficit Associated With Tourette's Syndrome,&rdquo;",
"      <i>",
"       Arch Neurol",
"      </i>",
"      , 1993, 50(3):286-8.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?24/54/25448/abstract-text/8442708/pubmed\" id=\"8442708\" target=\"_blank\">",
"        8442708",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Koller WC, Silver DE, and Lieberman A, &ldquo;An Algorithm for the Management of Parkinson's Disease,&rdquo;",
"      <i>",
"       Neurology",
"      </i>",
"      , 1994, 44(12 Suppl 10):1-52.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?24/54/25448/abstract-text/8290041/pubmed\" id=\"8290041\" target=\"_blank\">",
"        8290041",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Mohammadi MR, Ghanizadeh A, Alaghband-Rad J, et al, \"Selegiline in Comparison With Methylphenidate in Attention Deficit Hyperactivity Disorder Children and Adolescents in a Double-Blind, Randomized Clinical Trial,\"",
"      <i>",
"       J Child Adolesc Psychopharmacol",
"      </i>",
"      , 2004, 14(3):418-25.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?24/54/25448/abstract-text/15650498/pubmed\" id=\"15650498\" target=\"_blank\">",
"        15650498",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Olanow CW, Watts RL, and Koller WC, \"An Algorithm (Decision Tree) for the Management of Parkinson's Disease (2001): Treatment Guidelines,\"",
"      <i>",
"       Neurology",
"      </i>",
"      , 2001, 56(11 Suppl 5):1-88.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?24/54/25448/abstract-text/11402154/pubmed\" id=\"11402154\" target=\"_blank\">",
"        11402154",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Romberg RW, Needleman SB, Snyder JJ, et al, &ldquo;Methamphetamine and Amphetamine Derived from the Metabolism of Selegiline,&rdquo;",
"      <i>",
"       J Forensic Sci",
"      </i>",
"      , 1995, 40(6):1100-02.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?24/54/25448/abstract-text/8522918/pubmed\" id=\"8522918\" target=\"_blank\">",
"        8522918",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Shulman KI and Walker SE, &ldquo;A Reevaluation of Dietary Restrictions for Irreversible Monoamine Oxidase Inhibitors,&rdquo;",
"      <i>",
"       Psychiatr Ann",
"      </i>",
"      , 2001, 31(6):378-84.",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Shulman KI and Walker SE, &ldquo;Refining the MAOI Diet: Tyramine Content of Pizzas and Soy Products,&rdquo;",
"      <i>",
"       J Clin Psychiatry",
"      </i>",
"      , 1999, 60(3):191-3.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?24/54/25448/abstract-text/10192596/pubmed\" id=\"10192596\" target=\"_blank\">",
"        10192596",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Stern MB, &ldquo;Contemporary Approaches to the Pharmacotherapeutic Management of Parkinson's Disease: An Overview,&rdquo;",
"      <i>",
"       Neurology",
"      </i>",
"      , 1997, 49(1 Suppl 1):2-9.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?24/54/25448/abstract-text/9222162/pubmed\" id=\"9222162\" target=\"_blank\">",
"        9222162",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      The Parkinson Study Group, &ldquo;Effect of Deprenyl on the Progression of Disability in Early Parkinson's Disease,&rdquo;",
"      <i>",
"       N Engl J Med",
"      </i>",
"      , 1989, 321(20):1364-71.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?24/54/25448/abstract-text/2509910/pubmed\" id=\"2509910\" target=\"_blank\">",
"        2509910",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      The Parkinson Study Group, &ldquo;Effects of Tocopherol and Deprenyl on the Progression of Disability in Early Parkinson's Disease,&rdquo;",
"      <i>",
"       N Engl J Med",
"      </i>",
"      , 1993, 328(3):176-83.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?24/54/25448/abstract-text/8417384/pubmed\" id=\"8417384\" target=\"_blank\">",
"        8417384",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Walker SE, Shulman KI, Tailor SA, et al, &ldquo;Tyramine Content of Previously Restricted Foods in Monoamine Oxidase Inhibitor Diets,&rdquo;",
"      <i>",
"       J Clin Psychopharmacol",
"      </i>",
"      , 1996, 16(5):383-8.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?24/54/25448/abstract-text/8889911/pubmed\" id=\"8889911\" target=\"_blank\">",
"        8889911",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"   </ol>",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 9883 Version 37.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.3 - C21.34",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     Morehouse School of Medicine",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [0502-41.78.124.10-207A0925F2-S473950.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f24_54_25448=[""].join("\n");
var outline_f24_54_25448=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F5709409\">",
"      ALERT: U.S. Boxed Warning",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F220310\">",
"      Brand Names: U.S.",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F220311\">",
"      Brand Names: Canada",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F220352\">",
"      Pharmacologic Category",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F220315\">",
"      Dosing: Adult",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F220329\">",
"      Dosing: Pediatric",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F220316\">",
"      Dosing: Geriatric",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F2730980\">",
"      Dosing: Renal Impairment",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F2730981\">",
"      Dosing: Hepatic Impairment",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F220292\">",
"      Dosage Forms: U.S.",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F220278\">",
"      Generic Equivalent Available: U.S.",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F7874988\">",
"      Medication Guide",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F2730983\">",
"      Administration",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F220295\">",
"      Use",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F220349\">",
"      Use - Unlabeled",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F220361\">",
"      Medication Safety Issues",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F220350\">",
"      Adverse Reactions Significant",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F220298\">",
"      Contraindications",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F220282\">",
"      Warnings/Precautions",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F220347\">",
"      Metabolism/Transport Effects",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F220287\">",
"      Drug Interactions",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F220308\">",
"      Ethanol/Nutrition/Herb Interactions",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F220288\">",
"      Pregnancy Risk Factor",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F2730972\">",
"      Pregnancy Implications",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F220318\">",
"      Lactation",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F2730982\">",
"      Dietary Considerations",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F220301\">",
"      Pricing: U.S. (Medi-Span&reg;)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F220290\">",
"      Monitoring Parameters",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F220302\">",
"      International Brand Names",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F220281\">",
"      Mechanism of Action",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F220297\">",
"      Pharmacodynamics/Kinetics",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a href=\"#references\">",
"      REFERENCES",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   <div class=\"openRelatedGraphics\" id=\"DRUG_GEN/9883\" rel=\"outline_link\">",
"    GRAPHICS",
"    <a class=\"graphics_icon\" href=\"#\" title=\"View All Related Graphics\">",
"     View All",
"    </a>",
"   </div>",
"  </h1>",
"  <div id=\"relatedGraphics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"DRUG_GEN/9883|TAB\">",
"      <a href=\"#\" title=\"TABLES\">",
"       TABLES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?23/39/24183\" title=\"Lexicomp clinical abbreviations\">",
"      Lexicomp clinical abbreviations",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"drug drug_patient\" href=\"UTD.htm?17/52/18246?source=related_link\">",
"      Selegiline: Patient drug information",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f24_54_25449="Management of aortic dissection";
var content_f24_54_25449=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"4\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"topicTitle\">",
"   Management of aortic dissection",
"  </div>",
"  <div id=\"topicContributors\">",
"   <div>",
"    <a id=\"authors\">",
"    </a>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?24/54/25449/contributors\">",
"     Author",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?24/54/25449/contributors\">",
"     Warren J Manning, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?24/54/25449/contributors\">",
"     Section Editors",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?24/54/25449/contributors\">",
"     Emile R Mohler III, MD",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?24/54/25449/contributors\">",
"     John F Eidt, MD",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?24/54/25449/contributors\">",
"     Joseph L Mills, Sr, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?24/54/25449/contributors\">",
"     Deputy Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?24/54/25449/contributors\">",
"     Kathryn A Collins, MD, PhD, FACS",
"    </a>",
"    <br/>",
"   </div>",
"  </div>",
"  <div id=\"disclosures\">",
"   <a href=\"UTD.htm?24/54/25449/contributor-disclosure\" target=\"_blank\">",
"    Disclosures",
"   </a>",
"  </div>",
"  <div id=\"reviewProcess\">",
"   <span>",
"    All topics are updated as new evidence becomes available and our",
"   </span>",
"   <a href=\"/home/editorial-policy\" target=\"_blank\">",
"    peer review process",
"   </a>",
"   <span>",
"    is complete.",
"   </span>",
"  </div>",
"  <div id=\"literatureReviewDate\">",
"   <span class=\"emphasis\">",
"    Literature review current through:",
"   </span>",
"   Oct 2013.",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <span class=\"emphasis\">",
"    This topic last updated:",
"   </span>",
"   Aug 29, 2012.",
"  </div>",
"  <div id=\"topicText\">",
"   <p class=\"headingAnchor\" id=\"H1\">",
"    <span class=\"h1\">",
"     INTRODUCTION",
"    </span>",
"    &nbsp;&mdash;&nbsp;Thoracic aortic dissection is usually suspected clinically from the history and physical examination. The initial tear typically presents with severe, sharp or \"tearing\" anterior chest pain (in ascending aortic dissection) or posterior chest or back pain (in dissection distal to the left subclavian). If the dissection leads to impaired or absent blood flow to peripheral vessels, the physical examination may reveal a unilateral or bilateral pulse deficit, defined as a weak or absent carotid, brachial, or femoral pulse. The diagnosis of aortic dissection is generally made noninvasively by thoracic computed tomography (CT), transesophageal echocardiography (TEE), or thoracic magnetic resonance imaging (MRI).",
"   </p>",
"   <p>",
"    Two different anatomic classification systems, the DeBakey and the Stanford (Daily) systems, have been used to classify aortic dissection [",
"    <a class=\"abstract\" href=\"UTD.htm?24/54/25449/abstract/1,2\">",
"     1,2",
"    </a>",
"    ]. The Stanford system, which is more widely used, classifies dissections that involve the ascending aorta as type A, regardless of the site of the primary intimal tear; all other dissections are classified as type B. In comparison, the DeBakey system is based on the site of origin with type I originating in the ascending aorta and propagating to at least the aortic arch, type II originating in and confined to the ascending aorta, and type III originating in the descending aorta and extending distally or proximally.",
"   </p>",
"   <p>",
"    The acute and chronic management of confirmed aortic dissection will be reviewed here. The recommendations are generally in agreement with guidelines published by a task force of the European Society of Cardiology [",
"    <a class=\"abstract\" href=\"UTD.htm?24/54/25449/abstract/3\">",
"     3",
"    </a>",
"    ]. The clinical evaluation and diagnosis of aortic dissection is reviewed separately. Management of a variant of aortic dissection, aortic intramural hematoma, is discussed separately. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?25/19/25914?source=see_link\">",
"     \"Clinical manifestations and diagnosis of aortic dissection\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?25/19/25914?source=see_link&amp;anchor=H8#H8\">",
"     \"Clinical manifestations and diagnosis of aortic dissection\", section on 'Variants'",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?36/16/37126?source=see_link\">",
"     \"Aortic intramural hematoma\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H2\">",
"    <span class=\"h1\">",
"     GENERAL PRINCIPLES",
"    </span>",
"    &nbsp;&mdash;&nbsp;Acute dissections involving the ascending aorta are considered surgical emergencies. In contrast, dissections confined to the descending aorta are treated medically unless the patient demonstrates progressive dissection with end-organ ischemia or continued hemorrhage into the pleural or retroperitoneal space.",
"   </p>",
"   <p>",
"    In a review of 464 patients from the International Registry of Acute Aortic Dissection (IRAD) presenting with aortic dissection, 72 percent of those with a type A dissection were treated surgically [",
"    <a class=\"abstract\" href=\"UTD.htm?24/54/25449/abstract/4\">",
"     4",
"    </a>",
"    ]. Reasons for medical therapy included advanced age, comorbidity, patient refusal, intramural hematoma, or death prior to planned surgery. In contrast, only 20 percent of those with a type B dissection underwent surgery.",
"   </p>",
"   <p>",
"    A similar difference in management of older patients was noted in another IRAD review of 550 patients with a type A dissection, including 32 percent who were at least 70 years [",
"    <a class=\"abstract\" href=\"UTD.htm?24/54/25449/abstract/5\">",
"     5",
"    </a>",
"    ]. Elderly patients were significantly less likely than younger patients (mean age 55 years) to undergo surgery (64 versus 86 percent). Older patients also had a significantly higher mortality with either surgery or medical therapy (eg, in-hospital mortality 43 versus 28 percent).",
"   </p>",
"   <p>",
"    The prognosis of patients requiring surgery improved dramatically in 1955 after DeBakey's introduction of effective surgical techniques [",
"    <a class=\"abstract\" href=\"UTD.htm?24/54/25449/abstract/6\">",
"     6",
"    </a>",
"    ]. Surgical therapy involves:",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      Excision of the intimal tear",
"     </li>",
"     <li>",
"      Obliteration of entry into the false lumen proximally",
"     </li>",
"     <li>",
"      Reconstitution of the aorta with interposition of a synthetic vascular graft",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    In addition, restoration of aortic valve competence can be performed in patients who develop significant aortic regurgitation. This can be achieved by resuspension of the native aortic valve or by aortic valve replacement [",
"    <a class=\"abstract\" href=\"UTD.htm?24/54/25449/abstract/7\">",
"     7",
"    </a>",
"    ]. If the aortic valve is resuspended, intraoperative TEE should be used to document resolution of aortic regurgitation.",
"   </p>",
"   <p>",
"    Medical therapy of aortic dissection involves lowering the blood pressure and decreasing the velocity of left ventricular contraction, both of which will decrease aortic shear stress and minimize the tendency for the dissection to propagate.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H3\">",
"    <span class=\"h1\">",
"     ACUTE MANAGEMENT",
"    </span>",
"    &nbsp;&mdash;&nbsp;Patients with suspected thoracic aortic dissection should be admitted to an intensive care unit as rapidly as possible after confirmation of the diagnosis for pain control with",
"    <a class=\"drug drug_general\" href=\"UTD.htm?19/31/19962?source=see_link\">",
"     morphine",
"    </a>",
"    , and reduction of systolic blood pressure to 100 to 120 mmHg or the lowest level that is tolerated (",
"    <a class=\"graphic graphic_table graphicRef62587 \" href=\"UTD.htm?35/46/36588\">",
"     table 1",
"    </a>",
"    )&nbsp;[",
"    <a class=\"abstract\" href=\"UTD.htm?24/54/25449/abstract/3,8\">",
"     3,8",
"    </a>",
"    ]. Patients who are hemodynamically unstable or with airway compromise should be intubated (",
"    <a class=\"graphic graphic_table graphicRef60961 \" href=\"UTD.htm?8/57/9116\">",
"     table 2",
"    </a>",
"    ).",
"   </p>",
"   <p>",
"    For blood pressure control, initial treatment consists of an intravenous beta blocker to reduce the heart rate below 60",
"    <span class=\"nowrap\">",
"     beats/min;",
"    </span>",
"    the associated fall in both blood pressure and the rate of rise in systolic pressure will minimize aortic wall stress. Either",
"    <a class=\"drug drug_general\" href=\"UTD.htm?8/49/8986?source=see_link\">",
"     propranolol",
"    </a>",
"    (1 to 10 mg load, followed by 3",
"    <span class=\"nowrap\">",
"     mg/h)",
"    </span>",
"    or",
"    <a class=\"drug drug_general\" href=\"UTD.htm?34/45/35544?source=see_link\">",
"     labetalol",
"    </a>",
"    can be used. Labetalol can be given as a bolus (20 mg initially, followed by 20 to 80 mg every 10 minutes to a total dose of 300 mg) or as an infusion (0.5 to 2",
"    <span class=\"nowrap\">",
"     mg/min).",
"    </span>",
"    <a class=\"drug drug_general\" href=\"UTD.htm?39/37/40536?source=see_link\">",
"     Esmolol",
"    </a>",
"    has advantages in the acute setting, due to its short half-life and ability to titrate to effect. It is also advantageous in patients who might be intolerant of beta blockers due, for example, to asthma, or heart failure [",
"    <a class=\"abstract\" href=\"UTD.htm?24/54/25449/abstract/8\">",
"     8",
"    </a>",
"    ].",
"    <a class=\"drug drug_general\" href=\"UTD.htm?9/18/9514?source=see_link\">",
"     Verapamil",
"    </a>",
"    or",
"    <a class=\"drug drug_general\" href=\"UTD.htm?12/16/12554?source=see_link\">",
"     diltiazem",
"    </a>",
"    are alternatives in patients who cannot tolerate beta blockers [",
"    <a class=\"abstract\" href=\"UTD.htm?24/54/25449/abstract/8\">",
"     8",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    The patient can be switched to oral beta blocker therapy after heart rate control has been achieved. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?18/26/18853?source=see_link\">",
"     \"Drug treatment of hypertensive emergencies\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    If, after beta blockade, the systolic blood pressure remains above 100 mmHg with good mentation and renal function, intravenous sodium",
"    <a class=\"drug drug_general\" href=\"UTD.htm?20/51/21302?source=see_link\">",
"     nitroprusside",
"    </a>",
"    should be added. The initial dose is 0.25 to 0.5",
"    <span class=\"nowrap\">",
"     mcg/kg",
"    </span>",
"    per minute. Nitroprusside should not be used without first controlling the heart rate with beta blockade since vasodilation alone induces reflex activation of the sympathetic nervous system leading to enhanced ventricular contraction and increased aortic wall shear stress. Patients receiving nitroprusside should be continuously monitored, preferably using an intraarterial cannula from the arm with the highest auscultatory pressure.",
"   </p>",
"   <p>",
"    While",
"    <a class=\"drug drug_general\" href=\"UTD.htm?20/51/21302?source=see_link\">",
"     nitroprusside",
"    </a>",
"    is the preferred agent, angiotensin converting enzyme (ACE) inhibitors or intravenous",
"    <a class=\"drug drug_general\" href=\"UTD.htm?41/61/42969?source=see_link\">",
"     nicardipine",
"    </a>",
"    ,",
"    <a class=\"drug drug_general\" href=\"UTD.htm?9/18/9514?source=see_link\">",
"     verapamil",
"    </a>",
"    or",
"    <a class=\"drug drug_general\" href=\"UTD.htm?12/16/12554?source=see_link\">",
"     diltiazem",
"    </a>",
"    may also be effective in lowering blood pressure [",
"    <a class=\"abstract\" href=\"UTD.htm?24/54/25449/abstract/8\">",
"     8",
"    </a>",
"    ]. Other direct vasodilators, such as",
"    <a class=\"drug drug_general\" href=\"UTD.htm?14/57/15254?source=see_link\">",
"     hydralazine",
"    </a>",
"    , should be",
"    <strong>",
"     avoided",
"    </strong>",
"    , since they increase aortic wall shear stress and provide less accurate and reversible control of the blood pressure.",
"   </p>",
"   <p>",
"    Hypotensive patients should be evaluated to determine if the cause is blood loss, hemopericardium with tamponade, valvular dysfunction, or left ventricular systolic dysfunction before volume is administered. Inotropic agents should be avoided since they will increase aortic wall shear stress and worsen the dissection. In patients with cardiac tamponade, percutaneous pericardiocentesis can accelerate bleeding and shock [",
"    <a class=\"abstract\" href=\"UTD.htm?24/54/25449/abstract/9\">",
"     9",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Diagnostic evaluation should be accomplished as promptly as possible. In patients with severe hemodynamic instability, bedside TEE is the procedure of choice [",
"    <a class=\"abstract\" href=\"UTD.htm?24/54/25449/abstract/8\">",
"     8",
"    </a>",
"    ]. In more stable patients, diagnostic options include chest computed tomography (CT), thoracic magnetic resonance imaging (MRI) or transesophageal echocardiography (TEE). (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?25/19/25914?source=see_link&amp;anchor=H20#H20\">",
"     \"Clinical manifestations and diagnosis of aortic dissection\", section on 'Imaging'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H4\">",
"    <span class=\"h1\">",
"     DEFINITIVE THERAPY",
"    </span>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H5\">",
"    <span class=\"h2\">",
"     Descending (type B) aortic dissection",
"    </span>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H6\">",
"    <span class=\"h3\">",
"     Medical therapy",
"    </span>",
"    &nbsp;&mdash;&nbsp;Patients with uncomplicated aortic dissections confined to the descending thoracic aorta (Stanford type B or DeBakey type III) are best treated with medical therapy (",
"    <a class=\"graphic graphic_table graphicRef57498 \" href=\"UTD.htm?3/62/4076\">",
"     table 3",
"    </a>",
"    )&nbsp;[",
"    <a class=\"abstract\" href=\"UTD.htm?24/54/25449/abstract/3,10,11\">",
"     3,10,11",
"    </a>",
"    ]. In a series of 384 patients with type B dissections from the IRAD, 73 percent were managed medically. In-hospital mortality for these patients was 10 percent [",
"    <a class=\"abstract\" href=\"UTD.htm?24/54/25449/abstract/12\">",
"     12",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    The reported long-term survival rate with medical therapy is approximately 60 to 80 percent at four to five years [",
"    <a class=\"abstract\" href=\"UTD.htm?24/54/25449/abstract/11,13-15\">",
"     11,13-15",
"    </a>",
"    ] and approximately 40 to 45 percent at 10 years [",
"    <a class=\"abstract\" href=\"UTD.htm?24/54/25449/abstract/13,14\">",
"     13,14",
"    </a>",
"    ]. Survival is best in patients with noncommunicating and retrograde dissections [",
"    <a class=\"abstract\" href=\"UTD.htm?24/54/25449/abstract/16\">",
"     16",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Despite fair survival among patients treated medically, spontaneous healing of the dissection, characterized by disappearance of the false lumen due to complete thrombosis, is uncommon [",
"    <a class=\"abstract\" href=\"UTD.htm?24/54/25449/abstract/3,16,17\">",
"     3,16,17",
"    </a>",
"    ]. Continued flow through the false lumen (patent false lumen), which occurs with either partial thrombosis or no significant thrombosis, has been postulated to prevent healing.",
"   </p>",
"   <p>",
"    The relationship between long-term prognosis and the degree of patency of the false lumen was evaluated in 201 hospital survivors of type B acute aortic dissection who were enrolled in the IRAD [",
"    <a class=\"abstract\" href=\"UTD.htm?24/54/25449/abstract/17\">",
"     17",
"    </a>",
"    ]. Complete false lumen patency or partial thrombosis was present in 57 and 34 percent of patients, respectively. The mean three-year mortality rate was significantly worse in patients with partial thrombosis compared with those with complete patency (32 versus 14 percent).",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H7\">",
"    <span class=\"h3\">",
"     Intervention",
"    </span>",
"    &nbsp;&mdash;&nbsp;Intervention (surgical or endovascular) for descending aortic dissection is reserved for patients who have a complicated course. Indications for intervention (surgical or endovascular) for type B dissection include occlusion of a major aortic branch leading to end-organ ischemia, persistent severe hypertension or pain, propagation of the dissection (as may be manifested by persistent or recurrent pain), aneurysmal expansion, and rupture (",
"    <a class=\"graphic graphic_table graphicRef57498 \" href=\"UTD.htm?3/62/4076\">",
"     table 3",
"    </a>",
"    )&nbsp;[",
"    <a class=\"abstract\" href=\"UTD.htm?24/54/25449/abstract/8\">",
"     8",
"    </a>",
"    ]. Acute distal dissections in patients with Marfan syndrome may also be best treated surgically [",
"    <a class=\"abstract\" href=\"UTD.htm?24/54/25449/abstract/7\">",
"     7",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?5/51/5945?source=see_link\">",
"     \"Management of Marfan syndrome and related disorders\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Because patients treated surgically are primarily those with a complicated course, it is not surprising that short-term mortality for these patients is higher than those managed with medical therapy. In data from the IRAD, in-hospital mortality for surgical patients was 32 percent compared with 10 percent for those treated medically [",
"    <a class=\"abstract\" href=\"UTD.htm?24/54/25449/abstract/12\">",
"     12",
"    </a>",
"    ]. There were two independent predictors of surgical mortality: age &ge;70 years and hypotension or shock on admission [",
"    <a class=\"abstract\" href=\"UTD.htm?24/54/25449/abstract/18\">",
"     18",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Although short-term outcomes are better for medically treated patients with type B dissections [",
"    <a class=\"abstract\" href=\"UTD.htm?24/54/25449/abstract/11,13,15\">",
"     11,13,15",
"    </a>",
"    ], long-term outcomes may be similar [",
"    <a class=\"abstract\" href=\"UTD.htm?24/54/25449/abstract/11,13\">",
"     11,13",
"    </a>",
"    ]. This was illustrated in a report of 142 patients, 111 (78 percent) of whom were treated medically [",
"    <a class=\"abstract\" href=\"UTD.htm?24/54/25449/abstract/13\">",
"     13",
"    </a>",
"    ]. There was a trend toward lower mortality with medical therapy at one year (15 versus 33 percent); this difference tended to diminish over time. Both groups had similar survival at five and ten years (60 and 35 percent). (See",
"    <a class=\"local\" href=\"#H16\">",
"     'Long-term management'",
"    </a>",
"    below.)",
"   </p>",
"   <p>",
"    Endovascular stent-grafting has been employed as a less invasive alternative to surgery, particularly in stable patients with type B dissections. (See",
"    <a class=\"local\" href=\"#H11\">",
"     'Endovascular stent-grafts'",
"    </a>",
"    below.)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H8\">",
"    <span class=\"h2\">",
"     Ascending (type A) aortic dissection",
"    </span>",
"    &nbsp;&mdash;&nbsp;Acute ascending aortic dissections (Stanford type A) should be treated as a surgical emergency since these patients are at high risk for a life-threatening complication such as aortic regurgitation, tamponade, and myocardial infarction with mortality rate as high as 1 to 2 percent per hour early after symptom onset (",
"    <a class=\"graphic graphic_table graphicRef77273 \" href=\"UTD.htm?14/45/15068\">",
"     table 4",
"    </a>",
"    )&nbsp;[",
"    <a class=\"abstract\" href=\"UTD.htm?24/54/25449/abstract/19\">",
"     19",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    The use of and survival benefit from surgery were illustrated in an IRAD review of 547 patients with a type A dissection [",
"    <a class=\"abstract\" href=\"UTD.htm?24/54/25449/abstract/20\">",
"     20",
"    </a>",
"    ]:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      80 percent of patients were treated surgically. The main cited reasons for medical therapy were comorbid conditions, advanced age (mean 80 years), and patient refusal.",
"     </li>",
"     <li>",
"      The in-hospital mortality was 27 and 56 percent for surgical and medical therapy, a difference that was due, in part, to increased comorbidity in medically treated patients. A similar in-hospital mortality with surgical therapy (22 percent) was noted in a series of 487 patients [",
"      <a class=\"abstract\" href=\"UTD.htm?24/54/25449/abstract/21\">",
"       21",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      Not surprisingly, the patients who died had a higher rate of in-hospital complications including neurologic deficits, coronary or mesenteric ischemia, acute renal failure, and limb ischemia.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Even the presence of acute myocardial infarction, which may be due to the dissection involving a coronary ostium (particularly the right coronary artery), should not entirely exclude the option of rapid surgical intervention. However, patients with stroke in progress are at increased risk for hemorrhagic cerebral infarction due to intraoperative heparinization and restoration of cerebral blood flow. Thus, hemorrhagic stroke is a relative contraindication to urgent surgical intervention.",
"   </p>",
"   <p>",
"    In the IRAD registry, patients &ge;70 years of age were less likely to be treated surgically (64 versus 86 percent in younger patients [mean age 55 years]) [",
"    <a class=\"abstract\" href=\"UTD.htm?24/54/25449/abstract/5\">",
"     5",
"    </a>",
"    ]. However, older age alone should not preclude surgery [",
"    <a class=\"abstract\" href=\"UTD.htm?24/54/25449/abstract/5,22\">",
"     5,22",
"    </a>",
"    ]. In the registry report, in-hospital mortality was significantly higher in the older patients (38 versus 23 percent) but lower than in older patients treated surgically [",
"    <a class=\"abstract\" href=\"UTD.htm?24/54/25449/abstract/5\">",
"     5",
"    </a>",
"    ]. Thus, surgery should be considered in selected elderly patients, even some octogenarians.",
"   </p>",
"   <p>",
"    Women are also less likely to be treated surgically (71 versus 87 percent) in the IRAD registry [",
"    <a class=\"abstract\" href=\"UTD.htm?24/54/25449/abstract/23\">",
"     23",
"    </a>",
"    ]. As with elderly patients, women have a higher in-hospital mortality with surgical treatment than men (32 versus 22 percent), but a lower mortality than with medical therapy (32 versus 54 percent).",
"   </p>",
"   <p>",
"    Operative mortality for ascending aortic dissections at experienced centers varies from 7 to 36 percent, well below the more than 50 percent mortality with medical therapy&nbsp;[",
"    <a class=\"abstract\" href=\"UTD.htm?24/54/25449/abstract/4,11,20,22,24-29\">",
"     4,11,20,22,24-29",
"    </a>",
"    ]. An aggressive surgical approach, including a full root or hemiarch replacement when the aortic valve, sinuses, or arch are involved, may not be associated with an increased operative risk [",
"    <a class=\"abstract\" href=\"UTD.htm?24/54/25449/abstract/30,31\">",
"     30,31",
"    </a>",
"    ]. Hypothermic circulatory arrest has been used, especially in repairs involving the aortic arch, although a retrospective analysis of 307 patients failed to find a benefit in terms of survival, complications, or need for late reoperation [",
"    <a class=\"abstract\" href=\"UTD.htm?24/54/25449/abstract/29\">",
"     29",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Poor prognostic factors include [",
"    <a class=\"abstract\" href=\"UTD.htm?24/54/25449/abstract/4,5,20,21,24-26,28,32-35\">",
"     4,5,20,21,24-26,28,32-35",
"    </a>",
"    ]:",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      Age over 70 years",
"     </li>",
"     <li>",
"      Abrupt onset of chest pain",
"     </li>",
"     <li>",
"      Hypotension, shock, or tamponade at presentation",
"     </li>",
"     <li>",
"      Renal failure at presentation and before surgery",
"     </li>",
"     <li>",
"      Pulse deficit",
"     </li>",
"     <li>",
"      Abnormal ECG, particularly ST segment elevation",
"     </li>",
"     <li>",
"      Prior myocardial infarction",
"     </li>",
"     <li>",
"      Previous aortic valve replacement",
"     </li>",
"     <li>",
"      Renal",
"      <span class=\"nowrap\">",
"       and/",
"      </span>",
"      or visceral ischemia",
"     </li>",
"     <li>",
"      Underlying pulmonary disease",
"     </li>",
"     <li>",
"      Preoperative neurologic impairment",
"     </li>",
"     <li>",
"      Perioperative bleeding and massive blood transfusion",
"     </li>",
"     <li>",
"      Prolonged clamping time",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    The first six factors were the most important predictors of in-hospital mortality in the IRAD review [",
"    <a class=\"abstract\" href=\"UTD.htm?24/54/25449/abstract/20\">",
"     20",
"    </a>",
"    ]. Using a complicated predictive score that incorporated these parameters, patients could be identified with subsequent in-hospital mortality rates that ranged from 2 to over 80 percent.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H9\">",
"    <span class=\"h3\">",
"     Evaluation for CAD and aortic valve disease",
"    </span>",
"    &nbsp;&mdash;&nbsp;In addition to the imaging necessary to secure the diagnosis of type A aortic dissection, CT coronary angiography, percutaneous coronary angiography and TEE may be considered to evaluate the patient for concomitant coronary artery disease (CAD) or aortic valve disease (TEE, MRI, transthoracic echocardiography) prior to urgent surgical repair of the ascending aorta. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?25/19/25914?source=see_link&amp;anchor=H20#H20\">",
"     \"Clinical manifestations and diagnosis of aortic dissection\", section on 'Imaging'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Patients with acute aortic dissection have a significant prevalence of CAD. As a result, it has been suggested that x-ray coronary angiography be performed prior to surgery so that bypass surgery on critical stenoses can be performed while the patient is under cardiopulmonary bypass. There has been concern that the presence of undiagnosed critical coronary stenoses may make weaning from cardiopulmonary bypass more difficult and can increase the risk of perioperative myocardial infarction or death. However, the resulting delay of surgery increases the risk of cardiac tamponade or aortic rupture, which are important causes of preoperative mortality in aortic dissection.",
"   </p>",
"   <p>",
"    The role of percutaneous coronary angiography was evaluated in a study that retrospectively analyzed the outcome of 122 patients who underwent emergency aortic surgery, primarily for a type A aortic dissection [",
"    <a class=\"abstract\" href=\"UTD.htm?24/54/25449/abstract/33\">",
"     33",
"    </a>",
"    ]. There was no difference in the in-hospital mortality between those who did or did not undergo coronary angiography (22 versus 16 percent), including those who had a prior myocardial infarction which was the only predictor of in-hospital mortality. X-ray coronary angiography had no impact on the incidence of coronary artery bypass grafting (17 versus 25 percent), three-quarters of which were performed because of coronary artery dissection not atherosclerotic disease. These observations suggest limited value from coronary angiography and support the recommendation of proceeding to surgery as rapidly as possible [",
"    <a class=\"abstract\" href=\"UTD.htm?24/54/25449/abstract/33\">",
"     33",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    In addition to its important role in the diagnosis of aortic dissection, TEE can define the severity and mechanism of aortic regurgitation and involvement of the coronary ostia that complicates acute type A aortic dissection, particularly the right coronary artery [",
"    <a class=\"abstract\" href=\"UTD.htm?24/54/25449/abstract/36\">",
"     36",
"    </a>",
"    ]. This information is useful when considering aortic valve repair versus replacement. Patients with an intrinsically normal valve who have aortic regurgitation due to a correctable aortic lesion (incomplete leaflet closure, leaflet prolapse, or dissection flap prolapse) can undergo aortic valve repair; in comparison, abnormalities that cannot be repaired (Marfan, bicuspid valve, aortitis) require valve replacement. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?34/39/35445?source=see_link\">",
"     \"Transesophageal echocardiography in the evaluation of aortic valve disease\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H10\">",
"    <span class=\"h3\">",
"     Survival after repair",
"    </span>",
"    &nbsp;&mdash;&nbsp;Long-term survival after surgical repair of type A dissections is relatively good. This was illustrated in an IRAD report of 303 patients with type A dissection who were seen between 1996 and 2003, 90 percent of whom were managed surgically [",
"    <a class=\"abstract\" href=\"UTD.htm?24/54/25449/abstract/37\">",
"     37",
"    </a>",
"    ]. Survival at one and three years was 96 and 91 percent, respectively.",
"   </p>",
"   <p>",
"    Longer term follow-up was provided in a series of 208 patients presenting between 1978 and 1995 [",
"    <a class=\"abstract\" href=\"UTD.htm?24/54/25449/abstract/27\">",
"     27",
"    </a>",
"    ] Patient survival at 5 and 10 years was 68 and 52 percent, respectively; residual distal dissected aorta did not affect late survival and had a low risk for aneurysmal change and reoperation. Whether improvements in surgical and medical care have led to better long-term outcomes over time is not known.",
"   </p>",
"   <p>",
"    The natural history of the distal aorta was evaluated in an observational study of surgical survivors of Type A dissection. Serial CT in 89 patients identified a median expansion rate of approximately 1",
"    <span class=\"nowrap\">",
"     mm/year.",
"    </span>",
"    Male gender, an initial descending aorta diameter of greater than 4 cm, or an initial diameter of less than 4 cm with a patent false lumen were identified as predictive of more rapid descending aorta growth [",
"    <a class=\"abstract\" href=\"UTD.htm?24/54/25449/abstract/38\">",
"     38",
"    </a>",
"    ]. The overall risk of reoperation was 16 percent at 10 years.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H11\">",
"    <span class=\"h2\">",
"     Endovascular stent-grafts",
"    </span>",
"    &nbsp;&mdash;&nbsp;Endovascular stent-grafting has been employed as a less invasive alternative to surgery, primarily in patients with complicated type B dissections [",
"    <a class=\"abstract\" href=\"UTD.htm?24/54/25449/abstract/8\">",
"     8",
"    </a>",
"    ]. The stent graft is positioned to cover the intimal flap and seal the entry site of the dissection, resulting in thrombosis of the false lumen (",
"    <a class=\"graphic graphic_table graphicRef75376 \" href=\"UTD.htm?19/29/19932\">",
"     table 5",
"    </a>",
"    ).",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H12\">",
"    <span class=\"h3\">",
"     Type B dissections",
"    </span>",
"    &nbsp;&mdash;&nbsp;In the IRAD series of 384 type B dissections, 46 (12 percent) were managed with endovascular stent grafting [",
"    <a class=\"abstract\" href=\"UTD.htm?24/54/25449/abstract/12\">",
"     12",
"    </a>",
"    ]. This technique was reserved for patients who had undergone at least eight weeks of medical management. Only three (6.5 percent) died during the initial hospitalization.",
"   </p>",
"   <p>",
"    The outcome of stent grafting was compared with surgery in a nonrandomized evaluation of 24 consecutive patients with a subacute or chronic thoracic type B dissection who had at least one indication for surgery [",
"    <a class=\"abstract\" href=\"UTD.htm?24/54/25449/abstract/39\">",
"     39",
"    </a>",
"    ]. There was no morbidity (paraplegia, stroke, embolization, side-branch occlusion or infection) or mortality with stent grafting, while surgery was associated with a 33 percent mortality and a 42 percent incidence of adverse events within 12 months. At three months, thrombosis of the false lumen had occurred in all patients undergoing stent grafting.",
"   </p>",
"   <p>",
"    Stent grafting has also been evaluated for acute and, in some cases, life-threatening dissections, but the outcomes are not as good [",
"    <a class=\"abstract\" href=\"UTD.htm?24/54/25449/abstract/40-42\">",
"     40-42",
"    </a>",
"    ]. One report evaluated 19 patients with an acute dissection (four type A) and an indication for surgery [",
"    <a class=\"abstract\" href=\"UTD.htm?24/54/25449/abstract/40\">",
"     40",
"    </a>",
"    ]. This included involvement of aortic branches in 14, which led to symptomatic compromise of multiple branch vessels in 7. Complete thrombosis was achieved in 79 percent, and revascularization of ischemic branch vessels with relief of symptoms occurred in 76 percent of obstructed branches. However, the morbidity rate was 21 percent (small bowel and renal infarction and lower extremity gangrene) and 30-day mortality was 16 percent. Among patients who survived this period, there were no deaths or instances of aneurysm or aortic rupture during the subsequent 13-month follow-up period.",
"   </p>",
"   <p>",
"    Longer-term follow-up was described in a series of 49 patients with acute and chronic aortic dissection who were treated with stent grafts [",
"    <a class=\"abstract\" href=\"UTD.htm?24/54/25449/abstract/43\">",
"     43",
"    </a>",
"    ]. Serial CT studies in the 34 patients with descending aortic dissection showed that, at two years, total occlusion of the false lumen was more often achieved with acute compared with chronic dissection (76 versus 36 percent). The chronic dissections had similar reductions in false lumen diameter, but had larger false lumens prior to treatment (eg, 25.2 versus 16.2 mm in the middle descending aorta).",
"   </p>",
"   <p>",
"    In an attempt to overcome the small number of patients in most published series, a meta-analysis was performed of 39 studies involving a total of 609 patients who underwent stent-graft placement for a type B dissection [",
"    <a class=\"abstract\" href=\"UTD.htm?24/54/25449/abstract/42\">",
"     42",
"    </a>",
"    ]. The following findings were noted:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Procedure success was achieved in 98 percent of patients.",
"     </li>",
"     <li>",
"      Major complications occurred in 11.1 percent; neurologic complications, the most serious, occurred in 2.9 percent, mostly periprocedural stroke and paraplegia (1.9 and 0.8 percent, respectively). The major complication rate was significantly higher with acute compared with chronic dissections (21.7 versus 9.1 percent). Minor complications occurred in 2.5 percent. The rate of complications compared favorably with previously reported surgical series. The rate was higher in more recent studies, which may reflect inclusion of higher-risk patients with increasing experience with the procedure.",
"     </li>",
"     <li>",
"      The false lumen was not abolished in about 25 percent of patients and, at a mean follow-up of 19 months, aortic rupture occurred in 2.3 percent.",
"     </li>",
"     <li>",
"      The mortality rate was 5.2 percent in-hospital and 5.3 percent at 30 days, being significantly higher with acute dissections (9.8 versus 3.2 percent). Kaplan-Meier analysis revealed overall survival rates of 90 percent at one year and 89 percent at two years.",
"     </li>",
"     <li>",
"      The outcomes were much better in centers that had performed more than 20 endovascular procedures compared with less experienced centers. This included significantly lower rates of overall complications (7.7 versus 20.9 percent), neurologic complications (1.0 versus 5.7 percent), and 30-day mortality (3.2 versus 8.5 percent).",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H13\">",
"    <span class=\"h3\">",
"     Type A dissections",
"    </span>",
"    &nbsp;&mdash;&nbsp;A possible alternative to surgery in patients with type A dissections who have ischemic complications is endovascular stent-grafting [",
"    <a class=\"abstract\" href=\"UTD.htm?24/54/25449/abstract/8\">",
"     8",
"    </a>",
"    ]. There is only a limited experience in patients with acute type A dissections. In one series, the false lumen was completely obliterated in 14 of 15 patients with a type A dissection within three months [",
"    <a class=\"abstract\" href=\"UTD.htm?24/54/25449/abstract/43\">",
"     43",
"    </a>",
"    ]. Further study is required to determine the role for this approach in such patients.",
"   </p>",
"   <p>",
"    A hybrid approach to the repair of type A aortic dissection, sometimes referred to as the &ldquo;frozen elephant trunk repair,&rdquo; uses an open approach to surgically repair the ascending aorta while using a stent-graft to manage the descending aorta. Several case series have compared this technique with conventional open repair [",
"    <a class=\"abstract\" href=\"UTD.htm?24/54/25449/abstract/44-58\">",
"     44-58",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    In one case series, a triple-branched stent graft was placed into the three arch vessels and descending aorta in 30 patients with acute type A dissection. The procedure was technically successful in all patients and aortic cross clamp and lower body arrest times were 84 and 31 minutes, respectively, which is generally much lower than with conventional treatment [",
"    <a class=\"abstract\" href=\"UTD.htm?24/54/25449/abstract/44\">",
"     44",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H14\">",
"    <span class=\"h2\">",
"     Fenestration and other stents",
"    </span>",
"    &nbsp;&mdash;&nbsp;Aortic dissection frequently causes life-threatening ischemia of distal organs, and the mortality associated with such complications can exceed 60 percent. Although surgical repair of the dissection often results in resolution of peripheral ischemia, stenting",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    balloon fenestration of the dissecting membrane may be noninvasive alternatives for patients with a type A dissection in whom mesenteric, renal, or peripheral ischemia persists after surgical repair, or for patients with a type B dissection treated medically in whom mesenteric, renal, or peripheral ischemic complications arise (",
"    <a class=\"graphic graphic_table graphicRef75376 \" href=\"UTD.htm?19/29/19932\">",
"     table 5",
"    </a>",
"    ) [",
"    <a class=\"abstract\" href=\"UTD.htm?24/54/25449/abstract/8,41,59\">",
"     8,41,59",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    The efficacy of these approaches was evaluated in a series of 40 patients who were treated with percutaneous revascularization of the aortic branch artery using a stent placed in either the true or false lumen, with or without balloon fenestration of the intimal flap to restore flow to the involved organ [",
"    <a class=\"abstract\" href=\"UTD.htm?24/54/25449/abstract/59\">",
"     59",
"    </a>",
"    ]. Revascularization was successful in 93 percent of patients, but the 30-day mortality rate was 25 percent, primarily related to irreversible organ ischemia present before the procedure. Among the 30 patients who survived the first 30 days, the mortality at 29 months was 17 percent.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H15\">",
"    <span class=\"h1\">",
"     PROGNOSIS",
"    </span>",
"    &nbsp;&mdash;&nbsp;The 10-year actuarial survival rate of patients with an aortic dissection who leave the hospital has ranged from 30 to 88 percent in different studies; survival appears similar whether the patient has had a type A or a type B dissection [",
"    <a class=\"abstract\" href=\"UTD.htm?24/54/25449/abstract/11,13,14,21,25-27,60\">",
"     11,13,14,21,25-27,60",
"    </a>",
"    ]. This may be explained by the fact that adverse events, such as recurrent dissection or complications of aneurysm formation in the descending aorta, occur in both type A and type B dissection (DeBakey type 1) patients [",
"    <a class=\"abstract\" href=\"UTD.htm?24/54/25449/abstract/61\">",
"     61",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Late aneurysm formation and adverse outcomes, including death, are related to the initial diameter of the false lumen in the upper thoracic aorta. This was illustrated in a study of 100 patients (51 type I and 49 type III) who survived initial hospitalization for aortic dissection in whom contrast-enhanced CT was performed during the acute phase [",
"    <a class=\"abstract\" href=\"UTD.htm?24/54/25449/abstract/62\">",
"     62",
"    </a>",
"    ]. The following findings were noted at a mean CT follow-up of 31 months and a mean clinical follow-up of 53 months:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Aneurysm (diameter &ge;60 mm) formation occurred in 15 of the 53 patients, most often in the upper thoracic descending aorta.",
"     </li>",
"     <li>",
"      Patients with an initial false lumen diameter of &ge;22 mm at the upper thoracic aorta, compared with those with a smaller diameter, were significantly more likely to develop late aneurysm formation (42 versus 5 percent) or death.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    The causes of death were illustrated in a report of 380 survivors of an initial type A dissection in which there were 31 late deaths [",
"    <a class=\"abstract\" href=\"UTD.htm?24/54/25449/abstract/21\">",
"     21",
"    </a>",
"    ]. The causes were stroke (12 patients), aortic reoperation for redissection or progressive dilatation of the false lumen (seven patients), malignancy (five patients), myocardial infarction (four patients), and heart failure (three patients).",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H16\">",
"    <span class=\"h1\">",
"     LONG-TERM MANAGEMENT",
"    </span>",
"    &nbsp;&mdash;&nbsp;There are three main management issues in patients who have survived the initial dissection: medical therapy to minimize aortic wall shear stress; serial imaging to detect signs of dissection progression, re-dissection, or aneurysm formation; and reoperation when indicated.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H17\">",
"    <span class=\"h2\">",
"     Medical therapy",
"    </span>",
"    &nbsp;&mdash;&nbsp;All patients should receive life-long therapy with an oral beta blocker to reduce systemic blood pressure and the rate of rise in systolic pressure, both of which will minimize aortic wall stress [",
"    <a class=\"abstract\" href=\"UTD.htm?24/54/25449/abstract/8\">",
"     8",
"    </a>",
"    ]. Although not evaluated in controlled trials, we suggest a target blood pressure of less than",
"    <span class=\"nowrap\">",
"     120/80",
"    </span>",
"    mmHg [",
"    <a class=\"abstract\" href=\"UTD.htm?24/54/25449/abstract/8\">",
"     8",
"    </a>",
"    ]. Combination antihypertensive drug therapy is usually required.",
"   </p>",
"   <p>",
"    Avoidance of strenuous physical activity is also recommended as another method to minimize aortic shear stress. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?5/51/5945?source=see_link&amp;anchor=H11#H11\">",
"     \"Management of Marfan syndrome and related disorders\", section on 'Restriction of strenuous activity'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H18\">",
"    <span class=\"h2\">",
"     Serial imaging",
"    </span>",
"    &nbsp;&mdash;&nbsp;We generally perform a baseline thoracic MRI or chest CT scan prior to discharge with follow-up examinations at 3, 6, and 12 months, even if the patient remains asymptomatic (",
"    <a class=\"graphic graphic_table graphicRef58029 \" href=\"UTD.htm?19/34/20012\">",
"     table 6",
"    </a>",
"    )&nbsp;[",
"    <a class=\"abstract\" href=\"UTD.htm?24/54/25449/abstract/3,8\">",
"     3,8",
"    </a>",
"    ]. Subsequent screening studies are then performed every one to two years if there is no evidence of progression.",
"   </p>",
"   <p>",
"    The following abnormalities can be detected on serial imaging:",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      Extension or recurrence of the dissection",
"     </li>",
"     <li>",
"      Aneurysm formation",
"     </li>",
"     <li>",
"      Leakage at anastomoses or stent sites",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    MRI is as accurate as TEE and, because it is noninvasive, is more acceptable for serial studies. MRI does not expose patients to iodinated contrast and ionizing radiation, which are important factors for younger patients who will likely have many years of serial monitoring. CT scanning is an alternative, but exposes the patient to considerable ionizing radiation and requires iodinated contrast, which may cause nephrotoxicity. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?10/13/10457?source=see_link\">",
"     \"Pathogenesis, clinical features, and diagnosis of contrast-induced nephropathy\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Alternating chest CT and thoracic MRI is a reasonable option for patients with good renal function. Non-contrast MRI can be used for patients with impaired renal function to avoid the risk of nephrogenic systemic fibrosis. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?30/22/31082?source=see_link\">",
"     \"Nephrogenic systemic fibrosis/nephrogenic fibrosing dermopathy in advanced renal failure\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H19\">",
"    <span class=\"h2\">",
"     Reoperation",
"    </span>",
"    &nbsp;&mdash;&nbsp;Repeat surgery is required in 12 to 30 percent of patients, usually because of extension or recurrence of dissection at the previous site of intervention, localized aneurysm formation remote from the site of repair, graft dehiscence or infection, or aortic regurgitation (",
"    <a class=\"graphic graphic_table graphicRef80853 \" href=\"UTD.htm?14/41/15004\">",
"     table 7",
"    </a>",
"    and",
"    <a class=\"graphic graphic_table graphicRef74880 \" href=\"UTD.htm?12/33/12828\">",
"     table 8",
"    </a>",
"    ) [",
"    <a class=\"abstract\" href=\"UTD.htm?24/54/25449/abstract/3,16,25,26,60,63\">",
"     3,16,25,26,60,63",
"    </a>",
"    ]. The reoperation rate is higher in patients with Marfan syndrome [",
"    <a class=\"abstract\" href=\"UTD.htm?24/54/25449/abstract/3\">",
"     3",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?5/51/5945?source=see_link\">",
"     \"Management of Marfan syndrome and related disorders\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    The evolution of a type A aortic dissection after surgical repair was evaluated in a report of 58 patients who were discharged from the hospital and then followed with serial MRI scans [",
"    <a class=\"abstract\" href=\"UTD.htm?24/54/25449/abstract/63\">",
"     63",
"    </a>",
"    ]. Residual distal dissection was present in 45 (78 percent). The yearly aortic growth rate of this segment was 0.37 cm overall and significantly higher at 0.56 cm in the absence of thrombus in the false lumen. During a seven-year follow-up, 16 patients (28 percent) underwent reoperation because of progressive dilation of the untreated aortic segment. Residual dissection was present in all but one, and 13 had no thrombosis in the false lumen.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"PATIENT_INFORMATION\">",
"    <span class=\"h1\">",
"     INFORMATION FOR PATIENTS",
"    </span>",
"    &nbsp;&mdash;&nbsp;UpToDate offers two types of patient education materials, &ldquo;The Basics&rdquo; and &ldquo;Beyond the Basics.&rdquo; The Basics patient education pieces are written in plain language, at the 5",
"    <sup>",
"     th",
"    </sup>",
"    to 6",
"    <sup>",
"     th",
"    </sup>",
"    grade reading level, and they answer the four or five key questions a patient might have about a given condition. These articles are best for patients who want a general overview and who prefer short, easy-to-read materials. Beyond the Basics patient education pieces are longer, more sophisticated, and more detailed. These articles are written at the 10",
"    <sup>",
"     th",
"    </sup>",
"    to 12",
"    <sup>",
"     th",
"    </sup>",
"    grade reading level and are best for patients who want in-depth information and are comfortable with some medical jargon.",
"   </p>",
"   <p>",
"    Here are the patient education articles that are relevant to this topic. We encourage you to print or e-mail these topics to your patients. (You can also locate patient education articles on a variety of subjects by searching on &ldquo;patient info&rdquo; and the keyword(s) of interest.)",
"   </p>",
"   <p>",
"    Basics topics (see",
"    <a class=\"medical medical_basics\" href=\"UTD.htm?29/38/30307?source=see_link\">",
"     \"Patient information: Aortic dissection (The Basics)\"",
"    </a>",
"    )",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H519604286\">",
"    <span class=\"h1\">",
"     SUMMARY AND RECOMMENDATIONS",
"    </span>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Thoracic aortic dissection is usually suspected clinically from the history and physical examination. Patients typically present with severe, sharp or \"tearing\" anterior chest pain, or posterior chest or back pain. If the dissection leads to impaired or absent blood flow to peripheral vessels, the physical examination may reveal a unilateral or bilateral pulse deficit (weak or absent carotid, brachial, femoral pulse). The diagnosis of aortic dissection is generally made noninvasively using computed tomography (CT), transesophageal echocardiography (TEE), or magnetic resonance imaging (MRI). (See",
"      <a class=\"local\" href=\"#H1\">",
"       'Introduction'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Aortic dissection is classified using two anatomic systems. The more commonly used system (Stanford) classifies dissections that involve the ascending aorta as type A, regardless of the site of the primary intimal tear, and all other dissections as type B. Ascending aortic dissections are almost twice as common as descending dissections. Isolated abdominal aortic dissection can also occur. Several anatomic variants of aortic dissection are described including intimal tear without hematoma, aortic intramural hematoma. These variants are felt to be precursors to classic aortic dissection and are treated similarly. (See",
"      <a class=\"local\" href=\"#H1\">",
"       'Introduction'",
"      </a>",
"      above and",
"      <a class=\"medical medical_review\" href=\"UTD.htm?25/19/25914?source=see_link&amp;anchor=H8#H8\">",
"       \"Clinical manifestations and diagnosis of aortic dissection\", section on 'Variants'",
"      </a>",
"      and",
"      <a class=\"medical medical_review\" href=\"UTD.htm?36/16/37126?source=see_link\">",
"       \"Aortic intramural hematoma\"",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      Acute ascending aortic dissection (Stanford type A) is a surgical emergency since these patients are at high risk for early life-threatening complications such as acute aortic regurgitation, cardiac tamponade, and myocardial infarction. Hemorrhagic stroke is a relative contraindication to urgent surgical intervention. When the aortic valve, sinuses, or arch are involved, the surgical approach involves a full root or hemiarch replacement. Hypothermic circulatory arrest has been used in repairs involving the aortic arch. A hybrid approach to the repair of type A aortic dissection, sometimes referred to as the &ldquo;frozen elephant trunk repair,&rdquo; uses an open approach to surgically repair the ascending aorta while using a thoracic endograft to manage the descending aorta. (See",
"      <a class=\"local\" href=\"#H8\">",
"       'Ascending (type A) aortic dissection'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Patients who are hemodynamically stable with uncomplicated aortic dissections confined to the descending thoracic aorta (Stanford type B) are best treated with medical therapy, but intervention in descending aortic dissections may be needed for patients who have a complicated course. Indications for intervention (surgical or endovascular) for type B dissection include occlusion of a major aortic branch leading to end-organ ischemia, persistent severe hypertension or pain, propagation of the dissection (as may be manifested by persistent or recurrent pain), aneurysmal expansion, and aortic rupture. Acute distal dissections in patients with Marfan syndrome may also be best treated with surgery. (See",
"      <a class=\"local\" href=\"#H5\">",
"       'Descending (type B) aortic dissection'",
"      </a>",
"      above.) &nbsp;",
"     </li>",
"     <li>",
"      Patients who will be managed medically (uncomplicated descending aortic dissection) and those awaiting intervention should be cared for in an intensive care unit, intubated if indicated, receive",
"      <a class=\"drug drug_general\" href=\"UTD.htm?19/31/19962?source=see_link\">",
"       morphine",
"      </a>",
"      to adequately control pain, and treated to lower heart rate and blood pressure. Intravenous beta blockers are initiated to reduce the heart rate below 60",
"      <span class=\"nowrap\">",
"       beats/min,",
"      </span>",
"      and maintain the systolic blood pressure between 100 to 120 mmHg or to the lowest level that is tolerated.",
"      <a class=\"drug drug_general\" href=\"UTD.htm?20/51/21302?source=see_link\">",
"       Nitroprusside",
"      </a>",
"      can be added to further control blood pressure but should",
"      <strong>",
"       not",
"      </strong>",
"      be given without first controlling the heart rate with beta blockade since vasodilation alone induces reflex activation of the sympathetic nervous system, which enhances ventricular contraction and increases aortic wall shear stress. Direct vasodilators, such as",
"      <a class=\"drug drug_general\" href=\"UTD.htm?14/57/15254?source=see_link\">",
"       hydralazine",
"      </a>",
"      , should be",
"      <strong>",
"       avoided",
"      </strong>",
"      . (See",
"      <a class=\"local\" href=\"#H3\">",
"       'Acute management'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Endovascular stent-grafting has been employed as a less invasive alternative to surgery, primarily in patients with complicated type B dissections. Morbidity and mortality rates are lower with stent-grafting compared with surgery under less urgent settings (eg, subacute or chronic dissection), but outcomes for acute or life-threatening dissections are not as favorable. Major complication rates using stent-grafts are significantly higher with acute compared with chronic aortic dissections. Outcomes are better in high-volume endovascular centers. (See",
"      <a class=\"local\" href=\"#H11\">",
"       'Endovascular stent-grafts'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Following treatment of aortic dissection (medical or intervention), the patients should be maintained on beta blocker or other antihypertensive therapy to minimize aortic wall stress with a target blood pressure less than",
"      <span class=\"nowrap\">",
"       120/80",
"      </span>",
"      mmHg. Predischarge thoracic MRI or chest CT should be performed with follow-up examinations at 3, 6, and 12 months to detect signs of dissection progression, redissection, or aneurysm formation (even if the patient remains asymptomatic). The patient should also avoid strenuous physical activity. We prefer thoracic MRI for younger patients, but chest CT scanning is an alternative. However, CT exposes the patient to ongoing radiation and requires iodinated contrast. Alternating chest CT and thoracic MR is a reasonable option. (See",
"      <a class=\"local\" href=\"#H16\">",
"       'Long-term management'",
"      </a>",
"      above.)",
"     </li>",
"    </ul>",
"   </p>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <h1>",
"    REFERENCES",
"   </h1>",
"   <ol id=\"reference\">",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?24/54/25449/abstract/1\">",
"      DEBAKEY ME, HENLY WS, COOLEY DA, et al. SURGICAL MANAGEMENT OF DISSECTING ANEURYSMS OF THE AORTA. J Thorac Cardiovasc Surg 1965; 49:130.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?24/54/25449/abstract/2\">",
"      Daily PO, Trueblood HW, Stinson EB, et al. Management of acute aortic dissections. Ann Thorac Surg 1970; 10:237.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?24/54/25449/abstract/3\">",
"      Erbel R, Alfonso F, Boileau C, et al. Diagnosis and management of aortic dissection. Eur Heart J 2001; 22:1642.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?24/54/25449/abstract/4\">",
"      Hagan PG, Nienaber CA, Isselbacher EM, et al. The International Registry of Acute Aortic Dissection (IRAD): new insights into an old disease. JAMA 2000; 283:897.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?24/54/25449/abstract/5\">",
"      Mehta RH, O'Gara PT, Bossone E, et al. Acute type A aortic dissection in the elderly: clinical characteristics, management, and outcomes in the current era. J Am Coll Cardiol 2002; 40:685.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?24/54/25449/abstract/6\">",
"      DE BAKEY ME, COOLEY DA, CREECH O Jr. Surgical considerations of dissecting aneurysm of the aorta. Ann Surg 1955; 142:586.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?24/54/25449/abstract/7\">",
"      DeSanctis RW, Doroghazi RM, Austen WG, Buckley MJ. Aortic dissection. N Engl J Med 1987; 317:1060.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?24/54/25449/abstract/8\">",
"      Tsai TT, Nienaber CA, Eagle KA. Acute aortic syndromes. Circulation 2005; 112:3802.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?24/54/25449/abstract/9\">",
"      Isselbacher EM, Cigarroa JE, Eagle KA. Cardiac tamponade complicating proximal aortic dissection. Is pericardiocentesis harmful? Circulation 1994; 90:2375.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?24/54/25449/abstract/10\">",
"      Crawford ES. The diagnosis and management of aortic dissection. JAMA 1990; 264:2537.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?24/54/25449/abstract/11\">",
"      Doroghazi RM, Slater EE, DeSanctis RW, et al. Long-term survival of patients with treated aortic dissection. J Am Coll Cardiol 1984; 3:1026.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?24/54/25449/abstract/12\">",
"      Suzuki T, Mehta RH, Ince H, et al. Clinical profiles and outcomes of acute type B aortic dissection in the current era: lessons from the International Registry of Aortic Dissection (IRAD). Circulation 2003; 108 Suppl 1:II312.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?24/54/25449/abstract/13\">",
"      Uma&ntilde;a JP, Lai DT, Mitchell RS, et al. Is medical therapy still the optimal treatment strategy for patients with acute type B aortic dissections? J Thorac Cardiovasc Surg 2002; 124:896.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?24/54/25449/abstract/14\">",
"      Bernard Y, Zimmermann H, Chocron S, et al. False lumen patency as a predictor of late outcome in aortic dissection. Am J Cardiol 2001; 87:1378.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?24/54/25449/abstract/15\">",
"      Estrera AL, Miller CC 3rd, Safi HJ, et al. Outcomes of medical management of acute type B aortic dissection. Circulation 2006; 114:I384.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?24/54/25449/abstract/16\">",
"      Erbel R, Oelert H, Meyer J, et al. Effect of medical and surgical therapy on aortic dissection evaluated by transesophageal echocardiography. Implications for prognosis and therapy. The European Cooperative Study Group on Echocardiography. Circulation 1993; 87:1604.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?24/54/25449/abstract/17\">",
"      Tsai TT, Evangelista A, Nienaber CA, et al. Partial thrombosis of the false lumen in patients with acute type B aortic dissection. N Engl J Med 2007; 357:349.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?24/54/25449/abstract/18\">",
"      Trimarchi S, Nienaber CA, Rampoldi V, et al. Role and results of surgery in acute type B aortic dissection: insights from the International Registry of Acute Aortic Dissection (IRAD). Circulation 2006; 114:I357.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?24/54/25449/abstract/19\">",
"      Nienaber CA, Eagle KA. Aortic dissection: new frontiers in diagnosis and management: Part I: from etiology to diagnostic strategies. Circulation 2003; 108:628.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?24/54/25449/abstract/20\">",
"      Mehta RH, Suzuki T, Hagan PG, et al. Predicting death in patients with acute type a aortic dissection. Circulation 2002; 105:200.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?24/54/25449/abstract/21\">",
"      Chiappini B, Schepens M, Tan E, et al. Early and late outcomes of acute type A aortic dissection: analysis of risk factors in 487 consecutive patients. Eur Heart J 2005; 26:180.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?24/54/25449/abstract/22\">",
"      Kawahito K, Adachi H, Yamaguchi A, Ino T. Early and late surgical outcomes of acute type A aortic dissection in patients aged 75 years and older. Ann Thorac Surg 2000; 70:1455.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?24/54/25449/abstract/23\">",
"      Nienaber CA, Fattori R, Mehta RH, et al. Gender-related differences in acute aortic dissection. Circulation 2004; 109:3014.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?24/54/25449/abstract/24\">",
"      Miller DC, Mitchell RS, Oyer PE, et al. Independent determinants of operative mortality for patients with aortic dissections. Circulation 1984; 70:I153.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?24/54/25449/abstract/25\">",
"      Haverich A, Miller DC, Scott WC, et al. Acute and chronic aortic dissections--determinants of long-term outcome for operative survivors. Circulation 1985; 72:II22.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?24/54/25449/abstract/26\">",
"      Pansini S, Gagliardotto PV, Pompei E, et al. Early and late risk factors in surgical treatment of acute type A aortic dissection. Ann Thorac Surg 1998; 66:779.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?24/54/25449/abstract/27\">",
"      Sabik JF, Lytle BW, Blackstone EH, et al. Long-term effectiveness of operations for ascending aortic dissections. J Thorac Cardiovasc Surg 2000; 119:946.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?24/54/25449/abstract/28\">",
"      Kawahito K, Adachi H, Yamaguchi A, Ino T. Preoperative risk factors for hospital mortality in acute type A aortic dissection. Ann Thorac Surg 2001; 71:1239.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?24/54/25449/abstract/29\">",
"      Lai DT, Robbins RC, Mitchell RS, et al. Does profound hypothermic circulatory arrest improve survival in patients with acute type a aortic dissection? Circulation 2002; 106:I218.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?24/54/25449/abstract/30\">",
"      Moon MR, Sundt TM 3rd, Pasque MK, et al. Does the extent of proximal or distal resection influence outcome for type A dissections? Ann Thorac Surg 2001; 71:1244.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?24/54/25449/abstract/31\">",
"      Kazui T, Washiyama N, Muhammad BA, et al. Extended total arch replacement for acute type a aortic dissection: experience with seventy patients. J Thorac Cardiovasc Surg 2000; 119:558.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?24/54/25449/abstract/32\">",
"      Bossone E, Rampoldi V, Nienaber CA, et al. Usefulness of pulse deficit to predict in-hospital complications and mortality in patients with acute type A aortic dissection. Am J Cardiol 2002; 89:851.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?24/54/25449/abstract/33\">",
"      Penn MS, Smedira N, Lytle B, Brener SJ. Does coronary angiography before emergency aortic surgery affect in-hospital mortality? J Am Coll Cardiol 2000; 35:889.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?24/54/25449/abstract/34\">",
"      Ehrlich MP, Schillinger M, Grabenw&ouml;ger M, et al. Predictors of adverse outcome and transient neurological dysfunction following surgical treatment of acute type A dissections. Circulation 2003; 108 Suppl 1:II318.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?24/54/25449/abstract/35\">",
"      Collins JS, Evangelista A, Nienaber CA, et al. Differences in clinical presentation, management, and outcomes of acute type a aortic dissection in patients with and without previous cardiac surgery. Circulation 2004; 110:II237.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?24/54/25449/abstract/36\">",
"      Movsowitz HD, Levine RA, Hilgenberg AD, Isselbacher EM. Transesophageal echocardiographic description of the mechanisms of aortic regurgitation in acute type A aortic dissection: implications for aortic valve repair. J Am Coll Cardiol 2000; 36:884.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?24/54/25449/abstract/37\">",
"      Tsai TT, Evangelista A, Nienaber CA, et al. Long-term survival in patients presenting with type A acute aortic dissection: insights from the International Registry of Acute Aortic Dissection (IRAD). Circulation 2006; 114:I350.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?24/54/25449/abstract/38\">",
"      Halstead JC, Meier M, Etz C, et al. The fate of the distal aorta after repair of acute type A aortic dissection. J Thorac Cardiovasc Surg 2007; 133:127.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?24/54/25449/abstract/39\">",
"      Nienaber CA, Fattori R, Lund G, et al. Nonsurgical reconstruction of thoracic aortic dissection by stent-graft placement. N Engl J Med 1999; 340:1539.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?24/54/25449/abstract/40\">",
"      Dake MD, Kato N, Mitchell RS, et al. Endovascular stent-graft placement for the treatment of acute aortic dissection. N Engl J Med 1999; 340:1546.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?24/54/25449/abstract/41\">",
"      Duebener LF, Lorenzen P, Richardt G, et al. Emergency endovascular stent-grafting for life-threatening acute type B aortic dissections. Ann Thorac Surg 2004; 78:1261.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?24/54/25449/abstract/42\">",
"      Eggebrecht H, Nienaber CA, Neuh&auml;user M, et al. Endovascular stent-graft placement in aortic dissection: a meta-analysis. Eur Heart J 2006; 27:489.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?24/54/25449/abstract/43\">",
"      Kusagawa H, Shimono T, Ishida M, et al. Changes in false lumen after transluminal stent-graft placement in aortic dissections: six years' experience. Circulation 2005; 111:2951.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?24/54/25449/abstract/44\">",
"      Chen LW, Dai XF, Lu L, et al. Extensive primary repair of the thoracic aorta in acute type a aortic dissection by means of ascending aorta replacement combined with open placement of triple-branched stent graft: early results. Circulation 2010; 122:1373.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?24/54/25449/abstract/45\">",
"      Uchida N, Shibamura H, Katayama A, et al. Operative strategy for acute type a aortic dissection: ascending aortic or hemiarch versus total arch replacement with frozen elephant trunk. Ann Thorac Surg 2009; 87:773.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?24/54/25449/abstract/46\">",
"      Murzi M, Tiwari KK, Farneti PA, Glauber M. Might type A acute dissection repair with the addition of a frozen elephant trunk improve long-term survival compared to standard repair? Interact Cardiovasc Thorac Surg 2010; 11:98.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?24/54/25449/abstract/47\">",
"      Uchida N, Katayama A, Tamura K, et al. Long-term results of the frozen elephant trunk technique for extended aortic arch disease. Eur J Cardiothorac Surg 2010; 37:1338.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?24/54/25449/abstract/48\">",
"      Gorlitzer M, Weiss G, Meinhart J, et al. Fate of the false lumen after combined surgical and endovascular repair treating Stanford type A aortic dissections. Ann Thorac Surg 2010; 89:794.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?24/54/25449/abstract/49\">",
"      Pichlmaier MA, Teebken OE, Khaladj N, et al. Distal aortic surgery following arch replacement with a frozen elephant trunk. Eur J Cardiothorac Surg 2008; 34:600.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?24/54/25449/abstract/50\">",
"      Mestres CA, Fern&aacute;ndez C, Josa M, Mulet J. Hybrid antegrade repair of the arch and descending thoracic aorta with a new integrated stent-Dacron graft in acute type A aortic dissection: a look into the future with new devices. Interact Cardiovasc Thorac Surg 2007; 6:257.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?24/54/25449/abstract/51\">",
"      Baraki H, Hagl C, Khaladj N, et al. The frozen elephant trunk technique for treatment of thoracic aortic aneurysms. Ann Thorac Surg 2007; 83:S819.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?24/54/25449/abstract/52\">",
"      Schoenhoff FS, Schmidli J, Eckstein FS, et al. The frozen elephant trunk: an interesting hybrid endovascular-surgical technique to treat complex pathologies of the thoracic aorta. J Vasc Surg 2007; 45:597.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?24/54/25449/abstract/53\">",
"      Karck M, Kamiya H. Progress of the treatment for extended aortic aneurysms; is the frozen elephant trunk technique the next standard in the treatment of complex aortic disease including the arch? Eur J Cardiothorac Surg 2008; 33:1007.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?24/54/25449/abstract/54\">",
"      Roselli EE, Soltesz EG, Mastracci T, et al. Antegrade delivery of stent grafts to treat complex thoracic aortic disease. Ann Thorac Surg 2010; 90:539.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?24/54/25449/abstract/55\">",
"      Baraki H, Al Ahmad A, Sarikouch S, et al. The first fifty consecutive Bentall operations with a prefabricated tissue-valved aortic conduit: a single-center experience. J Heart Valve Dis 2010; 19:286.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?24/54/25449/abstract/56\">",
"      Karck M, Chavan A, Khaladj N, et al. The frozen elephant trunk technique for the treatment of extensive thoracic aortic aneurysms: operative results and follow-up. Eur J Cardiothorac Surg 2005; 28:286.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?24/54/25449/abstract/57\">",
"      Karck M, Chavan A, Hagl C, et al. The frozen elephant trunk technique: a new treatment for thoracic aortic aneurysms. J Thorac Cardiovasc Surg 2003; 125:1550.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?24/54/25449/abstract/58\">",
"      Usui A, Fujimoto K, Ishiguchi T, et al. Cerebrospinal dysfunction after endovascular stent-grafting via a median sternotomy: the frozen elephant trunk procedure. Ann Thorac Surg 2002; 74:S1821.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?24/54/25449/abstract/59\">",
"      Slonim SM, Miller DC, Mitchell RS, et al. Percutaneous balloon fenestration and stenting for life-threatening ischemic complications in patients with acute aortic dissection. J Thorac Cardiovasc Surg 1999; 117:1118.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?24/54/25449/abstract/60\">",
"      Glower DD, Speier RH, White WD, et al. Management and long-term outcome of aortic dissection. Ann Surg 1991; 214:31.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?24/54/25449/abstract/61\">",
"      Isselbacher EM. Dissection of the descending thoracic aorta: looking into the future. J Am Coll Cardiol 2007; 50:805.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?24/54/25449/abstract/62\">",
"      Song JM, Kim SD, Kim JH, et al. Long-term predictors of descending aorta aneurysmal change in patients with aortic dissection. J Am Coll Cardiol 2007; 50:799.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?24/54/25449/abstract/63\">",
"      Fattori R, Bacchi-Reggiani L, Bertaccini P, et al. Evolution of aortic dissection after surgical repair. Am J Cardiol 2000; 86:868.",
"     </a>",
"    </li>",
"   </ol>",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 8188 Version 9.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.6- C21.56",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     AsanBook Dig. Med. Lib.",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [0505-61.234.146.186-D9A34E86B4-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f24_54_25449=[""].join("\n");
var outline_f24_54_25449=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li>",
"     <a class=\"sr_button\" href=\"#H519604286\" id=\"summRecButton\">",
"      <span>",
"       SUMMARY &amp; RECOMMENDATIONS",
"      </span>",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H1\">",
"      INTRODUCTION",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H2\">",
"      GENERAL PRINCIPLES",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H3\">",
"      ACUTE MANAGEMENT",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H4\">",
"      DEFINITIVE THERAPY",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H5\">",
"      Descending (type B) aortic dissection",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H6\">",
"      - Medical therapy",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H7\">",
"      - Intervention",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H8\">",
"      Ascending (type A) aortic dissection",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H9\">",
"      - Evaluation for CAD and aortic valve disease",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H10\">",
"      - Survival after repair",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H11\">",
"      Endovascular stent-grafts",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H12\">",
"      - Type B dissections",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H13\">",
"      - Type A dissections",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H14\">",
"      Fenestration and other stents",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H15\">",
"      PROGNOSIS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H16\">",
"      LONG-TERM MANAGEMENT",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H17\">",
"      Medical therapy",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H18\">",
"      Serial imaging",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H19\">",
"      Reoperation",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#PATIENT_INFORMATION\">",
"      INFORMATION FOR PATIENTS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H519604286\">",
"      SUMMARY AND RECOMMENDATIONS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a href=\"#references\">",
"      REFERENCES",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   <div class=\"openRelatedGraphics\" id=\"SURG/8188\" rel=\"outline_link\">",
"    GRAPHICS",
"    <a class=\"graphics_icon\" href=\"#\" title=\"View All Related Graphics\">",
"     View All",
"    </a>",
"   </div>",
"  </h1>",
"  <div id=\"relatedGraphics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"SURG/8188|TAB\">",
"      <a href=\"#\" title=\"TABLES\">",
"       TABLES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?35/46/36588\" title=\"table 1\">",
"      Initial management of patients with suspected aortic dissection",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?8/57/9116\" title=\"table 2\">",
"      Management of unstable aortic dissection",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?3/62/4076\" title=\"table 3\">",
"      Therapy of acute type B aortic dissection",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?14/45/15068\" title=\"table 4\">",
"      Surgical therapy of acute type A aortic dissection",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?19/29/19932\" title=\"table 5\">",
"      Interventional therapy in aortic dissection",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?19/34/20012\" title=\"table 6\">",
"      Imaging in chronic aortic dissection",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?14/41/15004\" title=\"table 7\">",
"      Reoperation following repair of aortic dissection",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?12/33/12828\" title=\"table 8\">",
"      Therapy of chronic aortic dissection",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?36/16/37126?source=related_link\">",
"      Aortic intramural hematoma",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?25/19/25914?source=related_link\">",
"      Clinical manifestations and diagnosis of aortic dissection",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?18/26/18853?source=related_link\">",
"      Drug treatment of hypertensive emergencies",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?5/51/5945?source=related_link\">",
"      Management of Marfan syndrome and related disorders",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?30/22/31082?source=related_link\">",
"      Nephrogenic systemic fibrosis/nephrogenic fibrosing dermopathy in advanced renal failure",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?10/13/10457?source=related_link\">",
"      Pathogenesis, clinical features, and diagnosis of contrast-induced nephropathy",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_basics\" href=\"UTD.htm?29/38/30307?source=related_link\">",
"      Patient information: Aortic dissection (The Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?34/39/35445?source=related_link\">",
"      Transesophageal echocardiography in the evaluation of aortic valve disease",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f24_54_25450="Management of the complications of the myelodysplastic syndromes";
var content_f24_54_25450=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"5\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"topicTitle\">",
"   Management of the complications of the myelodysplastic syndromes",
"  </div>",
"  <div id=\"topicContributors\">",
"   <div>",
"    <a id=\"authors\">",
"    </a>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?24/54/25450/contributors\">",
"     Authors",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?24/54/25450/contributors\">",
"     Elihu H Estey, MD",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?24/54/25450/contributors\">",
"     Stanley L Schrier, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?24/54/25450/contributors\">",
"     Section Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?24/54/25450/contributors\">",
"     Richard A Larson, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?24/54/25450/contributors\">",
"     Deputy Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?24/54/25450/contributors\">",
"     Rebecca F Connor, MD",
"    </a>",
"    <br/>",
"   </div>",
"  </div>",
"  <div id=\"disclosures\">",
"   <a href=\"UTD.htm?24/54/25450/contributor-disclosure\" target=\"_blank\">",
"    Disclosures",
"   </a>",
"  </div>",
"  <div id=\"reviewProcess\">",
"   <span>",
"    All topics are updated as new evidence becomes available and our",
"   </span>",
"   <a href=\"/home/editorial-policy\" target=\"_blank\">",
"    peer review process",
"   </a>",
"   <span>",
"    is complete.",
"   </span>",
"  </div>",
"  <div id=\"literatureReviewDate\">",
"   <span class=\"emphasis\">",
"    Literature review current through:",
"   </span>",
"   Oct 2013.",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <span class=\"emphasis\">",
"    This topic last updated:",
"   </span>",
"   Apr 5, 2013.",
"  </div>",
"  <div id=\"topicText\">",
"   <p class=\"headingAnchor\" id=\"H2100015\">",
"    <span class=\"h1\">",
"     INTRODUCTION",
"    </span>",
"    &nbsp;&mdash;&nbsp;The myelodysplastic syndromes (MDS) encompass a series of hematologic conditions characterized by chronic cytopenias (anemia, neutropenia, thrombocytopenia) accompanied by abnormal cellular maturation. As a result, patients with MDS are at risk for symptomatic anemia, infection, and bleeding, as well as progression to acute myeloid leukemia (AML), which is often refractory to standard treatment. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?38/35/39480?source=see_link\">",
"     \"Therapy-related myeloid neoplasms: Acute myeloid leukemia and myelodysplastic syndrome\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Most patients with MDS die because of the consequences of bone marrow failure rather than transformation to AML. Thus, use of terms such as \"pre-leukemia\" or \"smoldering leukemia\" can be misleading, if taken to imply that death or morbidity from MDS results only when AML develops. Indeed, the distinction between MDS and AML is itself arbitrary, as patients with 20 to 30 percent blasts are considered to have MDS by French-American-British (FAB) criteria, but AML by the World Health Organization (WHO) classification.",
"   </p>",
"   <p>",
"    For many years, transfusion with packed red blood cells and platelets and the use of erythropoiesis-stimulating agents were the only therapy available. More recently, chemotherapy agents directed at the underlying disorder have been developed and continue to be studied for patients with MDS (eg,",
"    <a class=\"drug drug_general\" href=\"UTD.htm?12/40/12935?source=see_link\">",
"     azacitidine",
"    </a>",
"    ,",
"    <a class=\"drug drug_general\" href=\"UTD.htm?38/59/39861?source=see_link\">",
"     decitabine",
"    </a>",
"    , and",
"    <a class=\"drug drug_general\" href=\"UTD.htm?16/25/16793?source=see_link\">",
"     lenalidomide",
"    </a>",
"    ). However, due to the advanced age of most patients, the chronicity of the disease, and its attendant morbidities, supportive care remains a central component of the management of all patients with MDS. Patients should be treated as needed with antibiotics for infection and platelet transfusions for bleeding in the setting of thrombocytopenia.",
"   </p>",
"   <p>",
"    This topic will review the major complications of MDS and the role of supportive care in its management. The diagnosis of MDS, the prognosis of MDS, and the treatment of the underlying disorder are presented separately. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?30/30/31210?source=see_link\">",
"     \"Treatment of intermediate, low, or very low risk myelodysplastic syndromes\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?33/39/34425?source=see_link&amp;anchor=H2102505#H2102505\">",
"     \"Prognosis of the myelodysplastic syndromes in adults\", section on 'Other prognostic features'",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?8/39/8826?source=see_link\">",
"     \"Hematopoietic cell transplantation in myelodysplastic syndromes\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?14/35/14905?source=see_link\">",
"     \"Cytogenetics and molecular genetics of myelodysplastic syndromes\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H7193969\">",
"    <span class=\"h1\">",
"     ANEMIA",
"    </span>",
"    &nbsp;&mdash;&nbsp;Patients with MDS typically present with a normocytic or macrocytic anemia that can vary in severity. At least 80 percent of patients are anemic at the time of diagnosis, while about 50 percent have a hemoglobin level less than 10",
"    <span class=\"nowrap\">",
"     g/dL",
"    </span>",
"    [",
"    <a class=\"abstract\" href=\"UTD.htm?24/54/25450/abstract/1\">",
"     1",
"    </a>",
"    ]. Anemia can manifest as fatigue, weakness, exercise intolerance, angina, dizziness, cognitive impairment, or an altered sense of well being. The degree of anemia is also a prognostic marker in patients with MDS. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?33/39/34425?source=see_link&amp;anchor=H861596#H861596\">",
"     \"Prognosis of the myelodysplastic syndromes in adults\", section on 'WHO prognostic scoring system (WPSS)'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Patients with anemia should be evaluated for other causes of anemia including gastrointestinal blood loss, hemolysis, renal insufficiency, and nutritional deficiencies. An initial evaluation should include a drug exposure history, review of the peripheral smear, reticulocyte count, an investigation for occult blood loss, renal insufficiency, and measurement of iron, folate, and vitamin B12 levels. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?28/46/29418?source=see_link&amp;anchor=H15#H15\">",
"     \"Approach to the adult patient with anemia\", section on 'Causes of anemia'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    The anemia of MDS is primarily managed with red cell transfusions. However, chronic transfusional support may lead to iron overload and secondary hemochromatosis. Erythropoietic stimulating agents (ESAs) may decrease or minimize the need for red cell transfusions in patients with low or intermediate-risk disease, as calculated by the IPSS score (",
"    <a class=\"calc calc_professional\" href=\"UTD.htm?9/14/9441?source=see_link\">",
"     calculator 1",
"    </a>",
"    ), who demonstrate a low serum erythropoietin level (&le;500",
"    <span class=\"nowrap\">",
"     mU/ml)",
"    </span>",
"    and low transfusion requirements (&lt;2",
"    <span class=\"nowrap\">",
"     units/month).",
"    </span>",
"    Although patients with MDS have normal or elevated iron stores, red cell transfusions increase iron stores and therefore increase serum ferritin levels. As discussed below, high ferritin levels often prompt administration of iron chelators, although whether this practice improves survival is unknown. (See",
"    <a class=\"local\" href=\"#H2104230\">",
"     'Iron overload'",
"    </a>",
"    below and",
"    <a class=\"local\" href=\"#H7195992\">",
"     'Erythropoiesis stimulating agents'",
"    </a>",
"    below.)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H7195483\">",
"    <span class=\"h2\">",
"     Red cell transfusions",
"    </span>",
"    &nbsp;&mdash;&nbsp;Long term red cell transfusion support is the primary management option for anemia in MDS. The threshold for transfusion of packed red blood cells varies with patient age, symptoms, and the presence of medical comorbidities. In general, most centers recommend transfusion to asymptomatic patients with a hemoglobin &le;8",
"    <span class=\"nowrap\">",
"     g/dL",
"    </span>",
"    (5",
"    <span class=\"nowrap\">",
"     mmol/liter).",
"    </span>",
"   </p>",
"   <p>",
"    In order to diminish complications due to the presence of leukocytes within the transfusions (eg, platelet isosensitization, cytomegalovirus and other viral infections, febrile transfusion reactions, and immunosuppression), the use of prestorage leukoreduced transfusion products is encouraged [",
"    <a class=\"abstract\" href=\"UTD.htm?24/54/25450/abstract/2,3\">",
"     2,3",
"    </a>",
"    ]. Although graft-versus-host disease is very unusual in patients with MDS receiving transfusions, many centers routinely irradiate blood products for such patients. The administration of cytomegalovirus negative, irradiated blood products is of special importance for patients who are candidates for hematopoietic cell transplantation. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?24/5/24665?source=see_link\">",
"     \"Leukoreduction to prevent complications of blood transfusion\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?5/52/5961?source=see_link\">",
"     \"Indications for red cell transfusion in the adult\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Red blood cell (RBC) transfusions are almost universally successful in raising hemoglobin levels. Transfusions can often ameliorate the patient's symptoms rapidly and improve health-related quality of life. Exceptions include patients unable to be transfused because of the presence of multiple alloantibodies and those who refuse transfusions based on religious beliefs. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?10/46/10986?source=see_link\">",
"     \"The approach to the patient who refuses blood transfusion\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?2/22/2407?source=see_link&amp;anchor=H13#H13\">",
"     \"Compatibility testing\", section on 'Crossmatching in the presence of antibodies'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    The use of RBC transfusions to treat anemia is discussed in more detail separately. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?20/37/21081?source=see_link\">",
"     \"Use of red blood cells for transfusion\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?5/52/5961?source=see_link\">",
"     \"Indications for red cell transfusion in the adult\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H7195992\">",
"    <span class=\"h2\">",
"     Erythropoiesis stimulating agents",
"    </span>",
"    &nbsp;&mdash;&nbsp;The use of erythropoiesis stimulating agents (ESAs) for the treatment of symptomatic anemia in patients with MDS is an unlabeled or investigational use according to the US Food and Drug Administration. However, their use in MDS is supported by the American Society of Hematology (ASH), the American Society of Clinical Oncology (ASCO), and the National Comprehensive Cancer Network (NCCN) [",
"    <a class=\"abstract\" href=\"UTD.htm?24/54/25450/abstract/4-6\">",
"     4-6",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    ESAs (ie, erythropoietin or darbepoetin), administered alone or in combination with granulocyte colony stimulating factor (G-CSF) or granulocyte macrophage colony stimulating factor (GM-CSF), may decrease or minimize the need for red cell transfusions in patients with low or intermediate-1 risk MDS, as calculated by the IPSS score. Patients with lower endogenous serum erythropoietin levels and a lower red cell transfusion requirement are more likely to respond to ESAs. (See",
"    <a class=\"local\" href=\"#H7196544\">",
"     'Combination therapy (EPO + G-CSF)'",
"    </a>",
"    below.)",
"   </p>",
"   <p>",
"    We suggest that symptomatic anemic patients with low serum erythropoietin levels (&lt;500",
"    <span class=\"nowrap\">",
"     mU/mL),",
"    </span>",
"    particularly those with low transfusion requirements (&lt;2",
"    <span class=\"nowrap\">",
"     units/month)",
"    </span>",
"    and a low or intermediate-1 risk IPSS score (",
"    <a class=\"calc calc_professional\" href=\"UTD.htm?9/14/9441?source=see_link\">",
"     calculator 1",
"    </a>",
"    ) be treated with erythropoietin. G-CSF may be added if erythropoietin is unsuccessful after three months in a patient with severe anemia or after six months if the anemia is less severe. Our decision to use erythropoietin alone rather than combination therapy is principally based upon the lack of evidence that combination therapy is superior to high dose erythropoietin, the high cost of combination therapy, and the added toxicity (ie, bone pain and fevers) when G-CSF is administered. However, given the relatively high expense of these drugs at the doses employed and the unknown effects on quality of life, red cell transfusion therapy remains an acceptable alternative.",
"   </p>",
"   <p>",
"    Patients with low- or intermediate-1 risk MDS are an",
"    <strong>",
"     exception",
"    </strong>",
"    to the general recommendation from ASH and ASCO to avoid ESAs for the treatment of anemia associated with malignancy in patients who are not receiving concurrent myelosuppressive chemotherapy [",
"    <a class=\"abstract\" href=\"UTD.htm?24/54/25450/abstract/4,5\">",
"     4,5",
"    </a>",
"    ]. As with any clinical intervention, use of erythropoietin must be based upon the",
"    <span class=\"nowrap\">",
"     benefit/risk",
"    </span>",
"    ratio in a given patient. While the risk of shortened survival following use of erythropoietin has been seen with other cancers, the same has not been found with MDS. However, it is plausible that erythropoietin may shorten survival in MDS, particularly in patients with characteristics associated with a relatively long natural history (ie, low or intermediate-1 IPSS). (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?37/15/38138?source=see_link&amp;anchor=H13#H13\">",
"     \"Role of erythropoiesis-stimulating agents in the treatment of anemia in patients with cancer\", section on 'Effect on disease control and survival'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H1870050\">",
"    <span class=\"h3\">",
"     Erythropoietin or darbepoetin",
"    </span>",
"    &nbsp;&mdash;&nbsp;Clinical trials have established that the erythropoiesis stimulating agents (ESAs) erythropoietin and darbepoetin are effective in raising hemoglobin levels and decreasing transfusion requirements in patients with MDS who have an inappropriately low erythropoietin concentration for the degree of anemia present [",
"    <a class=\"abstract\" href=\"UTD.htm?24/54/25450/abstract/7,8\">",
"     7,8",
"    </a>",
"    ]. While some studies have demonstrated improvements in quality of life, ESAs have not been shown to improve overall survival rates. Both erythropoietin and darbepoetin appear to be equivalent with regard to efficacy and safety [",
"    <a class=\"abstract\" href=\"UTD.htm?24/54/25450/abstract/4,5\">",
"     4,5",
"    </a>",
"    ]. Initial prospective trials suggest that granulocyte colony stimulating factor (G-CSF) can synergize the effects of ESAs in this population. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?37/15/38138?source=see_link&amp;anchor=H7#H7\">",
"     \"Role of erythropoiesis-stimulating agents in the treatment of anemia in patients with cancer\", section on 'ESAs: efficacy, side effects, and clinical use'",
"    </a>",
"    and",
"    <a class=\"local\" href=\"#H7196544\">",
"     'Combination therapy (EPO + G-CSF)'",
"    </a>",
"    below.)",
"   </p>",
"   <p>",
"    Initial efficacy studies reported that 20 to 55 percent of patients with MDS respond to treatment with ESAs [",
"    <a class=\"abstract\" href=\"UTD.htm?24/54/25450/abstract/9-15\">",
"     9-15",
"    </a>",
"    ]. Several dosing strategies have been evaluated including:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Erythropoietin 150 to 300",
"      <span class=\"nowrap\">",
"       units/kg",
"      </span>",
"      daily [",
"      <a class=\"abstract\" href=\"UTD.htm?24/54/25450/abstract/9\">",
"       9",
"      </a>",
"      ]",
"     </li>",
"     <li>",
"      Erythropoietin &ge;150",
"      <span class=\"nowrap\">",
"       units/kg",
"      </span>",
"      three times weekly [",
"      <a class=\"abstract\" href=\"UTD.htm?24/54/25450/abstract/10\">",
"       10",
"      </a>",
"      ]",
"     </li>",
"     <li>",
"      Erythropoietin 40,000 units once per week [",
"      <a class=\"abstract\" href=\"UTD.htm?24/54/25450/abstract/11\">",
"       11",
"      </a>",
"      ]",
"     </li>",
"     <li>",
"      Darbepoetin alpha 75 to 400 micrograms",
"      <span class=\"nowrap\">",
"       once/week",
"      </span>",
"      [",
"      <a class=\"abstract\" href=\"UTD.htm?24/54/25450/abstract/13,15\">",
"       13,15",
"      </a>",
"      ]",
"     </li>",
"     <li>",
"      Darbepoetin alpha 500 micrograms every two to three weeks [",
"      <a class=\"abstract\" href=\"UTD.htm?24/54/25450/abstract/14\">",
"       14",
"      </a>",
"      ].",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Although prospective trials comparing the various regimens have not been performed, erythropoietin given alone at higher doses (60,000 to 80,000",
"    <span class=\"nowrap\">",
"     U/week)",
"    </span>",
"    may be more effective than erythropoietin given at lower doses along with G-CSF or GM-CSF [",
"    <a class=\"abstract\" href=\"UTD.htm?24/54/25450/abstract/16\">",
"     16",
"    </a>",
"    ]. Responses are more likely in those patients with serum erythropoietin levels &lt;100 or &lt;200",
"    <span class=\"nowrap\">",
"     mU/mL",
"    </span>",
"    [",
"    <a class=\"abstract\" href=\"UTD.htm?24/54/25450/abstract/9,12,14,17,18\">",
"     9,12,14,17,18",
"    </a>",
"    ], and in patients with lower transfusion needs (&lt;2",
"    <span class=\"nowrap\">",
"     units/month)",
"    </span>",
"    [",
"    <a class=\"abstract\" href=\"UTD.htm?24/54/25450/abstract/19\">",
"     19",
"    </a>",
"    ]. (See",
"    <a class=\"local\" href=\"#H7196544\">",
"     'Combination therapy (EPO + G-CSF)'",
"    </a>",
"    below.)",
"   </p>",
"   <p>",
"    The response to ESAs may be delayed, as shown in a study of 281 patients with MDS treated with erythropoietin (150",
"    <span class=\"nowrap\">",
"     units/kg",
"    </span>",
"    administered subcutaneously three times a week) for a minimum of 26 weeks [",
"    <a class=\"abstract\" href=\"UTD.htm?24/54/25450/abstract/20\">",
"     20",
"    </a>",
"    ]. Overall response rates at 12 and 26 weeks were 18 and 45 percent, respectively. At 26 weeks, response rates for patients with subtypes refractory anemia (RA), refractory anemia with ring sideroblasts (RARS), refractory anemia with excess blasts-I (RAEB-I) and refractory anemia with excess blasts-II (RAEB-II) were 48, 58, 34, and 13 percent, respectively (",
"    <a class=\"graphic graphic_table graphicRef71654 \" href=\"UTD.htm?9/48/9996\">",
"     table 1",
"    </a>",
"    ). Predictors of response at 26 weeks included patients with RA, those with \"good\" karyotype, and initial erythropoietin levels &lt;150",
"    <span class=\"nowrap\">",
"     mU/mL.",
"    </span>",
"    Side effects were few, and included irritation at local injection sites, hypertension, and skin rash. Thrombocytopenia was noted in six patients between 36 and 58 weeks of treatment. ESAs should",
"    <strong>",
"     not",
"    </strong>",
"    be continued indefinitely if no response is observed.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H7196544\">",
"    <span class=\"h3\">",
"     Combination therapy (EPO + G-CSF)",
"    </span>",
"    &nbsp;&mdash;&nbsp;Low dose granulocyte colony stimulating factor (G-CSF) appears to have a synergistic effect with erythropoiesis stimulating agents (ESAs) in MDS [",
"    <a class=\"abstract\" href=\"UTD.htm?24/54/25450/abstract/21\">",
"     21",
"    </a>",
"    ]. Randomized and nonrandomized prospective trials of ESAs in patients with MDS have substantiated this thesis by demonstrating improved erythroid response in patients given combination therapy with G-CSF and erythropoietin [",
"    <a class=\"abstract\" href=\"UTD.htm?24/54/25450/abstract/9,15,21-25\">",
"     9,15,21-25",
"    </a>",
"    ]. No randomized study has shown improvement in survival for patients with MDS treated with erythropoietin plus G-CSF and further randomized trials are needed to optimize dosing.",
"   </p>",
"   <p>",
"    The combination of G-CSF (initial dose 1",
"    <span class=\"nowrap\">",
"     microgram/kg",
"    </span>",
"    per day SQ) plus epoetin (150 to 300",
"    <span class=\"nowrap\">",
"     units/kg",
"    </span>",
"    per day SQ) results in a substantial erythroid response (ie, decreased transfusion requirements and increased hemoglobin concentrations) in approximately 40 to 47 percent of patients [",
"    <a class=\"abstract\" href=\"UTD.htm?24/54/25450/abstract/9\">",
"     9",
"    </a>",
"    ]. Initial response rates as high as 60 to 80 percent were noted in one study [",
"    <a class=\"abstract\" href=\"UTD.htm?24/54/25450/abstract/25\">",
"     25",
"    </a>",
"    ]. Nearly all patients receiving G-CSF and epoetin have responses in neutrophil count. Erythroid responses persist for many months in the majority of patients receiving both epoetin and G-CSF [",
"    <a class=\"abstract\" href=\"UTD.htm?24/54/25450/abstract/21,22,24\">",
"     21,22,24",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Granulocyte-macrophage colony stimulating factor (GM-CSF) has also been evaluated in patients with MDS. Although not studied in a randomized fashion, GM-CSF appears to result in lower response rates than G-CSF. As an example, in a study of 66 patients with MDS, most of whom had refractory anemia (RA) or refractory anemia with excess blasts (RAEB), stratified according to the serum erythropoietin concentration (&le;500 or &gt;500",
"    <span class=\"nowrap\">",
"     mU/mL)",
"    </span>",
"    and then randomly assigned to receive GM-CSF (0.3 to 5.0",
"    <span class=\"nowrap\">",
"     microgram/kg",
"    </span>",
"    per day) with or without erythropoietin (150",
"    <span class=\"nowrap\">",
"     units/kg",
"    </span>",
"    three times per week), a hemoglobin response was seen in 5 to 9 percent [",
"    <a class=\"abstract\" href=\"UTD.htm?24/54/25450/abstract/26\">",
"     26",
"    </a>",
"    ]. The mean neutrophil count increased from 948 to",
"    <span class=\"nowrap\">",
"     3831/microL",
"    </span>",
"    during treatment with GM-CSF with or without epoetin. A significant fall in transfusion requirements occurred only in those patients with lower serum erythropoietin concentrations who received epoetin. GM-CSF with or without epoetin had no effect on the platelet count. Although treatment was generally well tolerated, 10 patients withdrew from the study, primarily due to GM-CSF toxicity.",
"   </p>",
"   <p>",
"    Epoetin given alone at higher doses may be more effective than epoetin given at lower doses along with G-CSF or GM-CSF. This was suggested in a meta-analysis of 15 trials in patients with MDS which compared the effectiveness of epoetin in the following three treatment regimens: standard dose epoetin (30,000 to 40,000",
"    <span class=\"nowrap\">",
"     units/week),",
"    </span>",
"    standard dose epoetin plus G-CSF or GM-CSF, and epoetin at high dose (60,000 to 80,000",
"    <span class=\"nowrap\">",
"     U/week).",
"    </span>",
"    Results included [",
"    <a class=\"abstract\" href=\"UTD.htm?24/54/25450/abstract/16\">",
"     16",
"    </a>",
"    ]:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Overall erythroid response rates were 49, 51, and 64 percent for the three treatment groups, respectively.",
"     </li>",
"     <li>",
"      Major erythroid response rates (ie, hemoglobin increase &ge;2",
"      <span class=\"nowrap\">",
"       g/dL",
"      </span>",
"      <span class=\"nowrap\">",
"       and/or",
"      </span>",
"      complete transfusion independence) were 27, 30, and 45 percent, respectively.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    The issue of optimal epoetin dose and the value of adding G-CSF will require a randomized trial comparing standard to high doses of epoetin, each with or without added G-CSF.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H7197283\">",
"    <span class=\"h4\">",
"     Predictors of response",
"    </span>",
"    &nbsp;&mdash;&nbsp;The major predictors of a response to treatment with epoetin and G-CSF include lower endogenous serum erythropoietin levels (&lt;500",
"    <span class=\"nowrap\">",
"     mU/mL)",
"    </span>",
"    and a lower prior red cell transfusion requirement (&lt;2",
"    <span class=\"nowrap\">",
"     units/month)",
"    </span>",
"    [",
"    <a class=\"abstract\" href=\"UTD.htm?24/54/25450/abstract/9,22\">",
"     9,22",
"    </a>",
"    ]. This was validated in a separate prospective study, in which patients with both or only one of these predictors had response rates of 61 versus 14 percent, respectively [",
"    <a class=\"abstract\" href=\"UTD.htm?24/54/25450/abstract/19\">",
"     19",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    When compared with patients with higher IPSS scores (",
"    <a class=\"graphic graphic_table graphicRef50634 \" href=\"UTD.htm?26/37/27228\">",
"     table 2",
"    </a>",
"    ), patients with low or intermediate-1 IPSS scores has a higher rate of hemoglobin response (46 versus 27 percent, respectively), a longer duration of response (25 versus 7 months, respectively), and no increase in the risk of progression to AML or death [",
"    <a class=\"abstract\" href=\"UTD.htm?24/54/25450/abstract/27\">",
"     27",
"    </a>",
"    ]. Similar results were reported from the GFM (Groupe Francophone des Myelodysplasies) as well as in a phase III ECOG trial [",
"    <a class=\"abstract\" href=\"UTD.htm?24/54/25450/abstract/9,28\">",
"     9,28",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    In other studies, predictors of response to treatment with both agents included [",
"    <a class=\"abstract\" href=\"UTD.htm?24/54/25450/abstract/9,28-30\">",
"     9,28-30",
"    </a>",
"    ]:",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      Serum erythropoietin levels &lt;200",
"      <span class=\"nowrap\">",
"       mU/mL",
"      </span>",
"      or &lt;100",
"      <span class=\"nowrap\">",
"       mU/mL",
"      </span>",
"     </li>",
"     <li>",
"      Absence of aberrant (lymphoid) markers on bone marrow blasts",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Based upon this and other data, we suggest that symptomatic anemic patients with low serum erythropoietin levels (&lt;500",
"    <span class=\"nowrap\">",
"     mU/mL)",
"    </span>",
"    and a low or intermediate-1 risk IPSS score (",
"    <a class=\"calc calc_professional\" href=\"UTD.htm?9/14/9441?source=see_link\">",
"     calculator 1",
"    </a>",
"    ), particularly if accompanied by low transfusion requirements (&lt;2",
"    <span class=\"nowrap\">",
"     units/month),",
"    </span>",
"    be treated with epoetin, with G-CSF added, or the erythropoietin dose increased, if erythropoietin is unsuccessful at lower doses. However, given the relatively high expense of these drugs at the doses employed and the unknown effects on quality of life, red cell transfusion therapy remains an acceptable alternative.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H7197290\">",
"    <span class=\"h4\">",
"     Effect on survival",
"    </span>",
"    &nbsp;&mdash;&nbsp;No randomized study has shown improvement in survival for patients with MDS treated with epoetin plus G-CSF. While the risk of shortened survival following use of epoetin has been seen with other cancers, the same has not been found with MDS. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?37/15/38138?source=see_link&amp;anchor=H13#H13\">",
"     \"Role of erythropoiesis-stimulating agents in the treatment of anemia in patients with cancer\", section on 'Effect on disease control and survival'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    In a phase III ECOG trial of 110 evaluable patients with lower-risk MDS with a median follow-up of 5.8 years, subjects with MDS who were treated with epoetin &plusmn; G-CSF, when compared with those receiving supportive care only, had similar overall survival (3.1 versus 2.6 years, respectively) and a similar incidence of transformation to acute myeloid leukemia (7.5 versus 10.5 percent, respectively) [",
"    <a class=\"abstract\" href=\"UTD.htm?24/54/25450/abstract/9\">",
"     9",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Survival was indirectly addressed in two retrospective studies, in which patients with MDS treated with epoetin plus G-CSF were compared with contemporary or historical control groups treated with supportive care only [",
"    <a class=\"abstract\" href=\"UTD.htm?24/54/25450/abstract/28,31\">",
"     28,31",
"    </a>",
"    ]. In both reports, the use of this combination was associated with a benefit in survival. However, in one of the reports, the survival benefit was limited to those subjects with a transfusion requirement &lt;2",
"    <span class=\"nowrap\">",
"     units/month.",
"    </span>",
"    No effect on the rate of progression to AML was seen in either study.",
"   </p>",
"   <p>",
"    Patients with low- or intermediate-1 risk MDS are an",
"    <strong>",
"     exception",
"    </strong>",
"    to the general recommendation from ASH and ASCO to avoid ESAs for the treatment of anemia associated with malignancy in patients who are not receiving concurrent myelosuppressive chemotherapy [",
"    <a class=\"abstract\" href=\"UTD.htm?24/54/25450/abstract/4,5\">",
"     4,5",
"    </a>",
"    ]. As with any clinical intervention, use of epoetin must be based upon the",
"    <span class=\"nowrap\">",
"     benefit/risk",
"    </span>",
"    ratio in a given patient.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H7197297\">",
"    <span class=\"h3\">",
"     Administration",
"    </span>",
"    &nbsp;&mdash;&nbsp;The dosing of erythropoiesis stimulating agents (ESAs) in the setting of MDS is much higher than that used for patients with renal insufficiency. In contrast, the dosing of G-CSF administered in combination with an ESA for the treatment of anemia in MDS is lower than that used for other indications. A decreased responsiveness to hematopoietic growth factors is commonly seen in patients with MDS and is related to the defective proliferation of hematopoietic precursors within a dysplastic bone marrow [",
"    <a class=\"abstract\" href=\"UTD.htm?24/54/25450/abstract/32\">",
"     32",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    The NCCN guidelines suggest the following starting doses [",
"    <a class=\"abstract\" href=\"UTD.htm?24/54/25450/abstract/6\">",
"     6",
"    </a>",
"    ]:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Epoetin 40,000 to 60,000 units administered subcutaneously one to three times per week.",
"     </li>",
"     <li>",
"      Darbepoetin 150 to 300 micrograms administered subcutaneously once per week.",
"     </li>",
"     <li>",
"      G-CSF 1 to 2",
"      <span class=\"nowrap\">",
"       micrograms/kilogram",
"      </span>",
"      administered subcutaneously two to three times per week. Although there are no published data to support one method of administration over another, if G-CSF is used, the dosing is commonly titrated to reach a neutrophil count of 1000 to 2000.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Responses, if present, generally occur within six to eight weeks, although in one long-term study, 7 of the 20 responses occurred between 12 and 36 weeks of treatment [",
"    <a class=\"abstract\" href=\"UTD.htm?24/54/25450/abstract/25\">",
"     25",
"    </a>",
"    ]. The drugs should be discontinued if no response occurs within this latter period of time [",
"    <a class=\"abstract\" href=\"UTD.htm?24/54/25450/abstract/33\">",
"     33",
"    </a>",
"    ]. If a response is seen, the dose of epoetin may be decreased, as tolerated. The optimal target hemoglobin cannot be definitively determined from the available literature. HGB levels should be increased to the lowest concentration needed to avoid transfusion, which may vary by patient.",
"   </p>",
"   <p>",
"    Use of G-CSF or GM-CSF with or without erythropoietin, as described above, is inconvenient for patients in the United States, given that Medicare reimburses patients only if these medicines are given in a physician's office. On the other hand, the efficacy of this approach, plus the suggestion of improved survival noted in two non-randomized studies, makes it reasonable to consider use of G-CSF + erythropoietin in appropriate patients [",
"    <a class=\"abstract\" href=\"UTD.htm?24/54/25450/abstract/19\">",
"     19",
"    </a>",
"    ]. Long-lasting analogs of both G-CSF (pegylated recombinant human",
"    <a class=\"drug drug_general\" href=\"UTD.htm?23/13/23767?source=see_link\">",
"     granulocyte colony-stimulating factor",
"    </a>",
"    ,",
"    <a class=\"drug drug_general\" href=\"UTD.htm?12/28/12741?source=see_link\">",
"     pegfilgrastim",
"    </a>",
"    ) and erythropoietin (darbepoetin) are readily available, allowing injections of these agents as infrequently as once every two to three weeks [",
"    <a class=\"abstract\" href=\"UTD.htm?24/54/25450/abstract/13,34\">",
"     13,34",
"    </a>",
"    ]. Although these agents have not been formally compared in MDS, they are therapeutically equivalent in other disorders. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?9/13/9434?source=see_link&amp;anchor=H21#H21\">",
"     \"Anemia of chronic disease (anemia of chronic inflammation)\", section on 'Darbepoetin'",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?33/9/33945?source=see_link&amp;anchor=H938520#H938520\">",
"     \"Use of granulocyte colony stimulating factors in patients with chemotherapy-induced neutropenia\", section on 'GM-CSF versus G-CSF'",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?33/9/33945?source=see_link&amp;anchor=H523774254#H523774254\">",
"     \"Use of granulocyte colony stimulating factors in patients with chemotherapy-induced neutropenia\", section on 'Pegfilgrastim'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    To ensure that patients receiving ESAs in the setting of cancer are informed about the risks before they begin treatment, regardless of the intent of therapy, the US FDA has mandated a risk evaluation and mitigation strategy (REMS) risk management program, termed APPRISE (Assisting Provides and Cancer Patients with Risk Information for the Safe Use of ESAs) for use of ESAs in patients with cancer [",
"    <a class=\"abstract\" href=\"UTD.htm?24/54/25450/abstract/35\">",
"     35",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?37/15/38138?source=see_link&amp;anchor=H27#H27\">",
"     \"Role of erythropoiesis-stimulating agents in the treatment of anemia in patients with cancer\", section on 'APPRISE: the US FDA Risk Evaluation and Mitigation Strategy program'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H2104230\">",
"    <span class=\"h1\">",
"     IRON OVERLOAD",
"    </span>",
"    &nbsp;&mdash;&nbsp;The requirement of frequent red cell transfusions is a marker of poor prognosis among patients with MDS. Chronic transfusional support may lead to iron overload and secondary hemochromatosis, with the potential for long term hepatic, pancreatic, gonadal, and cardiac complications. As such, a number of guidelines suggest the use of iron chelating agents in patients with MDS and iron overload [",
"    <a class=\"abstract\" href=\"UTD.htm?24/54/25450/abstract/36-38\">",
"     36-38",
"    </a>",
"    ]. However, the relationship between red cell transfusions and shorter survival in MDS may have little to do with the iron overload per se, and the benefit of iron chelation in MDS is unproven at this time [",
"    <a class=\"abstract\" href=\"UTD.htm?24/54/25450/abstract/39,40\">",
"     39,40",
"    </a>",
"    ]. We reserve the use of iron chelation treatment in patients with lower risk MDS who have had, or are anticipated to have, prolonged red cell transfusion requirements (eg, more than 20 to 30 transfusions) and demonstrate evidence of iron overload (eg, serum ferritin &gt;1000",
"    <span class=\"nowrap\">",
"     mcg/L).",
"    </span>",
"    More sensitive and specific tests to assess clinically significant iron overload (eg, MRI scans of the heart",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    liver) may help to identify patients who may benefit from iron chelation therapy in the future [",
"    <a class=\"abstract\" href=\"UTD.htm?24/54/25450/abstract/41-43\">",
"     41-43",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?24/49/25370?source=see_link&amp;anchor=H14#H14\">",
"     \"Chelation therapy for iron overload states\", section on 'Deferasirox'",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?34/19/35129?source=see_link&amp;anchor=H9#H9\">",
"     \"Pathophysiology and diagnosis of iron overload syndromes\", section on 'CT, MRI, and SQUID techniques'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    There is a paucity of data regarding the efficacy of iron chelation in patients with MDS [",
"    <a class=\"abstract\" href=\"UTD.htm?24/54/25450/abstract/33,44-46\">",
"     33,44-46",
"    </a>",
"    ]. Indirect support for the use of iron chelation therapy to prevent secondary hemochromatosis comes from studies in other hematologic conditions. Randomized studies in beta thalassemia major have demonstrated that long-term iron chelation reverses iron-related organ damage, reduces morbidity, and prolongs survival. However, only data from nonrandomized studies are available to support the use of iron chelation in MDS at this time [",
"    <a class=\"abstract\" href=\"UTD.htm?24/54/25450/abstract/40,47-53\">",
"     40,47-53",
"    </a>",
"    ]. It is unknown whether iron chelation would be helpful in reducing other complications of MDS, such as infection, morbidity and mortality after hematopoietic cell transplantation, or transformation to acute leukemia [",
"    <a class=\"abstract\" href=\"UTD.htm?24/54/25450/abstract/54\">",
"     54",
"    </a>",
"    ]. A randomized, double-blind, placebo-controlled trial of",
"    <a class=\"drug drug_general\" href=\"UTD.htm?2/19/2360?source=see_link\">",
"     deferasirox",
"    </a>",
"    in patients with low or intermediate-1 risk disease and transfusional iron overload is underway, which may answer most of these questions. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?37/60/38856?source=see_link&amp;anchor=H11#H11\">",
"     \"Iron overload syndromes other than hereditary hemochromatosis\", section on 'Transfusional iron overload'",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?37/60/38856?source=see_link&amp;anchor=H16#H16\">",
"     \"Iron overload syndromes other than hereditary hemochromatosis\", section on 'Chelation therapy'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    In addition, issues regarding the safety of iron chelation in the setting of MDS have been raised. The United States FDA has indicated that treatment with the orally-active iron chelator",
"    <a class=\"drug drug_general\" href=\"UTD.htm?2/19/2360?source=see_link\">",
"     deferasirox",
"    </a>",
"    may be associated with an increased number of adverse events, such as renal injury, and deaths in patients with MDS over the age of 60 years [",
"    <a class=\"abstract\" href=\"UTD.htm?24/54/25450/abstract/29,55\">",
"     29,55",
"    </a>",
"    ]. A prospective multicenter trial evaluated the safety of deferasirox in 176 adults (median age 71 years) with low- or intermediate-1-risk MDS who had received &ge;20 units of red cells (median 41 units), had a serum ferritin &ge;1000",
"    <span class=\"nowrap\">",
"     mcg/L",
"    </span>",
"    (median 2771",
"    <span class=\"nowrap\">",
"     mcg/L),",
"    </span>",
"    and had ongoing red cell transfusion requirements [",
"    <a class=\"abstract\" href=\"UTD.htm?24/54/25450/abstract/46\">",
"     46",
"    </a>",
"    ]. Forty-five percent of patients discontinued deferasirox within the first year; 80 percent discontinued within the first three years. The most common severe adverse events were diarrhea (20 percent) and increased serum creatinine (10 percent). Severe increases in serum creatinine were more common among patients who had an elevated creatinine at baseline. &nbsp;",
"   </p>",
"   <p>",
"    When patients with IPSS low or intermediate-1 risk disease (",
"    <a class=\"graphic graphic_table graphicRef50634 \" href=\"UTD.htm?26/37/27228\">",
"     table 2",
"    </a>",
"    ) have had, or are anticipated to have, prolonged red cell transfusion requirements (eg, more than 20 to 30 transfusions) and demonstrate evidence of iron overload (eg, serum ferritin &gt;1000",
"    <span class=\"nowrap\">",
"     mcg/L),",
"    </span>",
"    we and others suggest the use of prophylactic or therapeutic iron chelation treatment [",
"    <a class=\"abstract\" href=\"UTD.htm?24/54/25450/abstract/1,36,56,57\">",
"     1,36,56,57",
"    </a>",
"    ]. We typically perform an MRI of the heart",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    liver to further assess iron status prior to initiating iron chelation in this population. While such studies are expensive, they appear to be more sensitive than serum ferritin in predicting the development of complications from iron overload. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?34/19/35129?source=see_link&amp;anchor=H9#H9\">",
"     \"Pathophysiology and diagnosis of iron overload syndromes\", section on 'CT, MRI, and SQUID techniques'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Our hesitance to use iron chelation therapy for a broader population of patients with MDS is primarily based upon an unknown benefit and a possible harm in older patients with MDS. Our preference to use iron chelation for patients with lower risk MDS reflects the relatively long survival of these patients and associated potential for long-term damage from iron and potential benefit from iron chelation. In contrast, the long-term benefit of iron chelation therapy in high risk patients is likely to be small because of their markedly reduced survival [",
"    <a class=\"abstract\" href=\"UTD.htm?24/54/25450/abstract/1\">",
"     1",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H7196296\">",
"    <span class=\"h1\">",
"     INFECTION",
"    </span>",
"    &nbsp;&mdash;&nbsp;Patients with MDS have a high incidence of infection related to neutropenia and granulocyte dysfunction (eg, impaired chemotaxis and microbial killing) and infection is the principal cause of death in patients with MDS [",
"    <a class=\"abstract\" href=\"UTD.htm?24/54/25450/abstract/58-61\">",
"     58-61",
"    </a>",
"    ]. Bacterial infections predominate, with the skin being the most common site of infection [",
"    <a class=\"abstract\" href=\"UTD.htm?24/54/25450/abstract/58\">",
"     58",
"    </a>",
"    ]. Fungal infections are not uncommon. Although viral, and mycobacterial infections can occur, they are rare in the absence of concurrent administration of immunosuppressive agents [",
"    <a class=\"abstract\" href=\"UTD.htm?24/54/25450/abstract/58,62\">",
"     58,62",
"    </a>",
"    ]. Infections may also be occult, respond poorly to antibiotics, and resolve slowly [",
"    <a class=\"abstract\" href=\"UTD.htm?24/54/25450/abstract/63\">",
"     63",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?40/57/41882?source=see_link&amp;anchor=H4010760#H4010760\">",
"     \"Clinical manifestations and diagnosis of the myelodysplastic syndromes\", section on 'White blood cells'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    The prophylaxis and treatment of infectious complications in neutropenic patients are presented separately. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?39/52/40778?source=see_link\">",
"     \"Treatment of neutropenic fever syndromes in adults with hematologic malignancies and hematopoietic cell transplant recipients (high-risk patients)\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?13/38/13930?source=see_link\">",
"     \"Overview of neutropenic fever syndromes\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?19/4/19530?source=see_link\">",
"     \"Prophylaxis of invasive fungal infections in adults with hematologic malignancies\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H1063376\">",
"    <span class=\"h2\">",
"     Evaluation",
"    </span>",
"    &nbsp;&mdash;&nbsp;Patients with MDS who develop signs of symptoms concerning for infection should undergo an initial evaluation that includes:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      A thorough general physical examination",
"     </li>",
"     <li>",
"      A complete blood cell count with differential, transaminases, bilirubin, amylase, electrolytes, two or more blood cultures, sputum Gram stain and culture, and urine Gram stain and culture",
"     </li>",
"     <li>",
"      A chest x-ray",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    If localizing signs or symptoms are present, other tests should be considered for further investigation. Smoking cessation should be strongly encouraged. Lumbar puncture is not necessary routinely, but should be performed in patients who have a change in mental status. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?27/56/28552?source=see_link\">",
"     \"Diagnostic approach to the adult presenting with neutropenic fever\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Opportunistic infections should be considered in any patient who develops persistent fever or unexplained pulmonary infiltrates. For patients with unexplained or unresponsive pulmonary infiltrates, we advocate the use of bronchoscopy with bronchoalveolar lavage or transbronchial biopsy to identify opportunistic pathogens such as Cytomegalovirus, Herpes simplex virus, Pneumocystis carinii, or mycobacterial infections. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?20/49/21273?source=see_link\">",
"     \"Pulmonary infections in immunocompromised patients\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?24/51/25402?source=see_link\">",
"     \"Approach to the immunocompromised patient with fever and pulmonary infiltrates\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H1063463\">",
"    <span class=\"h2\">",
"     Treatment",
"    </span>",
"    &nbsp;&mdash;&nbsp;The management of infections in patients with MDS depends upon the patient's risk factors for life-threatening infections (eg, neutropenia, recent therapy) and whether or not they appear septic or toxic at presentation.",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Patients who are septic",
"      <span class=\"nowrap\">",
"       and/or",
"      </span>",
"      have an absolute neutrophil count less than 500",
"      <span class=\"nowrap\">",
"       cells/microL",
"      </span>",
"      should be treated emergently with empiric broad spectrum coverage. If an organism is later identified, the spectrum of therapy can be narrowed to cover the identified pathogen. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?39/52/40778?source=see_link\">",
"       \"Treatment of neutropenic fever syndromes in adults with hematologic malignancies and hematopoietic cell transplant recipients (high-risk patients)\"",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      Patients who are not septic and have an absolute neutrophil count above 500",
"      <span class=\"nowrap\">",
"       cells/microL",
"      </span>",
"      can often be treated with antibiotics directed at the most likely pathogen given the presenting signs and symptoms.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    As an example, patients with signs",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    symptoms of a sinobronchial infection can often be treated with conventional antibiotics used in the general population. Most patients respond to such treatment, but some patients develop chronic sinusitis that may require referral to an ear, nose, and throat specialist. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?2/15/2297?source=see_link\">",
"     \"Acute sinusitis and rhinosinusitis in adults: Treatment\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Herpes simplex and herpes zoster infection often complicate advanced stage disease. Early institution of treatment with antivirals should be instituted. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?23/8/23688?source=see_link\">",
"     \"Epidemiology and pathogenesis of varicella-zoster virus infection: Herpes zoster\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?32/20/33096?source=see_link\">",
"     \"Treatment of herpes zoster in the immunocompetent host\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?35/40/36488?source=see_link\">",
"     \"Treatment of herpes simplex virus type 1 infection in immunocompetent patients\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H1063589\">",
"    <span class=\"h2\">",
"     Prevention",
"    </span>",
"    &nbsp;&mdash;&nbsp;Given the high rate of infection and associated morbidity and mortality among patients with MDS, attempts have been made to decrease the rate of infection by using vaccines, prophylactic antimicrobials, and myeloid growth factors. While most clinicians agree that patients with MDS should receive appropriate vaccinations, the use of other prophylactic measures and, in particular, antibiotics is not recommended (according to NCCN guidelines).",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H1063596\">",
"    <span class=\"h3\">",
"     Vaccination",
"    </span>",
"    &nbsp;&mdash;&nbsp;Patients with MDS should have yearly influenza vaccines and a pneumococcal vaccine every five years. Vaccines to pertussis and haemophilus influenza B may also be beneficial. Live vaccines should NOT be given to patients with MDS. Live vaccines include oral polio, oral typhoid, yellow fever, measles, mumps, rubella, bacillus calmette guerin (BCG), and herpes zoster. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?0/25/410?source=see_link&amp;anchor=H29#H29\">",
"     \"Overview of infectious complications following purine analog therapy\", section on 'Immunizations'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H1063603\">",
"    <span class=\"h3\">",
"     Antimicrobials",
"    </span>",
"    &nbsp;&mdash;&nbsp;The use of prophylactic antimicrobials in patients with MDS depends upon the treatment regimen and its associated immunodeficiencies. There have been no randomized trials evaluating the use of prophylactic antimicrobials in this population. Prophylactic antimicrobials have no proven benefit in patients with MDS that are not undergoing active treatment.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H7196900\">",
"    <span class=\"h3\">",
"     Myeloid growth factors",
"    </span>",
"    &nbsp;&mdash;&nbsp;The response of patients with MDS to treatment with granulocyte-colony stimulating factors (G-CSF) [",
"    <a class=\"abstract\" href=\"UTD.htm?24/54/25450/abstract/64-66\">",
"     64-66",
"    </a>",
"    ] or granulocyte macrophage colony stimulating factors (GM-CSF) [",
"    <a class=\"abstract\" href=\"UTD.htm?24/54/25450/abstract/67-73\">",
"     67-73",
"    </a>",
"    ] in efficacy trials, including randomized trials, has been disappointing, and the NCCN treatment guidelines do not recommend its routine use in patients with MDS [",
"    <a class=\"abstract\" href=\"UTD.htm?24/54/25450/abstract/6\">",
"     6",
"    </a>",
"    ]. These agents may have utility in combination with erythropoietin. (See",
"    <a class=\"local\" href=\"#H7196544\">",
"     'Combination therapy (EPO + G-CSF)'",
"    </a>",
"    above.)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H2104237\">",
"    <span class=\"h1\">",
"     BLEEDING",
"    </span>",
"    &nbsp;&mdash;&nbsp;Bleeding in a patient with MDS may be due to thrombocytopenia, other platelet disorders, or disorders of coagulation. Bleeding in thrombocytopenic patients is primarily managed with platelet transfusions.",
"    <a class=\"drug drug_general\" href=\"UTD.htm?29/38/30311?source=see_link\">",
"     Aminocaproic acid",
"    </a>",
"    or other antifibrinolytic agents may be considered for bleeding refractory to platelet transfusions or for those with profound thrombocytopenia. While initial reports are promising, further data regarding the use of thrombopoietin mimetics are required before these agents can be recommended in this setting.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H7197620\">",
"    <span class=\"h2\">",
"     Platelet transfusion",
"    </span>",
"    &nbsp;&mdash;&nbsp;Both morphologic and functional platelet abnormalities may be seen in patients with MDS. Based on the results of a number of randomized trials in patients with acute myeloid leukemia, platelets are usually transfused prophylactically to prevent hemorrhage at counts less than",
"    <span class=\"nowrap\">",
"     10,000/microL",
"    </span>",
"    and at higher counts in patients with active bleeding or with clinical problems such as fever, severe infection, pulmonary compromise, or coagulopathy [",
"    <a class=\"abstract\" href=\"UTD.htm?24/54/25450/abstract/74\">",
"     74",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?20/6/20586?source=see_link&amp;anchor=H558395349#H558395349\">",
"     \"Clinical and laboratory aspects of platelet transfusion therapy\", section on 'Leukemia and chemotherapy'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H2104265\">",
"    <span class=\"h2\">",
"     Thrombopoietin mimetics",
"    </span>",
"    &nbsp;&mdash;&nbsp;Thrombopoietin mimetics are used for the management of thrombocytopenia in patients with chronic immune thrombocytopenia (ITP). Initial studies have evaluated the use of these agents in patients with MDS and thrombocytopenia. Thrombopoietin mimetics have not been approved by the US Food and Drug Administration for use in MDS.",
"   </p>",
"   <p>",
"    Of importance, thrombopoietin mimetics are not known to alter the biology of MDS. As such, effects on platelet levels are expected to be transient and limited to the immediate time surrounding the administration of these agents. While the prospective trials of thrombopoietic mimetics in patients with MDS have demonstrated continued platelet responses in a subset of patients continuing to receive treatment for as long as eight weeks, it is unknown whether these responses will persist long-term. Experience with these agents in patients with ITP and experience with erythropoiesis stimulating agents (ESAs) in patients with anemia and MDS suggest that platelet counts would be expected to drop rapidly once thrombopoietic mimetics are discontinued. (See",
"    <a class=\"medical medical_review\" href=\"./treatment-and-prognosis-of-immune-thrombocytopenia-itp-in-adults?source=see_link&amp;anchor=H21#H21\">",
"     \"Treatment and prognosis of immune thrombocytopenia (ITP) in adults\", section on 'Thrombopoiesis-stimulating agents'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    The following trials have evaluated the thrombopoietin mimetics in MDS:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      The safety and efficacy of the thrombopoietin peptide mimetic",
"      <a class=\"drug drug_general\" href=\"UTD.htm?19/58/20389?source=see_link\">",
"       romiplostim",
"      </a>",
"      (initial weekly doses ranging from 300 to 1500",
"      <span class=\"nowrap\">",
"       microgram/week)",
"      </span>",
"      were evaluated in a phase",
"      <span class=\"nowrap\">",
"       I/II",
"      </span>",
"      trial in 44 patients with low- or intermediate-1-risk MDS and a mean baseline platelet count",
"      <span class=\"nowrap\">",
"       &lt;50,000/microL",
"      </span>",
"      (approximately one-quarter with platelet count",
"      <span class=\"nowrap\">",
"       &le;20,000/microL)",
"      </span>",
"      [",
"      <a class=\"abstract\" href=\"UTD.htm?24/54/25450/abstract/75\">",
"       75",
"      </a>",
"      ].",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    <ul class=\"hyphen-block\">",
"     <li>",
"      A durable platelet response (hematologic improvement &ge;8 consecutive weeks) was seen in 46 percent of the subjects, which was associated with a reduced incidence of bleeding and platelet transfusion.",
"     </li>",
"     <li>",
"      One or more adverse effects considered",
"      <a class=\"drug drug_general\" href=\"UTD.htm?19/58/20389?source=see_link\">",
"       romiplostim",
"      </a>",
"      -related were noted in 17 patients (39 percent), and serious side effects (eg, osteonecrosis; blast count increase; anemia, vertigo, and presyncope; febrile neutropenia; thrombocytopenia) were noted in five patients (11 percent).",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Another phase II multicenter trial evaluated the use of subcutaneous or intravenous",
"      <a class=\"drug drug_general\" href=\"UTD.htm?19/58/20389?source=see_link\">",
"       romiplostim",
"      </a>",
"      in 28 thrombocytopenic patients with low- or intermediate-1-risk MDS [",
"      <a class=\"abstract\" href=\"UTD.htm?24/54/25450/abstract/76\">",
"       76",
"      </a>",
"      ]. The most common toxicities were fatigue and headache, each seen in 18 percent of patients. One patient who received intravenous romiplostim had a hypersensitivity reaction. No patients developed neutralizing antibodies or bone marrow fibrosis. Of the 23 patients who completed 8 weeks of therapy, 57 percent attained a platelet count",
"      <span class=\"nowrap\">",
"       &gt;100,000/microL.",
"      </span>",
"     </li>",
"     <li>",
"      A phase II randomized study of weekly",
"      <a class=\"drug drug_general\" href=\"UTD.htm?19/58/20389?source=see_link\">",
"       romiplostim",
"      </a>",
"      (500 microgram or 750 microgram) versus placebo in 40 patients with low- or intermediate-risk MDS receiving",
"      <a class=\"drug drug_general\" href=\"UTD.htm?12/40/12935?source=see_link\">",
"       azacitidine",
"      </a>",
"      therapy reported higher median platelet counts for patients who received romiplostim 750 microgram when compared with placebo [",
"      <a class=\"abstract\" href=\"UTD.htm?24/54/25450/abstract/77\">",
"       77",
"      </a>",
"      ].",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    <ul class=\"hyphen-block\">",
"     <li>",
"      Rates of severe (grade",
"      <span class=\"nowrap\">",
"       3/4)",
"      </span>",
"      thrombocytopenia starting on day 15 of the first cycle or platelet transfusion any time during the treatment cycle were 62, 71, and 85 percent, for patients receiving",
"      <a class=\"drug drug_general\" href=\"UTD.htm?19/58/20389?source=see_link\">",
"       romiplostim",
"      </a>",
"      500 microgram, romiplostim 750 microgram, or placebo, respectively.",
"     </li>",
"     <li>",
"      The incidence of platelet transfusions were 46, 36, and 69 percent, respectively.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Additional experience with this agent is awaited. Issues including when to use",
"    <a class=\"drug drug_general\" href=\"UTD.htm?19/58/20389?source=see_link\">",
"     romiplostim",
"    </a>",
"    , its cost, potential for marrow fibrosis, a fall in platelet count once the drug is stopped, and the potential to stimulate myeloblasts in higher risk patients all need to be considered before this agent can be recommended for widespread use in MDS. It appears reasonable, however, to consider its use in patients with bleeding due to low platelet counts who do not respond to transfusions and in whom",
"    <a class=\"drug drug_general\" href=\"UTD.htm?29/38/30311?source=see_link\">",
"     aminocaproic acid",
"    </a>",
"    has been unsuccessful. Patients with platelet counts",
"    <span class=\"nowrap\">",
"     &lt;30,000/microL",
"    </span>",
"    are reasonable candidates for romiplostim therapy. It is unclear whether romiplostim would decrease the risk of bleeding in patients with platelet counts between",
"    <span class=\"nowrap\">",
"     30,000/microL",
"    </span>",
"    and",
"    <span class=\"nowrap\">",
"     50,000/microL.",
"    </span>",
"    (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?20/61/21466?source=see_link\">",
"     \"Clinical applications of thrombopoietic growth factors\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"./chronic-refractory-immune-thrombocytopenia-itp-in-adults?source=see_link&amp;anchor=H5#H5\">",
"     \"Chronic refractory immune thrombocytopenia (ITP) in adults\", section on 'Thrombopoiesis-stimulating agents'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H161272971\">",
"    <span class=\"h2\">",
"     Interleukin-11",
"    </span>",
"    &nbsp;&mdash;&nbsp;A pilot study employed low doses of recombinant human IL-11 (",
"    <a class=\"drug drug_general\" href=\"UTD.htm?33/58/34724?source=see_link\">",
"     Oprelvekin",
"    </a>",
"    , Neumega, 10",
"    <span class=\"nowrap\">",
"     mcg/kg",
"    </span>",
"    per day subcutaneously for two weeks, followed by a two-week rest period) in patients with MDS [",
"    <a class=\"abstract\" href=\"UTD.htm?24/54/25450/abstract/78\">",
"     78",
"    </a>",
"    ]. Increases in platelet counts were noted in 5 of 11 evaluable patients, with responses lasting from 12 to 30+ weeks. Side effects (peripheral edema, conjunctival injection) were mild. Although low doses of IL-11 are usually well tolerated, clinical experience suggests that increases in platelet count are much less frequent than initially reported. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?20/61/21466?source=see_link&amp;anchor=H10#H10\">",
"     \"Clinical applications of thrombopoietic growth factors\", section on 'Interleukins'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H304433\">",
"    <span class=\"h1\">",
"     PSYCHOLOGICAL DISTRESS",
"    </span>",
"    &nbsp;&mdash;&nbsp;The diagnosis of any malignant disease such as MDS can lead to considerable psychological distress [",
"    <a class=\"abstract\" href=\"UTD.htm?24/54/25450/abstract/79\">",
"     79",
"    </a>",
"    ]. This is compounded by the uncertainty regarding how rapidly the disease will progress. Even when the diagnosis is made early and the patient is still relatively free of symptoms and the need for transfusions, discussion is warranted to re-adjust short term and long term personal goals.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H9325216\">",
"    <span class=\"h1\">",
"     CUTANEOUS LESIONS",
"    </span>",
"    &nbsp;&mdash;&nbsp;Skin lesions are uncommon in patients with MDS; of these, Sweet syndrome and myeloid sarcoma merit particular attention since they may be indications for more aggressive therapy.",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Myeloid sarcoma (also called granulocytic sarcoma or chloroma) of the skin refers to cutaneous infiltration by leukemic cells and may herald disease transformation into acute leukemia. The approach to treatment of patients with myeloid sarcoma without evidence of AML on bone marrow biopsy is similar to that for patients with overt AML. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?19/58/20393?source=see_link&amp;anchor=H11#H11\">",
"       \"Clinical manifestations, pathologic features, and diagnosis of acute myeloid leukemia\", section on 'Myeloid sarcoma'",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      Sweet syndrome (acute febrile neutrophilic dermatosis) is an uncommon inflammatory disorder characterized by the abrupt appearance of painful, edematous, and erythematous papules, plaques, or nodules on the skin. Fever and leukocytosis frequently accompany the cutaneous lesions. When complicating the course of MDS, Sweet syndrome may herald transformation to acute leukemia and is an indication for bone marrow aspiration and biopsy. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?39/60/40905?source=see_link\">",
"       \"Sweet syndrome (acute febrile neutrophilic dermatosis): Pathogenesis, clinical manifestations, and diagnosis\"",
"      </a>",
"      .)",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H1063344\">",
"    <span class=\"h1\">",
"     TRANSFORMATION TO AML",
"    </span>",
"    &nbsp;&mdash;&nbsp;Patients with MDS have a variable rate of transformation to acute myeloid leukemia (AML). Indeed, the distinction between MDS and AML is itself arbitrary, as patients with 20 to 30 percent blasts are considered to have MDS by French-American-British (FAB) criteria, but AML by the World Health Organization (WHO) classification. The decision of when to treat a patient with AML directed therapy is individualized. The treatment of AML is discussed in more detail separately. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?29/41/30362?source=see_link\">",
"     \"Induction therapy for acute myeloid leukemia in younger adults\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?28/29/29146?source=see_link\">",
"     \"Treatment of acute myeloid leukemia in older adults\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"PATIENT_INFORMATION\">",
"    <span class=\"h1\">",
"     INFORMATION FOR PATIENTS",
"    </span>",
"    &nbsp;&mdash;&nbsp;UpToDate offers two types of patient education materials, &ldquo;The Basics&rdquo; and &ldquo;Beyond the Basics.&rdquo; The Basics patient education pieces are written in plain language, at the 5",
"    <sup>",
"     th",
"    </sup>",
"    to 6",
"    <sup>",
"     th",
"    </sup>",
"    grade reading level, and they answer the four or five key questions a patient might have about a given condition. These articles are best for patients who want a general overview and who prefer short, easy-to-read materials. Beyond the Basics patient education pieces are longer, more sophisticated, and more detailed. These articles are written at the 10",
"    <sup>",
"     th",
"    </sup>",
"    to 12",
"    <sup>",
"     th",
"    </sup>",
"    grade reading level and are best for patients who want in-depth information and are comfortable with some medical jargon.",
"   </p>",
"   <p>",
"    Here are the patient education articles that are relevant to this topic. We encourage you to print or e-mail these topics to your patients. (You can also locate patient education articles on a variety of subjects by searching on &ldquo;patient info&rdquo; and the keyword(s) of interest.)",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Basics topics (see",
"      <a class=\"medical medical_basics\" href=\"UTD.htm?9/1/9234?source=see_link\">",
"       \"Patient information: Myelodysplastic syndromes (MDS) (The Basics)\"",
"      </a>",
"      and",
"      <a class=\"medical medical_basics\" href=\"UTD.htm?2/47/2802?source=see_link\">",
"       \"Patient information: Bone marrow transplant (The Basics)\"",
"      </a>",
"      )",
"     </li>",
"     <li>",
"      Beyond the Basics topics (see",
"      <a class=\"medical medical_patient\" href=\"UTD.htm?6/26/6564?source=see_link\">",
"       \"Patient information: Myelodysplastic syndromes (MDS) in adults (Beyond the Basics)\"",
"      </a>",
"      and",
"      <a class=\"medical medical_patient\" href=\"UTD.htm?34/4/34886?source=see_link\">",
"       \"Patient information: Bone marrow transplantation (stem cell transplantation) (Beyond the Basics)\"",
"      </a>",
"      )",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H2106062\">",
"    <span class=\"h1\">",
"     SUMMARY AND RECOMMENDATIONS",
"    </span>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Supportive care remains a central component of the management of all patients with myelodysplastic syndrome (MDS).",
"     </li>",
"     <li>",
"      When anemia is noted in a patient with MDS, other causes of anemia should be excluded prior to initiating specific therapy. A serum erythropoietin level should be measured. The anemia of MDS is primarily managed with red cell transfusions. We suggest that symptomatic anemic patients with low serum erythropoietin levels (&lt;500",
"      <span class=\"nowrap\">",
"       mU/mL)",
"      </span>",
"      and a low or intermediate-1 risk IPSS score (",
"      <a class=\"calc calc_professional\" href=\"UTD.htm?9/14/9441?source=see_link\">",
"       calculator 1",
"      </a>",
"      ) be treated with erythropoietin, particularly if accompanied by low transfusion requirements (&lt;2",
"      <span class=\"nowrap\">",
"       units/month)",
"      </span>",
"      (",
"      <a class=\"grade\" href=\"._grade_5?title=Grade 2B\">",
"       Grade 2B",
"      </a>",
"      ). The dose of erythropoietin may be increased if a patient is receiving a relatively low dose or granulocyte colony stimulating factor (G-CSF) may be added if erythropoietin is unsuccessful after three months in a patient with severe anemia, or after six months if the anemia is less severe. (See",
"      <a class=\"local\" href=\"#H7193969\">",
"       'Anemia'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Chronic transfusional support may lead to iron overload and secondary hemochromatosis, with the potential for long term hepatic, pancreatic, gonadal, and cardiac complications. For patients with IPSS low or intermediate-1 risk disease who have had, or are anticipated to have, prolonged red cell transfusion requirements (eg, more than 20 to 30 transfusions) and demonstrate evidence of iron overload (eg, serum ferritin &gt;1000",
"      <span class=\"nowrap\">",
"       mcg/L),",
"      </span>",
"      we suggest the use of prophylactic or therapeutic iron chelation treatment. (",
"      <a class=\"grade\" href=\"._grade_6?title=Grade 2C\">",
"       Grade 2C",
"      </a>",
"      ). (See",
"      <a class=\"local\" href=\"#H2104230\">",
"       'Iron overload'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Patients with MDS have a high incidence of infection and infection is the principal cause of death in these patients. Bacterial infections predominate, with the skin being the most common site of infection. Although viral, and mycobacterial infections can occur, they are rare in the absence of concurrent administration of immunosuppressive agents. MDS should receive appropriate vaccinations. We do not advocate the use of other prophylactic measures. Smoking cessation should be strongly encouraged. (See",
"      <a class=\"local\" href=\"#H7196296\">",
"       'Infection'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Bleeding in a patient with MDS may be due to thrombocytopenia, other platelet disorders, or disorders of coagulation. Bleeding in thrombocytopenic patients is primarily managed with platelet transfusions.",
"      <a class=\"drug drug_general\" href=\"UTD.htm?29/38/30311?source=see_link\">",
"       Aminocaproic acid",
"      </a>",
"      or other antifibrinolytic agents may be considered for bleeding refractory to platelet transfusions or for those with profound thrombocytopenia. (See",
"      <a class=\"local\" href=\"#H2104237\">",
"       'Bleeding'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Patients with MDS have a variable rate of transformation to acute myeloid leukemia (AML), although most patients who die do so not as a consequence of transformation, but due to bone failure associated with MDS. The treatment of AML is discussed in more detail separately. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?29/41/30362?source=see_link\">",
"       \"Induction therapy for acute myeloid leukemia in younger adults\"",
"      </a>",
"      and",
"      <a class=\"medical medical_review\" href=\"UTD.htm?28/29/29146?source=see_link\">",
"       \"Treatment of acute myeloid leukemia in older adults\"",
"      </a>",
"      .)",
"     </li>",
"    </ul>",
"   </p>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <h1>",
"    REFERENCES",
"   </h1>",
"   <ol id=\"reference\">",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?24/54/25450/abstract/1\">",
"      Steensma DP, Bennett JM. The myelodysplastic syndromes: diagnosis and treatment. Mayo Clin Proc 2006; 81:104.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?24/54/25450/abstract/2\">",
"      Leukocyte reduction and ultraviolet B irradiation of platelets to prevent alloimmunization and refractoriness to platelet transfusions. The Trial to Reduce Alloimmunization to Platelets Study Group. N Engl J Med 1997; 337:1861.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?24/54/25450/abstract/3\">",
"      Bowden RA, Slichter SJ, Sayers MH, et al. Use of leukocyte-depleted platelets and cytomegalovirus-seronegative red blood cells for prevention of primary cytomegalovirus infection after marrow transplant. Blood 1991; 78:246.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?24/54/25450/abstract/4\">",
"      Rizzo JD, Brouwers M, Hurley P, et al. American Society of Hematology/American Society of Clinical Oncology clinical practice guideline update on the use of epoetin and darbepoetin in adult patients with cancer. Blood 2010; 116:4045.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?24/54/25450/abstract/5\">",
"      Rizzo JD, Brouwers M, Hurley P, et al. American Society of Clinical Oncology/American Society of Hematology clinical practice guideline update on the use of epoetin and darbepoetin in adult patients with cancer. J Clin Oncol 2010; 28:4996.",
"     </a>",
"    </li>",
"    <li>",
"     www.nccn.org (Accessed on February 04, 2011).",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?24/54/25450/abstract/7\">",
"      Jacobs A, Janowska-Wieczorek A, Caro J, et al. Circulating erythropoietin in patients with myelodysplastic syndromes. Br J Haematol 1989; 73:36.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?24/54/25450/abstract/8\">",
"      Ross SD, Allen IE, Probst CA, et al. Efficacy and safety of erythropoiesis-stimulating proteins in myelodysplastic syndrome: a systematic review and meta-analysis. Oncologist 2007; 12:1264.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?24/54/25450/abstract/9\">",
"      Greenberg PL, Sun Z, Miller KB, et al. Treatment of myelodysplastic syndrome patients with erythropoietin with or without granulocyte colony-stimulating factor: results of a prospective randomized phase 3 trial by the Eastern Cooperative Oncology Group (E1996). Blood 2009; 114:2393.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?24/54/25450/abstract/10\">",
"      Hellstr&ouml;m-Lindberg E. Efficacy of erythropoietin in the myelodysplastic syndromes: a meta-analysis of 205 patients from 17 studies. Br J Haematol 1995; 89:67.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?24/54/25450/abstract/11\">",
"      Musto P, Falcone A, Sanpaolo G, et al. Efficacy of a single, weekly dose of recombinant erythropoietin in myelodysplastic syndromes. Br J Haematol 2003; 122:269.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?24/54/25450/abstract/12\">",
"      Musto P, Lanza F, Balleari E, et al. Darbepoetin alpha for the treatment of anaemia in low-intermediate risk myelodysplastic syndromes. Br J Haematol 2005; 128:204.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?24/54/25450/abstract/13\">",
"      Giraldo P, Nomdedeu B, Loscertales J, et al. Darbepoetin alpha for the treatment of anemia in patients with myelodysplastic syndromes. Cancer 2006; 107:2807.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?24/54/25450/abstract/14\">",
"      Gabrilove J, Paquette R, Lyons RM, et al. Phase 2, single-arm trial to evaluate the effectiveness of darbepoetin alfa for correcting anaemia in patients with myelodysplastic syndromes. Br J Haematol 2008; 142:379.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?24/54/25450/abstract/15\">",
"      Gotlib J, Lavori P, Quesada S, et al. A Phase II intra-patient dose-escalation trial of weight-based darbepoetin alfa with or without granulocyte-colony stimulating factor in myelodysplastic syndromes. Am J Hematol 2009; 84:15.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?24/54/25450/abstract/16\">",
"      Mundle S, Lefebvre P, Vekeman F, et al. An assessment of erythroid response to epoetin alpha as a single agent versus in combination with granulocyte- or granulocyte-macrophage-colony-stimulating factor in myelodysplastic syndromes using a meta-analysis approach. Cancer 2009; 115:706.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?24/54/25450/abstract/17\">",
"      Rose EH, Abels RI, Nelson RA, et al. The use of r-HuEpo in the treatment of anaemia related to myelodysplasia (MDS). Br J Haematol 1995; 89:831.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?24/54/25450/abstract/18\">",
"      Stasi R, Abruzzese E, Lanzetta G, et al. Darbepoetin alfa for the treatment of anemic patients with low- and intermediate-1-risk myelodysplastic syndromes. Ann Oncol 2005; 16:1921.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?24/54/25450/abstract/19\">",
"      Hellstr&ouml;m-Lindberg E, Gulbrandsen N, Lindberg G, et al. A validated decision model for treating the anaemia of myelodysplastic syndromes with erythropoietin + granulocyte colony-stimulating factor: significant effects on quality of life. Br J Haematol 2003; 120:1037.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?24/54/25450/abstract/20\">",
"      Terpos E, Mougiou A, Kouraklis A, et al. Prolonged administration of erythropoietin increases erythroid response rate in myelodysplastic syndromes: a phase II trial in 281 patients. Br J Haematol 2002; 118:174.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?24/54/25450/abstract/21\">",
"      Negrin RS, Stein R, Doherty K, et al. Maintenance treatment of the anemia of myelodysplastic syndromes with recombinant human granulocyte colony-stimulating factor and erythropoietin: evidence for in vivo synergy. Blood 1996; 87:4076.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?24/54/25450/abstract/22\">",
"      Hellstr&ouml;m-Lindberg E, Negrin R, Stein R, et al. Erythroid response to treatment with G-CSF plus erythropoietin for the anaemia of patients with myelodysplastic syndromes: proposal for a predictive model. Br J Haematol 1997; 99:344.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?24/54/25450/abstract/23\">",
"      Negrin RS, Stein R, Vardiman J, et al. Treatment of the anemia of myelodysplastic syndromes using recombinant human granulocyte colony-stimulating factor in combination with erythropoietin. Blood 1993; 82:737.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?24/54/25450/abstract/24\">",
"      Hellstr&ouml;m-Lindberg E, Ahlgren T, Beguin Y, et al. Treatment of anemia in myelodysplastic syndromes with granulocyte colony-stimulating factor plus erythropoietin: results from a randomized phase II study and long-term follow-up of 71 patients. Blood 1998; 92:68.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?24/54/25450/abstract/25\">",
"      Mantovani L, Lentini G, Hentschel B, et al. Treatment of anaemia in myelodysplastic syndromes with prolonged administration of recombinant human granulocyte colony-stimulating factor and erythropoietin. Br J Haematol 2000; 109:367.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?24/54/25450/abstract/26\">",
"      Thompson JA, Gilliland DG, Prchal JT, et al. Effect of recombinant human erythropoietin combined with granulocyte/ macrophage colony-stimulating factor in the treatment of patients with myelodysplastic syndrome. GM/EPO MDS Study Group. Blood 2000; 95:1175.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?24/54/25450/abstract/27\">",
"      J&auml;dersten M, Montgomery SM, Dybedal I, et al. Long-term outcome of treatment of anemia in MDS with erythropoietin and G-CSF. Blood 2005; 106:803.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?24/54/25450/abstract/28\">",
"      Park S, Grabar S, Kelaidi C, et al. Predictive factors of response and survival in myelodysplastic syndrome treated with erythropoietin and G-CSF: the GFM experience. Blood 2008; 111:574.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?24/54/25450/abstract/29\">",
"      Golshayan AR, Jin T, Maciejewski J, et al. Efficacy of growth factors compared to other therapies for low-risk myelodysplastic syndromes. Br J Haematol 2007; 137:125.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?24/54/25450/abstract/30\">",
"      Westers TM, Alhan C, Chamuleau ME, et al. Aberrant immunophenotype of blasts in myelodysplastic syndromes is a clinically relevant biomarker in predicting response to growth factor treatment. Blood 2010; 115:1779.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?24/54/25450/abstract/31\">",
"      J&auml;dersten M, Malcovati L, Dybedal I, et al. Erythropoietin and granulocyte-colony stimulating factor treatment associated with improved survival in myelodysplastic syndrome. J Clin Oncol 2008; 26:3607.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?24/54/25450/abstract/32\">",
"      Smith TJ, Khatcheressian J, Lyman GH, et al. 2006 update of recommendations for the use of white blood cell growth factors: an evidence-based clinical practice guideline. J Clin Oncol 2006; 24:3187.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?24/54/25450/abstract/33\">",
"      Stone RM. How I treat patients with myelodysplastic syndromes. Blood 2009; 113:6296.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?24/54/25450/abstract/34\">",
"      Mannone L, Gardin C, Quarre MC, et al. High-dose darbepoetin alpha in the treatment of anaemia of lower risk myelodysplastic syndrome results of a phase II study. Br J Haematol 2006; 133:513.",
"     </a>",
"    </li>",
"    <li>",
"     www.fda.gov/Safety/MedWatch/SafetyInformation/SafetyAlertsforHumanMedicalProducts/ucm200391.htm (Accessed on November 02, 2010).",
"    </li>",
"    <li>",
"     National Comprehensive Cancer Network (NCCN) guidelines. Available at: www.nccn.org (Accessed on May 15, 2012).",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?24/54/25450/abstract/37\">",
"      Bennett JM, MDS Foundation's Working Group on Transfusional Iron Overload. Consensus statement on iron overload in myelodysplastic syndromes. Am J Hematol 2008; 83:858.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?24/54/25450/abstract/38\">",
"      Gattermann N. Overview of guidelines on iron chelation therapy in patients with myelodysplastic syndromes and transfusional iron overload. Int J Hematol 2008; 88:24.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?24/54/25450/abstract/39\">",
"      Balducci L. Transfusion independence in patients with myelodysplastic syndromes: impact on outcomes and quality of life. Cancer 2006; 106:2087.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?24/54/25450/abstract/40\">",
"      Chee CE, Steensma DP, Wu W, et al. Neither serum ferritin nor the number of red blood cell transfusions affect overall survival in refractory anemia with ringed sideroblasts. Am J Hematol 2008; 83:611.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?24/54/25450/abstract/41\">",
"      Chacko J, Pennell DJ, Tanner MA, et al. Myocardial iron loading by magnetic resonance imaging T2* in good prognostic myelodysplastic syndrome patients on long-term blood transfusions. Br J Haematol 2007; 138:587.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?24/54/25450/abstract/42\">",
"      Konen E, Ghoti H, Goitein O, et al. No evidence for myocardial iron overload in multitransfused patients with myelodysplastic syndrome using cardiac magnetic resonance T2 technique. Am J Hematol 2007; 82:1013.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?24/54/25450/abstract/43\">",
"      Devalia V. Transfusional myocardial iron overload in myelodysplastic patients. Br J Haematol 2008; 140:361.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?24/54/25450/abstract/44\">",
"      Tefferi A, Stone RM. Iron chelation therapy in myelodysplastic syndrome - Cui bono? Leukemia 2009; 23:1373.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?24/54/25450/abstract/45\">",
"      Cermak J, Jonasova A, Vondrakova J, et al. Efficacy and safety of administration of oral iron chelator deferiprone in patients with early myelodysplastic syndrome. Hemoglobin 2011; 35:217.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?24/54/25450/abstract/46\">",
"      List AF, Baer MR, Steensma DP, et al. Deferasirox reduces serum ferritin and labile plasma iron in RBC transfusion-dependent patients with myelodysplastic syndrome. J Clin Oncol 2012; 30:2134.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?24/54/25450/abstract/47\">",
"      Atallah E, Garcia-Manero G. Treatment strategies in myelodysplastic syndromes. Cancer Invest 2008; 26:208.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?24/54/25450/abstract/48\">",
"      Takatoku M, Uchiyama T, Okamoto S, et al. Retrospective nationwide survey of Japanese patients with transfusion-dependent MDS and aplastic anemia highlights the negative impact of iron overload on morbidity/mortality. Eur J Haematol 2007; 78:487.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?24/54/25450/abstract/49\">",
"      Jensen PD, Heickendorff L, Pedersen B, et al. The effect of iron chelation on haemopoiesis in MDS patients with transfusional iron overload. Br J Haematol 1996; 94:288.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?24/54/25450/abstract/50\">",
"      Tefferi A. Iron chelation therapy for myelodysplastic syndrome: if and when. Mayo Clin Proc 2006; 81:197.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?24/54/25450/abstract/51\">",
"      Leitch HA, Goodman TA, Wong KK, et al. Improved survival in patients with myelodysplastic syndrome (MDS) receiving iron chelation therapy (abstract). Blood 2006; 108:78a.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?24/54/25450/abstract/52\">",
"      Maggio A. Light and shadows in the iron chelation treatment of haematological diseases. Br J Haematol 2007; 138:407.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?24/54/25450/abstract/53\">",
"      Rose C, Brechignac S, Vassilief D, et al. Positive impact of iron chelation therapy (CT) on survival in regularly transfused MDS patients. A prospective analysis by the GFM (abstract). Blood 2007; 110:80a.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?24/54/25450/abstract/54\">",
"      Pullarkat V. Objectives of iron chelation therapy in myelodysplastic syndromes: more than meets the eye? Blood 2009; 114:5251.",
"     </a>",
"    </li>",
"    <li>",
"     Available on the United States FDA website at: file://www.fda.gov/Safety/MedWatch/SafetyInformation/SafetyAlertsforHumanMedicalProducts/ucm183840.htm. Accessed on September 28, 2009.",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?24/54/25450/abstract/56\">",
"      Schiffer CA. Clinical issues in the management of patients with myelodysplasia. Hematology Am Soc Hematol Educ Program 2006; :205.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?24/54/25450/abstract/57\">",
"      Jabbour E, Kantarjian HM, Koller C, Taher A. Red blood cell transfusions and iron overload in the treatment of patients with myelodysplastic syndromes. Cancer 2008; 112:1089.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?24/54/25450/abstract/58\">",
"      Pomeroy C, Oken MM, Rydell RE, Filice GA. Infection in the myelodysplastic syndromes. Am J Med 1991; 90:338.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?24/54/25450/abstract/59\">",
"      Boogaerts MA, Nelissen V, Roelant C, Goossens W. Blood neutrophil function in primary myelodysplastic syndromes. Br J Haematol 1983; 55:217.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?24/54/25450/abstract/60\">",
"      Dreyfus B. Preleukemic states. I. Definition and classification. II. Refractory anemia with an excess of myeloblasts in the bone marrow (smoldering acute leukemia). Nouv Rev Fr Hematol Blood Cells 1976; 17:33.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?24/54/25450/abstract/61\">",
"      Weisdorf DJ, Oken MM, Johnson GJ, Rydell RE. Chronic myelodysplastic syndrome: short survival with or without evolution to acute leukaemia. Br J Haematol 1983; 55:691.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?24/54/25450/abstract/62\">",
"      Hamblin T. Immunologic abnormalities in myelodysplastic syndromes. Hematol Oncol Clin North Am 1992; 6:571.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?24/54/25450/abstract/63\">",
"      Williamson PJ, Oscier DG, Mufti GJ, Hamblin TJ. Pyogenic abscesses in the myelodysplastic syndrome. BMJ 1989; 299:375.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?24/54/25450/abstract/64\">",
"      Negrin RS, Haeuber DH, Nagler A, et al. Treatment of myelodysplastic syndromes with recombinant human granulocyte colony-stimulating factor. A phase I-II trial. Ann Intern Med 1989; 110:976.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?24/54/25450/abstract/65\">",
"      Negrin RS, Haeuber DH, Nagler A, et al. Maintenance treatment of patients with myelodysplastic syndromes using recombinant human granulocyte colony-stimulating factor. Blood 1990; 76:36.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?24/54/25450/abstract/66\">",
"      Sultana TA, Harada H, Ito K, et al. Expression and functional analysis of granulocyte colony-stimulating factor receptors on CD34++ cells in patients with myelodysplastic syndrome (MDS) and MDS-acute myeloid leukaemia. Br J Haematol 2003; 121:63.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?24/54/25450/abstract/67\">",
"      Greenberg PL. Treatment of myelodysplastic syndromes with hemopoietic growth factors. Semin Oncol 1992; 19:106.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?24/54/25450/abstract/68\">",
"      Vadhan-Raj S, Keating M, LeMaistre A, et al. Effects of recombinant human granulocyte-macrophage colony-stimulating factor in patients with myelodysplastic syndromes. N Engl J Med 1987; 317:1545.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?24/54/25450/abstract/69\">",
"      Antin JH, Smith BR, Holmes W, Rosenthal DS. Phase I/II study of recombinant human granulocyte-macrophage colony-stimulating factor in aplastic anemia and myelodysplastic syndrome. Blood 1988; 72:705.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?24/54/25450/abstract/70\">",
"      Willemze R, van der Lely N, Zwierzina H, et al. A randomized phase-I/II multicenter study of recombinant human granulocyte-macrophage colony-stimulating factor (GM-CSF) therapy for patients with myelodysplastic syndromes and a relatively low risk of acute leukemia. EORTC Leukemia Cooperative Group. Ann Hematol 1992; 64:173.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?24/54/25450/abstract/71\">",
"      Economopoulos T, Papageorgiou E, Stathakis N, et al. Treatment of myelodysplastic syndromes with human granulocytic-macrophage colony stimulating factor (GM-CSF) or GM-CSF combined with low-dose cytosine arabinoside. Eur J Haematol 1992; 49:138.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?24/54/25450/abstract/72\">",
"      Gerhartz HH, Marcus R, Delmer A, et al. A randomized phase II study of low-dose cytosine arabinoside (LD-AraC) plus granulocyte-macrophage colony-stimulating factor (rhGM-CSF) in myelodysplastic syndromes (MDS) with a high risk of developing leukemia. EORTC Leukemia Cooperative Group. Leukemia 1994; 8:16.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?24/54/25450/abstract/73\">",
"      Miller KB, Kim K, Morrison FS, et al. The evaluation of low-dose cytarabine in the treatment of myelodysplastic syndromes: a phase-III intergroup study. Ann Hematol 1992; 65:162.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?24/54/25450/abstract/74\">",
"      Schiffer CA, Anderson KC, Bennett CL, et al. Platelet transfusion for patients with cancer: clinical practice guidelines of the American Society of Clinical Oncology. J Clin Oncol 2001; 19:1519.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?24/54/25450/abstract/75\">",
"      Kantarjian H, Fenaux P, Sekeres MA, et al. Safety and efficacy of romiplostim in patients with lower-risk myelodysplastic syndrome and thrombocytopenia. J Clin Oncol 2010; 28:437.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?24/54/25450/abstract/76\">",
"      Sekeres MA, Kantarjian H, Fenaux P, et al. Subcutaneous or intravenous administration of romiplostim in thrombocytopenic patients with lower risk myelodysplastic syndromes. Cancer 2011; 117:992.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?24/54/25450/abstract/77\">",
"      Kantarjian HM, Giles FJ, Greenberg PL, et al. Phase 2 study of romiplostim in patients with low- or intermediate-risk myelodysplastic syndrome receiving azacitidine therapy. Blood 2010; 116:3163.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?24/54/25450/abstract/78\">",
"      Kurzrock R, Cortes J, Thomas DA, et al. Pilot study of low-dose interleukin-11 in patients with bone marrow failure. J Clin Oncol 2001; 19:4165.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?24/54/25450/abstract/79\">",
"      Thomas ML. The impact of myelodysplastic syndromes on quality of life: lessons learned from 70 voices. J Support Oncol 2012; 10:37.",
"     </a>",
"    </li>",
"   </ol>",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 15776 Version 14.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.6- C21.56",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     AsanBook Dig. Med. Lib.",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [1105-183.1.191.153-3399DFF423-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f24_54_25450=[""].join("\n");
var outline_f24_54_25450=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li>",
"     <a class=\"sr_button\" href=\"#H2106062\" id=\"summRecButton\">",
"      <span>",
"       SUMMARY &amp; RECOMMENDATIONS",
"      </span>",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H2100015\">",
"      INTRODUCTION",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H7193969\">",
"      ANEMIA",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H7195483\">",
"      Red cell transfusions",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H7195992\">",
"      Erythropoiesis stimulating agents",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H1870050\">",
"      - Erythropoietin or darbepoetin",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H7196544\">",
"      - Combination therapy (EPO + G-CSF)",
"     </a>",
"    </li>",
"    <li class=\"bulletItem2\">",
"     <a class=\"outlineLink\" href=\"#H7197283\">",
"      Predictors of response",
"     </a>",
"    </li>",
"    <li class=\"bulletItem2\">",
"     <a class=\"outlineLink\" href=\"#H7197290\">",
"      Effect on survival",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H7197297\">",
"      - Administration",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H2104230\">",
"      IRON OVERLOAD",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H7196296\">",
"      INFECTION",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H1063376\">",
"      Evaluation",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H1063463\">",
"      Treatment",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H1063589\">",
"      Prevention",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H1063596\">",
"      - Vaccination",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H1063603\">",
"      - Antimicrobials",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H7196900\">",
"      - Myeloid growth factors",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H2104237\">",
"      BLEEDING",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H7197620\">",
"      Platelet transfusion",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H2104265\">",
"      Thrombopoietin mimetics",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H161272971\">",
"      Interleukin-11",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H304433\">",
"      PSYCHOLOGICAL DISTRESS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H9325216\">",
"      CUTANEOUS LESIONS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H1063344\">",
"      TRANSFORMATION TO AML",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#PATIENT_INFORMATION\">",
"      INFORMATION FOR PATIENTS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H2106062\">",
"      SUMMARY AND RECOMMENDATIONS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a href=\"#references\">",
"      REFERENCES",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   <div class=\"openRelatedGraphics\" id=\"HEME/15776\" rel=\"outline_link\">",
"    GRAPHICS",
"    <a class=\"graphics_icon\" href=\"#\" title=\"View All Related Graphics\">",
"     View All",
"    </a>",
"   </div>",
"  </h1>",
"  <div id=\"relatedGraphics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"HEME/15776|TAB\">",
"      <a href=\"#\" title=\"TABLES\">",
"       TABLES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?9/48/9996\" title=\"table 1\">",
"      MDS classification WHO",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?26/37/27228\" title=\"table 2\">",
"      IPSS in MDS",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   CALCULATORS",
"  </h1>",
"  <div id=\"relatedCalculators\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"calc calc_professional\" href=\"UTD.htm?9/14/9441?source=related_link\" title=\"calculator 1\">",
"      Calculator: Myelodysplastic syndrome international prognostic scoring system (Original IPSS)",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?2/15/2297?source=related_link\">",
"      Acute sinusitis and rhinosinusitis in adults: Treatment",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?9/13/9434?source=related_link\">",
"      Anemia of chronic disease (anemia of chronic inflammation)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?28/46/29418?source=related_link\">",
"      Approach to the adult patient with anemia",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?24/51/25402?source=related_link\">",
"      Approach to the immunocompromised patient with fever and pulmonary infiltrates",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?24/49/25370?source=related_link\">",
"      Chelation therapy for iron overload states",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"./chronic-refractory-immune-thrombocytopenia-itp-in-adults?source=related_link\">",
"      Chronic refractory immune thrombocytopenia (ITP) in adults",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?20/6/20586?source=related_link\">",
"      Clinical and laboratory aspects of platelet transfusion therapy",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?20/61/21466?source=related_link\">",
"      Clinical applications of thrombopoietic growth factors",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?40/57/41882?source=related_link\">",
"      Clinical manifestations and diagnosis of the myelodysplastic syndromes",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?19/58/20393?source=related_link\">",
"      Clinical manifestations, pathologic features, and diagnosis of acute myeloid leukemia",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?2/22/2407?source=related_link\">",
"      Compatibility testing",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?14/35/14905?source=related_link\">",
"      Cytogenetics and molecular genetics of myelodysplastic syndromes",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?27/56/28552?source=related_link\">",
"      Diagnostic approach to the adult presenting with neutropenic fever",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?23/8/23688?source=related_link\">",
"      Epidemiology and pathogenesis of varicella-zoster virus infection: Herpes zoster",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?8/39/8826?source=related_link\">",
"      Hematopoietic cell transplantation in myelodysplastic syndromes",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?5/52/5961?source=related_link\">",
"      Indications for red cell transfusion in the adult",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?29/41/30362?source=related_link\">",
"      Induction therapy for acute myeloid leukemia in younger adults",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?37/60/38856?source=related_link\">",
"      Iron overload syndromes other than hereditary hemochromatosis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?24/5/24665?source=related_link\">",
"      Leukoreduction to prevent complications of blood transfusion",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?0/25/410?source=related_link\">",
"      Overview of infectious complications following purine analog therapy",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?13/38/13930?source=related_link\">",
"      Overview of neutropenic fever syndromes",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?34/19/35129?source=related_link\">",
"      Pathophysiology and diagnosis of iron overload syndromes",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_basics\" href=\"UTD.htm?2/47/2802?source=related_link\">",
"      Patient information: Bone marrow transplant (The Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_patient\" href=\"UTD.htm?34/4/34886?source=related_link\">",
"      Patient information: Bone marrow transplantation (stem cell transplantation) (Beyond the Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_basics\" href=\"UTD.htm?9/1/9234?source=related_link\">",
"      Patient information: Myelodysplastic syndromes (MDS) (The Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_patient\" href=\"UTD.htm?6/26/6564?source=related_link\">",
"      Patient information: Myelodysplastic syndromes (MDS) in adults (Beyond the Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?33/39/34425?source=related_link\">",
"      Prognosis of the myelodysplastic syndromes in adults",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?19/4/19530?source=related_link\">",
"      Prophylaxis of invasive fungal infections in adults with hematologic malignancies",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?20/49/21273?source=related_link\">",
"      Pulmonary infections in immunocompromised patients",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?37/15/38138?source=related_link\">",
"      Role of erythropoiesis-stimulating agents in the treatment of anemia in patients with cancer",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?39/60/40905?source=related_link\">",
"      Sweet syndrome (acute febrile neutrophilic dermatosis): Pathogenesis, clinical manifestations, and diagnosis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?10/46/10986?source=related_link\">",
"      The approach to the patient who refuses blood transfusion",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?38/35/39480?source=related_link\">",
"      Therapy-related myeloid neoplasms: Acute myeloid leukemia and myelodysplastic syndrome",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"./treatment-and-prognosis-of-immune-thrombocytopenia-itp-in-adults?source=related_link\">",
"      Treatment and prognosis of immune thrombocytopenia (ITP) in adults",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?28/29/29146?source=related_link\">",
"      Treatment of acute myeloid leukemia in older adults",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?35/40/36488?source=related_link\">",
"      Treatment of herpes simplex virus type 1 infection in immunocompetent patients",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?32/20/33096?source=related_link\">",
"      Treatment of herpes zoster in the immunocompetent host",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?30/30/31210?source=related_link\">",
"      Treatment of intermediate, low, or very low risk myelodysplastic syndromes",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?39/52/40778?source=related_link\">",
"      Treatment of neutropenic fever syndromes in adults with hematologic malignancies and hematopoietic cell transplant recipients (high-risk patients)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?33/9/33945?source=related_link\">",
"      Use of granulocyte colony stimulating factors in patients with chemotherapy-induced neutropenia",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?20/37/21081?source=related_link\">",
"      Use of red blood cells for transfusion",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f24_54_25451="Lower extremity vein list";
var content_f24_54_25451=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=PC%2F77469&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=PC%2F77469&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\">",
"   <div class=\"ttl\">",
"    Lower extremity (CEAP) vein list",
"   </div>",
"   <div class=\"cntnt\">",
"    <table cellspacing=\"0\">",
"     <tbody>",
"      <tr>",
"       <td class=\"subtitle1\">",
"        Superficial veins",
"       </td>",
"       <td class=\"subtitle1\">",
"        Deep veins",
"       </td>",
"       <td class=\"subtitle1\">",
"        Perforator veins",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        <p>",
"         Telangiectasias or reticular veins",
"        </p>",
"        <p>",
"         Great saphenous vein above the knee",
"        </p>",
"        <p>",
"         Great saphenous vein below the knee",
"        </p>",
"        <p>",
"         Small saphenous vein",
"        </p>",
"        <p>",
"         Nonsaphenous veins",
"        </p>",
"       </td>",
"       <td>",
"        <p>",
"         Inferior vena cava",
"        </p>",
"        <p>",
"         Common iliac vein",
"        </p>",
"        <p>",
"         Internal iliac vein",
"        </p>",
"        <p>",
"         External iliac vein",
"        </p>",
"        <p>",
"         Pelvic: gonadal, broad ligament veins, other",
"        </p>",
"        <p>",
"         Common femoral vein",
"        </p>",
"        <p>",
"         Deep femoral vein",
"        </p>",
"        <p>",
"         Femoral vein",
"        </p>",
"        <p>",
"         Popliteal vein",
"        </p>",
"        <p>",
"         Crural: anterior tibial, posterior tibial, peroneal veins (all paired)",
"        </p>",
"        <p>",
"         Muscular: gastrocnemial, soleal veins, other",
"        </p>",
"       </td>",
"       <td>",
"        <p>",
"         Thigh",
"        </p>",
"        <p>",
"         Calf",
"        </p>",
"       </td>",
"      </tr>",
"     </tbody>",
"    </table>",
"   </div>",
"   <div class=\"lgnd\">",
"    <div class=\"footnotes\">",
"     CEAP: Clinical-Etiology-Anatomy-Pathophysiology classification of lower extremity chronic venous disorders.",
"    </div>",
"    <div class=\"reference\">",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f24_54_25451=[""].join("\n");
var outline_f24_54_25451=null;
var title_f24_54_25452="Wilms tumor rx regimen";
var content_f24_54_25452=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=PEDS%2F64794&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=4\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=PEDS%2F64794&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=4\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\">",
"   <div class=\"ttl\">",
"    Treatment regimens for Wilms' tumor with favorable or standard histologic features from recently 	completed NWTSG and SIOP studies",
"   </div>",
"   <div class=\"cntnt\">",
"    <table cellspacing=\"0\">",
"     <tbody>",
"      <tr>",
"       <td class=\"subtitle1\" rowspan=\"3\">",
"        Stage*",
"       </td>",
"       <td class=\"subtitle1\" colspan=\"2\">",
"        NWTS-5",
"       </td>",
"       <td class=\"subtitle1\" colspan=\"3\">",
"        SIOP 93-01",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"subtitle2\" rowspan=\"2\">",
"        Chemotherapy",
"       </td>",
"       <td class=\"subtitle2\" rowspan=\"2\">",
"        Radiation therapy",
"       </td>",
"       <td class=\"subtitle2\" colspan=\"2\">",
"        Chemotherapy",
"       </td>",
"       <td class=\"subtitle2\" rowspan=\"2\">",
"        Radiation therapy",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"subtitle3\">",
"        Preoperative",
"       </td>",
"       <td class=\"subtitle3\">",
"        Postoperative",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        I",
"       </td>",
"       <td>",
"        VA x 18 weeks",
"       </td>",
"       <td>",
"        -",
"       </td>",
"       <td>",
"        VA x 4 weeks",
"       </td>",
"       <td>",
"        VA x 4 weeks&bull;",
"       </td>",
"       <td>",
"        -",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        II",
"       </td>",
"       <td>",
"        VA x 18 weeks",
"       </td>",
"       <td>",
"        -",
"       </td>",
"       <td>",
"        VA x 4 weeks",
"       </td>",
"       <td>",
"        VDA x 27 weeks",
"       </td>",
"       <td>",
"        Node-negative: none Node-positive: 15 Gy",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        III",
"       </td>",
"       <td>",
"        VDA x 24 weeks",
"       </td>",
"       <td>",
"        10.8 Gy",
"       </td>",
"       <td>",
"        VA x 4 weeks",
"       </td>",
"       <td>",
"        VDA x 27 weeks",
"       </td>",
"       <td>",
"        15 Gy",
"       </td>",
"      </tr>",
"      <tr>",
"       <td rowspan=\"2\">",
"        IV",
"       </td>",
"       <td rowspan=\"2\">",
"        VDA x 24 weeks",
"       </td>",
"       <td>",
"        12 Gy lung (if lung metastasis)",
"       </td>",
"       <td rowspan=\"2\">",
"        VDA x 6 weeks",
"       </td>",
"       <td>",
"        CR after 9 weeks: VDA x 27 weeks",
"       </td>",
"       <td rowspan=\"2\">",
"        None if lung lesions disappear by week 9, otherwise 12 Gy",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        10.8 Gy flank (if local stage III)",
"       </td>",
"       <td>",
"        No CR after 9 weeks: ICED x 34 weeks",
"       </td>",
"      </tr>",
"     </tbody>",
"    </table>",
"   </div>",
"   <div class=\"lgnd\">",
"    <div class=\"footnotes\">",
"     A: dactinomycin; C: carboplatin; CR: complete remission; D: doxorubicin; E: etoposide; I: ifosfamide; NWTS: National Wilms Tumor Study; NWTSG: National Wilms' Tumor Study Group; SIOP: International Society of Pediatric Oncology; V: vincristine.",
"     <br>",
"      * Note that the NWTSG stage is determined before surgical resection and the SIOP stage after resection; the staging systems are not equivalent.",
"      <br>",
"       &bull; Patients were randomly assigned to receive postoperative VA for 4 or 18 weeks. Treatment with VA was no less effective for 4 weeks than for 18 weeks.",
"      </br>",
"     </br>",
"    </div>",
"    <div class=\"reference\">",
"     Reproduced with permission from: Metzger ML, Dome JS. Current therapy for Wilms' tumor. Oncologist 2005; 10:815. Copyright &copy;2005 AlphaMed Press.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f24_54_25452=[""].join("\n");
var outline_f24_54_25452=null;
var title_f24_54_25453="Time course lacunar stroke";
var content_f24_54_25453=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=NEURO%2F52246&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=NEURO%2F52246&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    Time course of lacunar infarction",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 393px; height: 311px; background-image: url(data:image/gif;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    Penetrating artery occlusions usually cause symptoms that develop over a short period of time, hours or at most a few days, compared to large artery-related brain ischemia which can evolve over a longer period. A stuttering course may ensue, as with large artery thrombosis. This patient had a pure motor hemiparesis.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f24_54_25453=[""].join("\n");
var outline_f24_54_25453=null;
var title_f24_54_25454="Insulin receptor subunits";
var content_f24_54_25454=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=ENDO%2F51047&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=ENDO%2F51047&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    Structure of the insulin receptor",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 392px; height: 306px; background-image: url(data:image/gif;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    Schematic representation of the structure of the insulin receptor showing both the insulin binding and tyrosine kinase domains. See text for details of the function of each of these sites.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f24_54_25454=[""].join("\n");
var outline_f24_54_25454=null;
var title_f24_54_25455="ASFA apheresis indications";
var content_f24_54_25455=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=HEME%2F86468&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=HEME%2F86468&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\">",
"   <div class=\"ttl\">",
"    American Society for Apheresis 2010 indication categories for therapeutic apheresis",
"   </div>",
"   <div class=\"cntnt\">",
"    <table cellspacing=\"0\">",
"     <tbody>",
"      <tr>",
"       <td class=\"subtitle1_single\">",
"        Modality: Therapeutic plasma exchange; Category: I",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Acute inflammatory demyelinating polyneuropathy (Guillain-Barr&eacute; syndrome)",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        ANCA-associated rapidly progressive glomerulonephritis (Granulomatosis with polyangiitis [Wegener's])",
"        <ul>",
"         <li>",
"          Dialysis dependence",
"         </li>",
"         <li>",
"          Diffuse alveolar hemorrhage",
"         </li>",
"        </ul>",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Anti-glomerular basement membrane disease (Goodpasture's syndrome)",
"        <ul>",
"         <li>",
"          Dialysis independence",
"         </li>",
"         <li>",
"          Diffuse alveolar hemorrhage",
"         </li>",
"        </ul>",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Chronic inflammatory demyelinating polyradiculoneuropathy",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Cryoglobulinemia",
"        <ul>",
"         <li>",
"          Severe/symptomatic",
"         </li>",
"        </ul>",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Focal segmental glomerulosclerosis recurrent",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Hemolytic-uremic syndrome",
"        <ul>",
"         <li>",
"          Atypical HUS due to autoantibody to factor H",
"         </li>",
"        </ul>",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Hyperviscosity in monoclonal gammopathies",
"        <ul>",
"         <li>",
"          Treatment of symptoms",
"         </li>",
"         <li>",
"          Prophylaxis for rituximab",
"         </li>",
"        </ul>",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Myasthenia gravis",
"        <ul>",
"         <li>",
"          Moderate-severe",
"         </li>",
"         <li>",
"          Pre-thymectomy",
"         </li>",
"        </ul>",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Paraproteinemic polyneuropathies",
"        <ul>",
"         <li>",
"          IgG/IgA",
"         </li>",
"         <li>",
"          IgM",
"         </li>",
"        </ul>",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Pediatric autoimmune neuropsychiatric disorders associated with streptococcal infections (PANDAS) (exacerbation)",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Renal transplantation",
"        <ul>",
"         <li>",
"          Antibody mediated rejection",
"         </li>",
"        </ul>",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Sydenham's chorea",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Thrombotic microangiopathy: drug-associated",
"        <ul>",
"         <li>",
"          Ticlopidine/clopidogrel",
"         </li>",
"        </ul>",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Thrombotic thrombocytopenic purpura",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Wilson's disease, fulminant hepatic failure with hemolysis",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"subtitle1_single\">",
"        Modality: Therapeutic plasma exchange; Category: II",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        ABO incompatible&nbsp;hematopoietic cell transplantation&nbsp;",
"        <ul>",
"         <li>",
"          HPC, marrow",
"         </li>",
"         <li>",
"          HPC, apheresis",
"         </li>",
"        </ul>",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        ABO incompatible solid organ transplantation",
"        <ul>",
"         <li>",
"          Kidney",
"         </li>",
"         <li>",
"          Heart (&lt;40 months of age)",
"         </li>",
"        </ul>",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Acute disseminated encephalomyelitis",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Autoimmune hemolytic anemia",
"        <ul>",
"         <li>",
"          Cold agglutinin disease (life-threatening)",
"         </li>",
"        </ul>",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Catastrophic antiphospholipid syndrome",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Chronic focal enc&eacute;phalites (Rasmussen's enc&eacute;phalites)",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Familial hypercholesterolemia",
"        <ul>",
"         <li>",
"          Homozygotes with small blood volume",
"         </li>",
"        </ul>",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Hemolytic-uremic syndrome",
"        <ul>",
"         <li>",
"          Atypical HUS due to complement factor gene mutations",
"         </li>",
"        </ul>",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Lambert-Eaton myasthenic syndrome",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Multiple sclerosis",
"        <ul>",
"         <li>",
"          Acute CNS inflammatory demyelinating disease unresponsive to steroids",
"         </li>",
"        </ul>",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Myeloma cast nephropathy",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Neuromyelitis optica (Devic's syndrome)",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Overdose, venoms, and poisoning",
"        <ul>",
"         <li>",
"          Mushroom poisoning",
"         </li>",
"        </ul>",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Phytanic acid storage disease (Refsum's disease)",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Pure red cell aplasia",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Red cell alloimmunization in pregnancy, before intrauterine transfusion availability",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Renal transplantation",
"        <ul>",
"         <li>",
"          Desensitization, living donor, positive crossmatch due to donor specific HLA antibody",
"         </li>",
"        </ul>",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Systemic lupus erythematosus, severe (eg, cerebritis, diffuse alveolar hemorrhage)",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"subtitle1_single\">",
"        Modality: Therapeutic plasma exchange; Category: III",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        ABO incompatible solid organ transplantation",
"        <ul>",
"         <li>",
"          Liver perioperative",
"         </li>",
"        </ul>",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Acute liver failure",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        ANCA-associated rapidly progressive glomerulonephritis (Wegener's Granulomatosis)",
"        <ul>",
"         <li>",
"          Dialysis independence",
"         </li>",
"        </ul>",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Aplastic anemia",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Autoimmune hemolytic anemia",
"        <ul>",
"         <li>",
"          Warm autoimmune hemolytic anemia",
"         </li>",
"        </ul>",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Cardiac allograft rejection",
"        <ul>",
"         <li>",
"          Treatment of antibody mediated rejection",
"         </li>",
"        </ul>",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Dilated cardiomyopathy",
"        <ul>",
"         <li>",
"          NYHA II-IV",
"         </li>",
"        </ul>",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Hypertriglyceridemic pancreatitis",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Immune complex rapidly progressive glomerulonephritis",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Multiple sclerosis",
"        <ul>",
"         <li>",
"          Chronic progressive",
"         </li>",
"        </ul>",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Nephrogenic systemic fibrosis",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Overdose, venoms, and poisoning",
"        <ul>",
"         <li>",
"          Envenomation",
"         </li>",
"         <li>",
"          Monoclonal antibody with PML",
"         </li>",
"         <li>",
"          Other compounds",
"         </li>",
"        </ul>",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Paraneoplastic neurologic syndromes",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Paraproteinemic polyneuropathies",
"        <ul>",
"         <li>",
"          Multiple myeloma",
"         </li>",
"        </ul>",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Post-transfusion purpura",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Renal transplantation",
"        <ul>",
"         <li>",
"          High PRA, cadaveric donor",
"         </li>",
"        </ul>",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Scleroderma (progressive systemic sclerosis)",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Sepsis with multiorgan failure",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Thrombotic microangiopathy: drug-associated",
"        <ul>",
"         <li>",
"          Cyclosporine/tacrolimus",
"         </li>",
"        </ul>",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Thrombotic microangiopathy: hematopoietic stem cell transplant-associated",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Thyroid storm",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"subtitle1_single\">",
"        Modality: Rheopheresis; Category: III",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Age-related macular degeneration, dry",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"subtitle1_single\">",
"        Modality: RBC exchange; Category: I",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Babesiosis",
"        <ul>",
"         <li>",
"          Severe",
"         </li>",
"        </ul>",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Sickle cell disease",
"        <ul>",
"         <li>",
"          Acute stroke",
"         </li>",
"        </ul>",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"subtitle1_single\">",
"        Modality: RBC exchange; Category: II",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Babesiosis",
"        <ul>",
"         <li>",
"          High-risk population",
"         </li>",
"        </ul>",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Malaria, severe",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Sickle cell disease",
"        <ul>",
"         <li>",
"          Acute chest syndrome",
"         </li>",
"         <li>",
"          Prophylaxis for primary or secondary stroke; prevention of transfusional iron overload",
"         </li>",
"        </ul>",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"subtitle1_single\">",
"        Modality: RBC exchange; Category: III",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Sickle cell disease",
"        <ul>",
"         <li>",
"          Multi-organ failure",
"         </li>",
"        </ul>",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"subtitle1_single\">",
"        Modality: Extracorporeal photopheresis; Category: I",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Cardiac allograft rejection",
"        <ul>",
"         <li>",
"          Prophylaxis",
"         </li>",
"        </ul>",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Cutaneous T cell lymphoma; mycosis fungoides; S&eacute;zary syndrome",
"        <ul>",
"         <li>",
"          Erythrodermic",
"         </li>",
"        </ul>",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"subtitle1_single\">",
"        Modality: Extracorporeal photopheresis; Category: II",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Cardiac allograft rejection",
"        <ul>",
"         <li>",
"          Treatment of rejection",
"         </li>",
"        </ul>",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Graft-versus-host disease",
"        <ul>",
"         <li>",
"          Skin (chronic)",
"         </li>",
"         <li>",
"          Skin (acute)",
"         </li>",
"        </ul>",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Lung allograft rejection",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"subtitle1_single\">",
"        Modality: Extracorporeal photopheresis; Category: III",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Graft-versus-host disease",
"        <ul>",
"         <li>",
"          Non-skin (acute/chronic)",
"         </li>",
"        </ul>",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Cutaneous T cell lymphoma; mycosis fungoides; S&eacute;zary syndrome",
"        <ul>",
"         <li>",
"          Non-erythrodermic",
"         </li>",
"        </ul>",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Nephrogenic systemic fibrosis",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Pemphigus vulgaris",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"subtitle1_single\">",
"        Modality: Immune adsorption; Category: II",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Chronic focal enc&eacute;phalites (Rasmussen's enc&eacute;phalites)",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Cryoglobulinemia",
"        <ul>",
"         <li>",
"          Secondary to hepatitis C virus",
"         </li>",
"        </ul>",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Rheumatoid arthritis, refractory",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"subtitle1_single\">",
"        Modality: Immune adsorption; Category: III",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Coagulation factor inhibitors",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Dilated cardiomyopathy",
"        <ul>",
"         <li>",
"          NYHA II-IV",
"         </li>",
"        </ul>",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Paraneoplastic neurologic syndromes",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Paraproteinemic polyneuropathies",
"        <ul>",
"         <li>",
"          IgG/IgA or IgM",
"         </li>",
"        </ul>",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"subtitle1_single\">",
"        Modality: Selective removal; Category: I",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Familial hypercholesterolemia",
"        <ul>",
"         <li>",
"          Homozygotes",
"         </li>",
"        </ul>",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"subtitle1_single\">",
"        Modality: Selective removal; Category: II",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Familial hypercholesterolemia",
"        <ul>",
"         <li>",
"          Heterozygotes",
"         </li>",
"        </ul>",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"subtitle1_single\">",
"        Modality: Erythrocytapheresis; Category: III",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Hereditary hemochromatosis",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Polycythemia vera and erythrocytosis",
"        <ul>",
"         <li>",
"          Polycythemia vera",
"         </li>",
"         <li>",
"          Secondary erythrocytosis",
"         </li>",
"        </ul>",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"subtitle1_single\">",
"        Modality: Leukocytapheresis; Category: I",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Hyperleukocytosis",
"        <ul>",
"         <li>",
"          Leukostasis",
"         </li>",
"        </ul>",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"subtitle1_single\">",
"        Modality: Leukocytapheresis; Category: III",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Hyperleukocytosis",
"        <ul>",
"         <li>",
"          Prophylaxis",
"         </li>",
"        </ul>",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"subtitle1_single\">",
"        Modality: Adsorptive cytapheresis; Category: II",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Inflammatory bowel disease",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"subtitle1_single\">",
"        Modality: Thrombocytapheresis; Category: II",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Thrombocytosis",
"        <ul>",
"         <li>",
"          Symptomatic",
"         </li>",
"        </ul>",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"subtitle1_single\">",
"        Modality: Thrombocytapheresis; Category: III",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Thrombocytosis",
"        <ul>",
"         <li>",
"          Prophylactic or secondary",
"         </li>",
"        </ul>",
"       </td>",
"      </tr>",
"     </tbody>",
"    </table>",
"   </div>",
"   <div class=\"lgnd\">",
"    Disease entities listed under category IV (see topic text) have been omitted from the table.",
"    <br/>",
"    Category I: Disorders for which apheresis is accepted as first-line therapy.",
"    <br/>",
"    Category II: Disorders for which apheresis is accepted as second-line therapy.",
"    <br/>",
"    Category III: Disorders for which the optimum role of apheresis therapy is not established.",
"    <br/>",
"    Category IV: Disorders for which published evidence demonstrates or suggests apheresis to be ineffective or harmful.",
"    <div class=\"footnotes\">",
"     ANCA: anti-neutrophil cytoplasmic autoantibody; CNS: central nervous system; HLA: human leukocyte antigen; HPC: hematopoietic progenitor cell; HCT; hematopoietic stem cell transplantation; HUS: hemolytic-uremic syndrome; NYHA: New York Heart Association; PANDAS: pediatric autoimmune neuropsychiatric disorders associated with streptococcal infections; PML: progressive multifocal leukoencephalopathy; PRA: panel reactive antibody.",
"    </div>",
"    <div class=\"reference\">",
"     Modified from: Szczepiorkowski ZM, Winters JL, Bandarenko N, et al. Guidelines on the use of therapeutic apheresis in clinical practice--evidence-based approach from the Apheresis Applications Committee of the American Society for Apheresis. J Clin Apher 2010; 25:83.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f24_54_25455=[""].join("\n");
var outline_f24_54_25455=null;
